In IN 0 0 2 O
both DT 0 0 12 O
species NNS 1 1 1 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
( ( 0 0 2 O
+ NN 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM CC 0 0 UNK I-Drug_n
antagonized VBD 1 0 UNK O
the DT 0 0 12 O
rate NN 0 1 1 O
- : 0 0 2 O
decreasing NN 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
on IN 0 0 12 O
FI NNP 0 1 UNK O
and CC 0 0 12 O
FR NNP 0 1 UNK O
responding NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
conclusion NN 0 1 12 O
we PRP 0 0 12 O
demonstrated VBD 1 0 1 O
an DT 0 0 12 O
isolated JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
( ( 0 0 2 O
as IN 1 0 12 O
chloride NN 0 1 14 O
) ) 0 0 2 O
on IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
iron NN 0 1 3 O
provided VBN 1 1 1 O
as IN 1 0 12 O
nonheme NN 0 0 UNK B-Drug
( ( 0 0 2 O
as IN 1 0 12 O
sulfate NN 0 1 14 O
) ) 0 0 2 O
and CC 0 0 12 O
heme NN 0 1 14 B-Drug
( ( 0 0 2 O
as IN 1 0 12 O
CRBC NNP 0 0 UNK O
) ) 0 0 2 O
iron NN 0 1 3 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
distribution NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
replacement NN 0 1 1 O
therapies NNS 1 1 6 O
were VBD 1 0 12 O
: : 0 0 2 O
9 CD 0 0 2 O
peritoneal JJ 0 1 8 O
dialysis NN 0 1 6 O
9 CD 0 0 2 O
conventional JJ 0 1 1 O
hemodialysis NN 0 1 14 O
and CC 0 0 12 O
9 CD 0 0 2 O
nocturnal JJ 0 1 6 O
hemodialysis NN 0 1 14 O
. . 0 0 12 O

cases NNS 1 1 UNK O
occurred VBD 1 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
and CC 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
day NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

For IN 0 0 2 O
conditioned JJ 0 1 UNK O
place NN 0 1 12 O
preference NN 0 1 1 O
subjects NNS 1 1 UNK O
were VBD 1 0 12 O
conditioned VBN 1 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
consecutive JJ 0 1 1 O
days NNS 1 1 12 O
( ( 0 0 2 O
P9 NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
with IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
saline NN 0 1 14 O
and CC 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
free JJ 0 1 12 O
preference NN 0 1 1 O
test NN 0 1 1 O
was VBD 1 0 12 O
conducted VBN 1 1 1 O
at IN 0 0 12 O
P9 NNP 0 1 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
the DT 0 0 12 O
enhanced JJ 0 1 1 O
secretion NN 0 1 14 O
of IN 0 0 12 O
colonic JJ 0 1 6 O
fluid NN 0 1 3 O
by IN 0 0 12 O
dmPGE9 NN 0 0 UNK B-Drug_n
given VBN 1 1 12 O
intraluminally RB 0 0 UNK O
was VBD 1 0 12 O
only RB 0 1 12 O
half NN 0 1 12 O
of IN 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
whereas VBP 0 0 UNK O
the DT 0 0 12 O
colonic JJ 0 1 6 O
transit NN 0 1 1 O
- : 0 0 2 O
enhancing VBG 1 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
dmPGE9 NN 0 0 UNK B-Drug_n
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
was VBD 1 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
than IN 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
9 CD 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
after IN 0 0 12 O
its PRP$ 1 0 12 O
administration NN 0 1 1 O
. . 0 0 12 O

Recovery NN 0 1 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
twitch NN 0 1 3 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
fade JJ 0 0 UNK O
recovery NN 0 1 1 O
took VBD 1 1 12 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
plus CC 0 1 16 O
gentamycin NN 0 1 14 B-Drug
. . 0 0 12 O

Differences NNS 0 1 UNK O
in IN 0 0 12 O
iron NN 0 1 3 B-Drug
balance NN 0 1 1 O
were VBD 1 0 12 O
only RB 0 1 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
both DT 0 0 12 O
dietary JJ 0 1 6 O
concentrations NNS 1 1 13 O
showing VBG 1 1 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
absolute NN 0 1 1 O
but CC 0 0 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
relative JJ 0 1 1 O
absorption NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
retention NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
groups NNS 1 1 1 O
fed VBP 1 1 12 O
further JJ 0 1 1 O
Fe NNP 0 1 2 B-Drug
. . 0 0 12 O
( ( 0 0 2 O
ABSTRACT NNP 0 1 UNK O
TRUNCATED NNP 0 0 UNK O
AT NNP 0 0 11 O
9 CD 0 0 2 O
WORDS NNP 0 1 UNK O
) ) 0 0 2 O

( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
microtubules NNS 1 1 UNK O
per IN 0 0 1 O
axon NN 0 1 UNK O
. . 0 0 12 O

Today NN 0 1 2 O
pharmacological JJ 0 1 14 O
magnesium NN 0 1 14 B-Drug
therapy NN 0 1 6 O
mainly RB 0 0 1 O
concerns VBZ 1 1 1 O
the DT 0 0 12 O
obstetrical JJ 0 1 13 O
cardiological NN 0 1 UNK O
and CC 0 0 12 O
anaesthesiological JJ 0 1 UNK O
fields NNS 1 1 1 O
. . 0 0 12 O

For IN 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
range NN 0 1 1 O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
doses NNS 1 1 6 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
differential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
dosing NN 0 0 14 O
or CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
evidence NN 0 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
role NN 0 1 1 O
for IN 0 0 12 O
norepinephrine NN 0 1 14 O
and CC 0 0 12 O
dopamine NN 0 1 14 O
and CC 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistaminics NNS 0 1 UNK B-Group
on IN 0 0 12 O
them PRP 0 0 12 O
are VBP 1 0 12 O
less RB 0 1 12 O
well RB 0 1 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Internal NNP 0 1 2 O
application NN 0 1 1 O
of IN 0 0 12 O
InsP9 NNP 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
microM NN 0 0 UNK O
) ) 0 0 2 O
increased VBD 1 1 1 O
intracellular JJ 0 1 UNK O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
concentration NN 0 1 1 O
( ( 0 0 2 O
[ JJ 0 0 2 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
] NN 0 0 2 O
( ( 0 0 2 O
i NN 0 1 12 O
) ) 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
activated VBD 1 1 1 O
the DT 0 0 12 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
- : 0 0 2 O
dependent JJ 0 1 1 O
K NNP 0 1 2 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
current JJ 0 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
PICR NNP 0 0 UNK O
could MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
by IN 0 0 12 O
simple JJ 0 1 1 O
recommendations NNS 1 1 1 O
; : 0 0 2 O

Mice NN 0 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
generation NN 0 1 UNK O
of IN 0 0 12 O
three CD 0 1 12 O
lines NNS 1 1 3 O
divergently RB 0 0 UNK O
selected VBN 1 1 UNK O
for IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
pentobarbital VB 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
sedation NN 0 1 6 O
times NNS 1 1 12 O
[ VBP 0 0 2 O
long JJ 0 1 12 O
- : 0 0 2 O
sedation NN 0 1 6 O
time NN 0 1 12 O
( ( 0 0 2 O
LST NNP 0 1 UNK O
) ) 0 0 2 O
short JJ 0 1 12 O
sedation NN 0 1 6 O
time NN 0 1 12 O
( ( 0 0 2 O
SST NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
randomly RB 0 0 UNK O
bred VBN 1 1 UNK O
control NN 0 1 1 O
( ( 0 0 2 O
RBC NNP 0 1 13 O
) ) 0 0 2 O
] NN 0 0 2 O
were VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
study VB 0 1 1 O
cocaine JJ 0 1 6 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
behavioral JJ 0 1 13 O
sensitization NN 0 1 13 O
. . 0 0 12 O

Analyses NNS 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
sequence NN 0 1 UNK O
however RB 0 0 12 O
usually RB 0 1 12 O
give VBP 0 1 12 O
little JJ 0 1 12 O
consideration NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
nature NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
target NN 0 1 1 O
cell NN 0 1 1 O
or CC 0 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
characteristics NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
resultant JJ 0 0 1 O
tumors NNS 1 1 6 O
. . 0 0 12 O

After IN 0 0 2 O
one CD 0 1 12 O
day NN 0 1 12 O
fecal JJ 0 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
both DT 0 0 12 O
elements NNS 1 1 1 O
had VBD 1 0 12 O
already RB 0 0 12 O
responded VBN 1 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
dietary JJ 0 1 6 O
treatments NNS 1 1 6 O
with IN 0 0 12 O
constant JJ 0 1 1 O
values NNS 1 1 1 O
being VBG 1 0 12 O
reached VBN 1 1 12 O
after IN 0 0 12 O
approximately RB 0 1 1 O
three CD 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

Acetylcysteine NNP 0 1 UNK B-Drug
interference NN 0 1 13 O
with IN 0 0 12 O
urine JJ 0 1 6 O
ketone NN 0 1 13 O
test NN 0 1 1 O
. . 0 0 12 O

Atracurium NNP 0 1 UNK B-Drug
infusion NN 0 1 14 O
was VBD 1 0 12 O
continued VBN 1 1 12 O
for IN 0 0 12 O
a DT 0 0 12 O
third JJ 0 1 12 O
hour NN 0 1 12 O
and CC 0 0 12 O
then RB 0 1 12 O
hoof VB 0 1 UNK O
twitch NN 0 1 3 O
was VBD 1 0 12 O
again RB 0 0 12 O
allowed VBN 1 1 12 O
to TO 0 0 12 O
recover VB 0 1 1 O
spontaneously RB 0 0 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Intraventricular JJ 0 1 UNK O
injection NN 0 1 3 O
of IN 0 0 12 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
produced VBD 1 0 1 O
an DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
heat NN 0 1 3 O
stimulus NN 0 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Limited JJ 0 1 2 O
comparative NN 0 0 UNK O
data NNS 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
high JJ 0 1 1 O
viral JJ 0 1 6 O
loads NNS 1 1 13 O
treated VBN 1 1 1 O
with IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
- : 0 0 2 O
or CC 0 0 12 O
delavirdine VB 0 1 13 B-Drug
- : 0 0 2 O
based VBN 1 1 1 O
regimens NNS 1 1 UNK O
currently RB 0 1 12 O
exist VBP 0 1 UNK O
. . 0 0 12 O

Glutathione NNP 0 1 UNK O
- : 0 0 2 O
S NNP 0 1 2 O
- : 0 0 2 O
transferase NN 0 1 14 O
( ( 0 0 2 O
GST NNP 0 0 UNK O
) ) 0 0 2 O
activity NN 0 1 1 O
however RB 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
differ VB 0 0 UNK O
from IN 0 0 12 O
control NN 0 1 1 O
values NNS 1 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
dose NN 0 1 6 O
or CC 0 0 12 O
at IN 0 0 12 O
any DT 0 0 12 O
time NN 0 1 12 O
point NN 0 1 12 O
in IN 0 0 12 O
cerebral JJ 0 0 6 O
and CC 0 0 12 O
hepatic JJ 0 1 14 O
tissues NNS 1 1 6 O
. . 0 0 12 O

Still RB 0 0 2 O
other JJ 0 0 12 O
pathways NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
proposed VBN 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
period NN 0 1 1 O
A NNP 0 0 2 O
all DT 0 0 12 O
volunteers NNS 1 1 UNK O
took VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
orally RB 0 1 14 O
. . 0 0 12 O

N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
methyllevallorphan NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
s.c. NN 0 1 UNK O
) ) 0 0 2 O
completely RB 0 1 12 O
antagonized VBD 1 0 UNK O
the DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
loperamide NN 0 1 0 B-Drug
and CC 0 0 12 O
partly RB 0 0 UNK O
antagonized VBD 1 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

Sprague NNP 0 0 UNK O
- : 0 0 2 O
Dawley NNP 0 0 UNK O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
quinpirole NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
saline NN 0 1 14 O
from IN 0 0 12 O
postnatal JJ 0 1 13 O
days NNS 1 1 12 O
( ( 0 0 2 O
P NNP 0 1 2 O
) ) 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
raised VBD 1 1 12 O
to TO 0 0 12 O
adolescence VB 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
generated VBD 1 1 1 O
to TO 0 0 12 O
date NN 0 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
thus RB 0 0 1 O
support VB 0 1 1 O
its PRP$ 1 0 12 O
use NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
broad JJ 0 1 1 O
population NN 0 1 13 O
of IN 0 0 12 O
hypercholesterolaemic JJ 0 0 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

Uncontrolled VBN 0 1 UNK O
hy SYM 0 1 13 O
- : 0 0 2 O
per IN 0 0 1 O
- : 0 0 2 O
parathyroidism NN 0 0 UNK O
causes VBZ 1 1 6 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
fibrosis NN 0 1 6 O
leading VBG 1 1 1 O
to TO 0 0 12 O
erythropoietin VB 0 1 UNK B-Drug
( ( 0 0 2 O
EPO NNP 0 0 UNK B-Drug
) ) 0 0 2 O
resistance NN 0 1 1 O
. . 0 0 12 O

Therapeutic JJ 0 1 UNK O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
can MD 0 0 12 O
avoid VB 0 0 12 O
iatrogenic JJ 0 1 13 O
alterations NNS 1 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
9mTc CD 0 0 UNK B-Drug
- : 0 0 2 O
methylene NN 0 1 14 I-Drug
diphosphonate NN 0 1 UNK I-Drug
( ( 0 0 2 O
MDP NNP 0 1 UNK O
) ) 0 0 2 O
- : 0 0 2 O
gentamicin NN 0 1 14 B-Drug
interaction NN 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
will MD 0 0 12 O
compete VB 0 0 UNK O
with IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
( ( 0 0 2 O
Plavix NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
prasugrel NN 0 1 13 B-Drug
( ( 0 0 2 O
Effient NNP 0 1 UNK B-Brand
) ) 0 0 2 O
for IN 0 0 12 O
such JJ 0 0 1 O
use NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
ofloxacin JJ 0 1 0 B-Drug
KRM NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
exhibited VBN 1 1 1 O
strong JJ 0 1 12 O
synergistic JJ 0 1 UNK O
activity NN 0 1 1 O
while IN 0 0 12 O
only RB 0 1 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
rifampicin NN 0 1 UNK B-Drug
( ( 0 0 2 O
or CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
ofloxacin $ 0 1 0 B-Drug
. . 0 0 12 O

phase NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
: : 0 0 2 O
fluoxetine NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
; : 0 0 2 O

Some DT 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
via IN 0 0 1 O
the DT 0 0 12 O
biliary JJ 0 1 8 O
route NN 0 1 12 O
with IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
this DT 0 0 12 O
being VBG 1 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
compound NN 0 1 13 O
. . 0 0 12 O

All PDT 0 0 2 O
the DT 0 0 12 O
animals NNS 1 1 12 O
were VBD 1 0 12 O
killed VBN 1 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
end NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
week NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
experiment NN 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
also RB 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
after IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
daily JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
chlordiazepoxide JJ 0 1 16 B-Drug
withdrawal NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
not RB 0 1 12 O
only RB 0 1 12 O
re VB 0 0 12 O
- : 0 0 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
almost RB 0 1 12 O
complete JJ 0 1 1 O
loss NN 0 1 1 O
of IN 0 0 12 O
bar NN 0 1 3 O
- : 0 0 2 O
press NN 0 0 13 O
response NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
E NNP 0 0 2 O
- : 0 0 2 O
strain NN 0 1 3 O
subjects NNS 1 1 UNK O
but CC 0 0 12 O
also RB 0 0 12 O
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
temporary JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
acquired JJ 0 1 1 O
behavioral JJ 0 1 13 O
response NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
stable JJ 0 1 1 O
A NNP 0 0 2 O
- : 0 0 2 O
strain NN 0 1 3 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

While IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
have VBP 0 0 12 O
similar JJ 0 1 1 O
affinities NNS 1 1 UNK O
for IN 0 0 12 O
kappa NN 0 1 13 O
opioid NN 0 1 13 O
and CC 0 0 12 O
possibly RB 0 1 12 O
nicotinic JJ 0 1 13 O
receptors NNS 1 1 13 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
has VBZ 1 0 12 O
much RB 0 0 12 O
lower JJR 1 1 1 O
affinities NNS 1 1 UNK O
than IN 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
for IN 0 0 12 O
NMDA NNP 0 1 UNK O
and CC 0 0 12 O
sigma VBD 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
receptors NNS 1 1 13 O
sodium JJ 0 1 14 O
channels NNS 1 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
HT NN 0 1 UNK O
transporter NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
phenotype NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
tumor NN 0 1 6 O
that WDT 0 0 12 O
results NNS 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
pulse NN 0 1 3 O
of IN 0 0 12 O
a DT 0 0 12 O
chemical NN 0 1 13 O
carcinogen NN 0 1 UNK O
may MD 0 0 1 O
depend VB 0 1 1 O
upon IN 0 0 12 O
the DT 0 0 12 O
target NN 0 1 1 O
cell NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
obtained VBD 1 1 1 O
confirm VBP 0 1 1 O
the DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
inflammatory JJ 0 1 6 O
processes NNS 1 1 1 O
in IN 0 0 12 O
parkinsonism NN 0 1 13 O
and CC 0 0 12 O
suggest JJ 0 1 1 O
expediency NN 0 0 UNK O
of IN 0 0 12 O
combined JJ 0 1 1 O
pharmacotherapy NN 0 1 UNK O
of IN 0 0 12 O
neurodegenerative JJ 0 0 UNK O
diseases NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
cells NNS 1 1 6 O
express VBP 0 0 UNK O
the DT 0 0 12 O
vitamin NN 0 1 6 O
D NNP 0 1 2 O
receptor NN 0 1 14 O
and CC 0 0 12 O
exhibit NN 0 1 1 O
doubling VBG 1 1 13 O
times NNS 1 1 12 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
parental JJ 0 1 UNK O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
even RB 0 0 12 O
when WRB 0 0 12 O
grown VBN 1 0 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
. . 0 0 12 O

In IN 0 0 2 O
both DT 0 0 12 O
sexes NNS 1 1 UNK O
of IN 0 0 12 O
swiss JJ 0 1 UNK O
albino NN 0 1 UNK O
mice NN 1 1 UNK O
; : 0 0 2 O

The DT 0 0 2 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
stereoisomers NNS 0 1 UNK O
of IN 0 0 12 O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
allylnormetazocine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
NANM NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
were VBD 1 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
phencyclidine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
PCP NNP 0 1 13 B-Drug_n
) ) 0 0 2 O
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
and CC 0 0 12 O
squirrel JJ 0 1 UNK O
monkeys NNS 1 1 UNK O
responding VBG 1 0 1 O
under IN 0 0 12 O
a DT 0 0 12 O
multiple JJ 0 1 1 O
fixed JJ 0 1 1 O
- : 0 0 2 O
interval NN 0 1 1 O
fixed VBN 1 1 1 O
- : 0 0 2 O
ratio NN 0 1 1 O
( ( 0 0 2 O
FI NNP 0 1 UNK O
FR NNP 0 1 UNK O
) ) 0 0 2 O
schedule NN 0 1 12 O
of IN 0 0 12 O
food NN 0 1 12 O
presentation NN 0 1 1 O
. . 0 0 12 O

Carbamazepine NNP 0 1 UNK B-Drug
overdose MD 0 1 6 O
recognized VBN 1 0 13 O
by IN 0 0 12 O
a DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
assay NN 0 1 14 O
. . 0 0 12 O

Cobalt NNP 0 1 UNK B-Drug
excretion NN 0 1 14 O
was VBD 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
supplementary JJ 0 0 UNK O
cobalt NN 0 1 UNK B-Drug
; : 0 0 2 O

We PRP 0 0 12 O
conclude VBP 0 1 1 O
that IN 0 0 12 O
ADL NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
prevents NNS 0 1 UNK O
morphine JJ 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
increases NNS 1 1 1 O
in IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
transit NN 0 1 1 O
time NN 0 1 12 O
by IN 0 0 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
selective JJ 0 1 13 O
peripheral JJ 0 1 6 O
opioid JJ 0 1 13 O
anitagonism NN 0 0 UNK O
without IN 0 0 12 O
affecting VBG 1 1 1 O
central JJ 0 1 1 O
opioid JJ 0 1 13 O
analgesia NN 0 1 6 O
. . 0 0 12 O

Rats NNS 0 1 UNK O
treated VBD 1 1 1 O
with IN 0 0 12 O
neonatal JJ 0 1 6 O
quinpirole NN 0 1 UNK B-Drug_n
enhanced VBD 1 1 1 O
time NN 0 1 12 O
spent VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
amphetamine JJ 0 1 13 B-Drug
- : 0 0 2 O
paired VBN 1 1 UNK O
context NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
quinpirole JJ 0 1 UNK B-Drug_n
- : 0 0 2 O
free JJ 0 1 12 O
controls NNS 1 1 UNK O
conditioned VBN 1 1 UNK O
with IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
but CC 0 0 12 O
only RB 0 1 12 O
female JJ 0 1 12 O
controls NNS 1 1 UNK O
conditioned VBN 1 1 UNK O
with IN 0 0 12 O
amphetamine JJ 0 1 13 B-Drug
spent VBN 1 1 12 O
more JJR 0 1 12 O
time NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
paired VBN 1 1 UNK O
context NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
saline JJ 0 1 14 O
- : 0 0 2 O
treated JJ 0 1 1 O
controls NNS 1 1 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Multiple NNP 0 1 2 O
occupational JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
solvents NNS 1 1 13 O
] VB 0 0 2 O
This DT 0 0 2 O
article NN 0 1 UNK O
review NN 0 1 2 O
papers NNS 1 1 UNK O
published VBN 1 1 UNK O
over IN 0 1 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
on IN 0 0 12 O
multiple JJ 0 1 1 O
occupational JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
solvents NNS 1 1 13 O
. . 0 0 12 O

Misonidazole NNP 0 1 UNK B-Drug_n
also RB 0 0 12 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
`` `` 0 0 13 O
early JJ 0 1 12 O
'' '' 0 0 13 O

PCP NNP 0 1 13 B-Drug_n
produced VBD 1 0 1 O
distinctive JJ 0 0 1 O
effects NNS 1 1 1 O
in IN 0 0 12 O
each DT 0 0 12 O
task NN 0 1 16 O
: : 0 0 2 O
it PRP 0 0 12 O
substituted VBD 1 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
training NN 0 1 1 O
dose NN 0 1 6 O
in IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
discrimination NN 0 1 13 O
and CC 0 0 12 O
it PRP 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
responses NNS 1 1 1 O
with IN 0 0 12 O
short JJ 0 1 12 O
( ( 0 0 2 O
< JJ 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
interresponse NN 0 0 UNK O
times NNS 1 1 12 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
increasing VBG 1 1 1 O
overall JJ 0 1 1 O
response NN 0 1 1 O
rates NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
DRL NNP 0 0 UNK O
schedule NN 0 1 12 O
. . 0 0 12 O

METHOD NN 0 1 UNK O
: : 0 0 2 O
This DT 0 0 2 O
study NN 0 1 1 O
was VBD 1 0 12 O
a DT 0 0 12 O
multicenter NN 0 1 UNK O
randomized VBN 1 1 6 O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
randomly RB 0 0 UNK O
assigned VBN 1 1 UNK O
9:9:9 CD 0 0 UNK O
to TO 0 0 12 O
receive VB 0 1 1 O
everolimus JJ 0 1 13 B-Drug
tablets NNS 1 1 3 O
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
9 CD 0 0 2 O
mg NN 0 1 0 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
. . 0 0 12 O

Further JJ 0 1 2 O
studies NNS 1 1 1 O
are VBP 1 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
clinical JJ 0 1 6 O
role NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
regimen VBZ 0 1 6 O
as IN 1 0 12 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
alternative NN 0 1 1 O
for IN 0 0 12 O
certain JJ 0 1 1 O
types NNS 1 1 1 O
of IN 0 0 12 O
MRSA NNP 0 1 6 O
infections NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
higher JJR 1 1 1 O
verografine NN 0 0 UNK B-Drug
and CC 0 0 12 O
iodamide JJ 0 1 UNK B-Drug
excretion NN 0 1 14 O
was VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
increased VBN 1 1 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
. . 0 0 12 O

CASE NNP 0 1 UNK O
SUMMARY NNP 0 1 11 O
: : 0 0 2 O
A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
- : 0 0 2 O
old JJ 0 1 12 O
African JJ 0 1 UNK O
- : 0 0 2 O
American JJ 0 1 2 O
man NN 0 1 12 O
was VBD 1 0 12 O
admitted VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
hospital NN 0 1 12 O
for IN 0 0 12 O
worsening VBG 1 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
elevated VBD 1 1 1 O
creatine JJ 0 1 14 O
phosphokinase NN 0 1 8 O
diffuse NN 0 1 6 O
muscle NN 0 1 6 O
pain NN 0 1 6 O
and CC 0 0 12 O
severe JJ 0 1 6 O
muscle NN 0 1 6 O
weakness NN 0 1 6 O
. . 0 0 12 O

or CC 0 0 12 O
=9 CD 0 0 UNK O
% NN 0 0 18 O
biocytin NN 0 1 UNK O
was VBD 1 0 12 O
included VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
recording NN 0 0 1 O
pipette NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
neurons NNS 1 1 UNK O
recorded VBN 1 1 12 O
without IN 0 0 12 O
biocytin NN 0 1 UNK O
. . 0 0 12 O

'' '' 0 0 13 O
hippocampal JJ 0 1 8 O
- : 0 0 2 O
independent JJ 0 1 1 O
'' '' 0 0 13 O

[ VB 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
verografin NN 0 1 UNK B-Drug
and CC 0 0 12 O
iodamide NN 0 1 UNK B-Drug
in IN 0 0 12 O
dogs NNS 1 1 UNK O
] VBP 0 0 2 O
The DT 0 0 2 O
intravenous JJ 0 1 14 O
injection NN 0 1 3 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
enhanced VBD 1 1 1 O
verografine NN 0 0 UNK B-Drug
and CC 0 0 12 O
iodamide JJ 0 1 UNK B-Drug
excretion NN 0 1 14 O
in IN 0 0 12 O
chronic JJ 0 1 6 O
canine NN 0 1 UNK O
experiments NNS 1 1 UNK O
. . 0 0 12 O

Moreover RB 0 0 1 O
the DT 0 0 12 O
acquisition NN 0 1 UNK O
of IN 0 0 12 O
tasks NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
facilitated VBN 1 0 UNK O
by IN 0 0 12 O
hippocampal JJ 0 1 8 O
lesions NNS 1 1 6 O
( ( 0 0 2 O
or CC 0 0 12 O
dysfunction NN 0 1 6 O
) ) 0 0 2 O
is VBZ 1 0 12 O
nevertheless RB 0 0 1 O
associated VBN 1 1 1 O
in IN 0 0 12 O
intact JJ 0 1 1 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
specific JJ 0 1 1 O
neurobiological JJ 0 1 UNK O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
on IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
QTc NNP 0 0 14 O
intervals NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
radiopharmaceutical NN 0 1 UNK B-Group
in IN 0 0 12 O
the DT 0 0 12 O
kidneys NNS 1 1 6 O
along IN 0 0 12 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
retention NN 0 1 1 O
tend VBP 0 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
scintigraphic JJ 0 1 UNK O
results NNS 1 1 1 O
that WDT 0 0 12 O
falsely RB 0 0 1 O
identify VBP 0 0 1 O
characteristics NNS 1 1 UNK O
related VBN 1 1 1 O
to TO 0 0 12 O
diseases NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
renal JJ 0 1 6 O
vascular NN 0 1 6 O
or CC 0 0 12 O
urinary JJ 0 1 6 O
tract NN 0 1 6 O
obstruction NN 0 1 6 O
and CC 0 0 12 O
even RB 0 0 12 O
renal JJ 0 1 6 O
cancer NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
next JJ 0 1 12 O
chapter NN 0 1 UNK O
presents NNS 1 1 12 O
information NN 0 1 1 O
on IN 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
pregnancy NN 0 1 6 O
outcomes NNS 1 1 13 O
in IN 0 0 12 O
terms NNS 1 1 1 O
of IN 0 0 12 O
pregnancy NN 0 1 6 O
rates NNS 1 1 1 O
compliance NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
ectopic NN 0 1 6 O
pregnancies VBZ 0 1 6 O
the DT 0 0 12 O
outcome NN 0 1 1 O
of IN 0 0 12 O
pregnancies NNS 1 1 6 O
conceived VBN 1 1 UNK O
while IN 0 0 12 O
using VBG 1 1 1 O
POCs NNP 0 1 UNK B-Group
and CC 0 0 12 O
fertility NN 0 1 6 O
following VBG 1 1 1 O
discontinuation NN 0 1 6 O
. . 0 0 12 O

Drug NN 0 1 2 O
regimens NNS 1 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
are VBP 1 0 12 O
frequently RB 0 1 1 O
complex JJ 0 1 1 O
and CC 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
latter JJ 0 0 UNK O
displayed NN 0 1 1 O
midazolam NN 0 1 16 B-Drug
clearances NNS 1 1 UNK O
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
two CD 0 1 12 O
larger JJR 1 1 1 O
cohorts NNS 1 1 UNK O
of IN 0 0 12 O
nonmatched JJ 0 0 UNK O
tacrolimus NN 0 1 16 B-Drug
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NN 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
to TO 0 0 12 O
those DT 0 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
calcineurin NN 0 1 UNK B-Group
inhibitor NN 0 1 14 I-Group
- : 0 0 2 O
free JJ 0 1 12 O
regimen NNS 0 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
( ( 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
altered JJ 0 1 1 O
topo NN 0 1 UNK O
I PRP 0 1 12 O
expression VBP 0 1 1 O
in IN 0 0 12 O
certain JJ 0 1 1 O
tumor NN 0 1 6 O
types NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
but CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
importance NN 0 1 1 O
of IN 0 0 12 O
topoisomerases NNS 0 1 UNK O
in IN 0 0 12 O
proliferating VBG 1 1 UNK O
cell NN 0 1 1 O
functions NNS 1 1 13 O
( ( 0 0 2 O
transcription NN 0 1 UNK O
replication NN 0 1 UNK O
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
aberrant NN 0 1 6 O
and CC 0 0 12 O
chronic JJ 0 1 6 O
activation NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
functions NNS 1 1 13 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
specific JJ 0 1 1 O
tumorigenic JJ 0 1 UNK O
alterations NNS 1 1 1 O
. . 0 0 12 O

AAV9 NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
mediated VBD 1 1 13 O
retinal JJ 0 1 6 O
transduction NN 0 1 UNK O
is VBZ 1 0 12 O
improved VBN 1 1 1 O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
injection NN 0 1 3 O
of IN 0 0 12 O
heparinase NN 0 1 UNK B-Drug_n
III NNP 0 1 2 I-Drug_n
or CC 0 0 12 O
chondroitin VB 0 1 13 B-Drug_n
ABC NNP 0 1 UNK I-Drug_n
lyase NN 0 1 UNK I-Drug_n
. . 0 0 12 O

Such JJ 0 0 1 O
data NNS 0 1 1 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
herein NN 0 0 UNK O
with IN 0 0 12 O
emphasis NN 0 0 1 O
on IN 0 0 12 O
those DT 0 0 12 O
aspects NNS 1 1 1 O
that WDT 0 0 12 O
impact VBP 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
calcium NN 0 1 14 B-Group
- : 0 0 2 O
entry NN 0 1 1 I-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

metabolic JJ 0 1 6 O
interference NN 0 1 13 O
has VBZ 1 0 12 O
sometimes RB 0 1 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
behaviour NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
biological JJ 0 1 13 O
indicators NNS 1 1 UNK O
differs NNS 0 0 UNK O
from IN 0 0 12 O
what WP 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Selective JJ 0 1 7 O
survival NN 0 1 1 O
in IN 0 0 12 O
pentazocine NN 0 1 UNK B-Drug
and CC 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug
of IN 0 0 12 O
Pseudomonas NNP 0 1 14 O
aeruginosa NN 0 0 14 O
serotype NN 0 1 UNK O
O9 NNP 0 0 UNK O
from IN 0 0 12 O
drug NN 0 1 1 O
addicts NNS 1 1 UNK O
. . 0 0 12 O

Modification NN 0 1 UNK O
of IN 0 0 12 O
surface NN 0 1 3 O
histidine NN 0 1 13 O
residues VBZ 0 1 UNK O
abolishes VBZ 1 0 UNK O
the DT 0 0 12 O
cytotoxic NN 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
Clostridium NNP 0 1 14 B-Drug_n
difficile NN 0 0 14 I-Drug_n
toxin NN 0 1 14 I-Drug_n
A NNP 0 0 2 I-Drug_n
. . 0 0 12 O

Survanta NNP 0 1 0 B-Brand
increased VBD 1 1 1 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
dissolution NN 0 0 UNK O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
in IN 0 0 12 O
proportion NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
added VBN 1 1 12 O
concentration NN 0 1 1 O
which WDT 0 0 12 O
was VBD 1 0 12 O
also RB 0 0 12 O
verified VBN 1 1 1 O
by IN 0 0 12 O
equilibrium NN 0 1 UNK O
solubilization NN 0 0 UNK O
studies NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
fluoroquinolones NNS 0 1 UNK B-Group
for IN 0 0 12 O
urinary JJ 0 1 6 O
tract NN 0 1 6 O
infections NNS 1 1 6 O
: : 0 0 2 O
a DT 0 0 12 O
review NN 0 1 2 O
. . 0 0 12 O

In IN 0 0 2 O
monkeys NNS 1 1 UNK O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
was VBD 1 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
more RBR 0 1 12 O
potent JJ 0 1 UNK O
than IN 0 0 12 O
( ( 0 0 2 O
+ NN 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
in IN 0 0 12 O
decreasing VBG 1 1 1 O
responding VBG 1 0 1 O
whereas NNS 0 0 UNK O
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
was VBD 1 0 12 O
about IN 0 1 12 O
equipotent NN 0 0 UNK O
with IN 0 0 12 O
( ( 0 0 2 O
+ NN 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
. . 0 0 12 O

ALOX9 NNP 0 0 UNK O
was VBD 1 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
down JJ 0 0 12 O
- : 0 0 2 O
regulated VBN 1 1 1 O
gene NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
in IN 0 0 12 O
sensitive JJ 0 1 1 O
cells NNS 1 1 6 O
and CC 0 0 12 O
was VBD 1 0 12 O
expressed VBN 1 0 1 O
at IN 0 0 12 O
low JJ 0 1 1 O
level NN 0 1 1 O
in IN 0 0 12 O
resistant JJ 0 1 3 O
cells NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
hepatoxicity NN 0 0 UNK O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
in IN 0 0 12 O
alcoholic JJ 0 1 12 O
beverages NNS 1 1 1 O
is VBZ 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
its PRP$ 1 0 12 O
congeners NNS 1 1 13 O
and CC 0 0 12 O
acetaldehyde NN 0 1 UNK B-Drug_n
; : 0 0 2 O

In IN 0 0 2 O
contrast NN 0 1 1 O
preliminary JJ 0 1 1 O
results NNS 1 1 1 O
from IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
suggested VBD 1 1 12 O
risperidone RB 0 1 0 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
was VBD 1 0 12 O
superior JJ 0 1 1 O
to TO 0 0 12 O
olanzapine VB 0 1 16 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
against IN 0 0 12 O
positive JJ 0 1 1 O
and CC 0 0 12 O
anxiety NN 0 1 6 O
/ NNP 0 0 2 O
depressive NN 0 0 13 O
symptoms NNS 1 1 6 O
( ( 0 0 2 O
p JJ 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
although IN 0 0 12 O
consistent NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
study NN 0 1 1 O
both DT 0 0 12 O
agents NNS 1 1 1 O
demonstrated VBD 1 0 1 O
similar JJ 0 1 1 O
efficacy NN 0 1 UNK O
on IN 0 0 12 O
measures NNS 1 1 1 O
of IN 0 0 12 O
overall JJ 0 1 1 O
psychopathology NN 0 1 UNK O
. . 0 0 12 O

phenobarbital NN 0 1 16 B-Drug
reduced VBD 1 1 1 O
it PRP 0 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
change NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
FDF NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
at IN 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O

No DT 0 0 2 O
change NN 0 1 1 O
in IN 0 0 12 O
phase NN 0 1 1 O
was VBD 1 0 12 O
detected VBN 1 1 1 O
although IN 0 0 12 O
the DT 0 0 12 O
aerosol JJ 0 1 3 O
particles NNS 1 1 UNK O
appeared VBD 1 1 12 O
to TO 0 0 12 O
contain VB 0 1 UNK O
residual JJ 0 1 1 O
solvent NN 0 1 13 B-Group
. . 0 0 12 O

Morphine NNP 0 1 0 B-Drug
analgesia NN 0 1 6 O
and CC 0 0 12 O
pupil JJ 0 1 1 O
constriction NN 0 1 8 O
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
ADL NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
and CC 0 0 12 O
differed VBD 1 0 UNK O
from IN 0 0 12 O
placebo NN 0 1 13 O
( ( 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Dexamethasone NN 0 1 0 B-Drug
had VBD 1 0 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
in IN 0 0 12 O
isolated JJ 0 1 1 O
single JJ 0 1 12 O
pancreatic JJ 0 1 6 O
acinar NN 0 1 UNK O
cells NNS 1 1 6 O
RR NNP 0 0 13 B-Drug_n
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
InsP9 NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
responses NNS 1 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
constituents NNS 1 1 13 O
of IN 0 0 12 O
alcoholic JJ 0 1 12 O
beverages NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
promotion NN 0 1 UNK O
of IN 0 0 12 O
liver JJ 0 1 6 O
damage NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
therapeutic JJ 0 1 6 O
outcome NN 0 1 1 O
for IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
cell NN 0 1 1 O
acute JJ 0 1 6 O
lymphoblastic JJ 0 1 13 O
leukemia NN 0 1 6 O
( ( 0 0 2 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
) ) 0 0 2 O
remains VBZ 1 0 12 O
poor JJ 0 1 12 O
; : 0 0 2 O

Like IN 0 0 UNK O
ibogaine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NNP 0 1 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
self NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
and CC 0 0 12 O
cocaine NN 0 1 6 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
self NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
and CC 0 0 12 O
nicotine NN 0 1 6 B-Drug
in IN 0 0 12 O
rats NNS 1 1 UNK O
; : 0 0 2 O

We PRP 0 0 12 O
have VBP 0 0 12 O
selected VBN 1 1 UNK O
a DT 0 0 12 O
subclone NN 0 1 UNK O
of IN 0 0 12 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
( ( 0 0 2 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9D9Res CD 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Rate NN 0 1 2 O
of IN 0 0 12 O
achievement NN 0 1 UNK O
of IN 0 0 12 O
target NN 0 1 1 O
BP NNP 0 1 13 O
with IN 0 0 12 O
fixed JJ 0 1 1 O
combination NN 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
was VBD 1 0 12 O
comparable JJ 0 0 1 O
with IN 0 0 12 O
that DT 0 0 12 O
on IN 0 0 12 O
traditional JJ 0 1 UNK O
therapy NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
DCG NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
IV NN 0 1 2 I-Drug_n
and CC 0 0 12 O
L NNP 0 1 2 B-Drug_n
- : 0 0 2 O
CCG NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
upon IN 0 0 12 O
phencyclidine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
PCP NNP 0 1 13 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
induced VBN 1 1 6 O
locomotion NN 0 1 UNK O
and CC 0 0 12 O
behavioral JJ 0 1 13 O
changes NNS 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

Eight CD 0 1 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
were VBD 1 0 12 O
randomized VBN 1 1 6 O
in IN 0 0 12 O
an DT 0 0 12 O
open JJ 0 1 12 O
- : 0 0 2 O
label NN 0 1 13 O
two CD 0 1 12 O
- : 0 0 2 O
way NN 0 0 12 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
to TO 0 0 12 O
receive VB 0 1 1 O
oxycodone NN 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
p.o NN 0 1 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
proposed VBN 1 1 UNK O
methodology NN 0 1 UNK O
for IN 0 0 12 O
deriving VBG 1 1 UNK O
experimental JJ 0 1 UNK O
designs NNS 1 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
applied VBN 1 1 1 O
to TO 0 0 12 O
any DT 0 0 12 O
nonlinear JJ 0 0 UNK O
regression NN 0 1 UNK O
model NN 0 1 UNK O
primary JJ 0 1 1 O
focus NN 0 1 1 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
additive JJ 0 1 16 O
and CC 0 0 12 O
nonadditive JJ 0 0 UNK O
independent JJ 0 1 1 O
joint JJ 0 1 1 O
action NN 0 1 13 O
( ( 0 0 2 O
IJA NNP 0 0 UNK O
) ) 0 0 2 O
models NNS 1 1 UNK O
for IN 0 0 12 O
individual JJ 0 1 1 O
and CC 0 0 12 O
combined JJ 0 1 1 O
exposures NNS 1 1 UNK O
proposed VBN 1 1 UNK O
by IN 0 0 12 O
Barton NNP 0 0 UNK O
Braunberg NNP 0 0 UNK O
and CC 0 0 12 O
Friedman NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Pantoprazole NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
much RB 0 0 12 O
weaker JJR 1 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
's POS 0 1 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
on IN 0 0 12 O
platelet NN 0 1 14 O
reactivity NN 0 1 14 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
current JJ 0 1 1 O
study NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
allograft NN 0 1 8 O
recipients NNS 1 1 UNK O
we PRP 0 0 12 O
used VBD 1 1 12 O
intravenously RB 0 0 14 O
and CC 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
midazolam NN 0 1 16 B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
probe NN 0 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
drugs NNS 1 1 6 O
at IN 0 0 12 O
doses NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
generally RB 0 0 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
have VBP 0 0 12 O
differential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
hepatic NN 0 1 14 O
and CC 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
CYP9A NNP 0 0 UNK O
activities NNS 1 1 1 O
. . 0 0 12 O

Clopidogrel NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
become VB 0 0 12 O
available JJ 0 1 1 O
generically RB 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
US NNP 0 0 2 O
within IN 0 0 1 O
the DT 0 0 12 O
next JJ 0 1 12 O
few JJ 0 1 12 O
months NNS 1 1 12 O
. . 0 0 12 O

Thus RB 0 0 1 O
in IN 0 0 12 O
addition NN 0 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
proposed VBN 1 1 UNK O
specific JJ 0 1 1 O
information NN 0 1 1 O
processing NN 0 1 13 O
functions NNS 1 1 13 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
relational NN 0 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
would MD 0 0 12 O
play VB 0 1 13 O
a DT 0 0 12 O
role NN 0 1 1 O
in IN 0 0 12 O
addressing VBG 1 1 UNK O
information NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
memory NN 0 1 1 O
system NN 0 1 1 O
that WDT 0 0 12 O
in IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
situation NN 0 0 12 O
has VBZ 1 0 12 O
the DT 0 0 12 O
best JJS 0 1 12 O
adaptive JJ 0 1 1 O
value NN 0 1 1 O
. . 0 0 12 O
( ( 0 0 2 O
ABSTRACT NNP 0 1 UNK O
TRUNCATED NNP 0 0 UNK O
AT NNP 0 0 11 O
9 CD 0 0 2 O
WORDS NNP 0 1 UNK O
) ) 0 0 2 O

Imipramine NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
moclobemide NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
clonazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
fluoxetine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
sertraline NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
vehicle NN 0 1 1 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
goal NN 0 1 12 O
of IN 0 0 12 O
this DT 0 0 12 O
review NN 0 1 2 O
was VBD 1 0 12 O
to TO 0 0 12 O
cite VB 0 0 UNK O
primary JJ 0 1 1 O
sources NNS 1 1 1 O
for IN 0 0 12 O
virtually RB 0 0 1 O
all DT 0 0 12 O
research NN 0 1 13 O
specific NN 0 1 1 O
to TO 0 0 12 O
POPs NNP 0 0 UNK O
since IN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
appropriateness NN 0 1 UNK O
of IN 0 0 12 O
inhospital JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
fixed JJ 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
combination NN 0 1 1 O
as IN 1 0 12 O
an DT 0 0 12 O
approach NN 0 1 1 O
allowing VBG 1 1 1 O
to TO 0 0 12 O
achieve VB 0 0 1 O
target NN 0 1 1 O
BP NNP 0 1 13 O
in IN 0 0 12 O
shorter JJR 1 1 UNK O
time NN 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
fewer JJR 1 1 UNK O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
diminishing VBG 1 1 UNK O
concealed JJ 0 1 UNK O
inefficacy NN 0 0 UNK O
of IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Ectopic NNP 0 1 UNK O
expression NN 0 1 1 O
of IN 0 0 12 O
ALOX9 NNP 0 0 UNK O
reduced VBD 1 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
in IN 0 0 12 O
H9 NNP 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
paper NN 0 1 13 O
attempts VBZ 1 1 12 O
to TO 0 0 12 O
provide VB 0 1 1 O
a DT 0 0 12 O
basis NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
understanding NN 0 1 1 O
and CC 0 0 12 O
identifications NNS 1 1 UNK O
of IN 0 0 12 O
important JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Questioning VBG 0 1 UNK O
revealed VBD 1 1 12 O
the DT 0 0 12 O
child NN 0 1 12 O
was VBD 1 0 12 O
taking VBG 1 0 12 O
Infacol NNP 0 0 UNK B-Brand
drops NNS 1 1 3 O
before IN 0 1 12 O
feeds NNS 1 1 1 O
while IN 0 0 12 O
on IN 0 0 12 O
levothyroxine NN 0 1 0 B-Drug
. . 0 0 12 O

Interaction NN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
between IN 0 0 12 O
neurotensin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
enkephalins VBZ 0 1 UNK B-Drug_n
or CC 0 0 12 O
tuftsin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
The DT 0 0 2 O
two CD 0 1 12 O
treatment NN 0 1 6 O
groups NNS 1 1 1 O
were VBD 1 0 12 O
well RB 0 1 12 O
matched VBN 1 1 1 O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
patient VB 0 1 6 O
demographics NNS 1 1 UNK O
NHL NNP 0 1 UNK O
characteristics NNS 1 1 UNK O
HIV NNP 0 1 6 O
status NN 0 1 1 O
and CC 0 0 12 O
treatment NN 0 1 6 O
i.e. VBP 0 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
cycles NNS 1 1 1 O
and CC 0 0 12 O
chemotherapy NN 0 1 6 O
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
authors NNS 1 1 UNK O
examined VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
cyclooxygenase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
COX NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
inhibitor NN 0 1 14 O
rofecoxib NN 0 1 16 B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Results NNS 0 1 2 O
showed VBD 1 1 12 O
that IN 0 0 12 O
GSLS NNP 0 1 UNK B-Drug_n
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
antibody NN 0 1 14 O
level NN 0 1 1 O
against IN 0 0 12 O
ND NNP 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
of IN 0 0 12 O
chickens NNS 1 1 UNK O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
didanosine NN 0 1 16 B-Drug
significantly RB 0 0 1 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
indinavir VB 0 1 16 B-Drug
but CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unclear JJ 0 0 1 O
how WRB 0 0 12 O
soon RB 0 0 12 O
after IN 0 0 12 O
didanosine JJ 0 1 16 B-Drug
administration NN 0 1 1 O
indinavir NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
given VBN 1 1 12 O
safely RB 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
our PRP$ 0 0 12 O
laboratory NN 0 1 1 O
preliminary JJ 0 1 1 O
whole JJ 0 1 12 O
- : 0 0 2 O
cell NN 0 1 1 O
tight JJ 0 1 3 O
seal JJ 0 1 UNK O
recordings NNS 1 0 1 O
of IN 0 0 12 O
rat NN 0 1 13 O
spinal JJ 0 1 6 O
substantia NN 0 0 UNK O
gelatinosa NN 0 0 UNK O
neurons NNS 1 1 UNK O
including VBG 1 1 1 O
biocytin NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
patch NN 0 1 3 O
pipette NN 0 1 UNK O
yielded VBD 1 0 1 O
a DT 0 0 12 O
significantly RB 0 0 1 O
smaller JJR 1 1 3 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
neurons NNS 1 1 UNK O
hyperpolarized VBN 0 0 UNK O
by IN 0 0 12 O
selective JJ 0 1 13 B-Group
opioid NN 0 1 13 I-Group
agonists NNS 1 1 UNK I-Group
compared VBN 1 1 1 O
with IN 0 0 12 O
recordings NNS 1 0 1 O
without IN 0 0 12 O
biocytin NN 0 1 UNK O
. . 0 0 12 O

aeruginosa NN 0 0 14 O
strains NNS 1 1 6 O
isolated VBN 1 1 1 O
from IN 0 0 12 O
various JJ 0 1 1 O
hospitals NNS 1 1 1 O
were VBD 1 0 12 O
tested VBN 1 1 1 O
for IN 0 0 12 O
their PRP$ 0 0 12 O
resistances NNS 1 1 UNK O
against IN 0 0 12 O
many JJ 0 0 12 O
antibiotics NNS 1 1 6 B-Group
most JJS 0 0 12 O
of IN 0 0 12 O
which WDT 0 0 12 O
are VBP 1 0 12 O
applied VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

When WRB 0 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
a DT 0 0 12 O
pharmacological JJ 0 1 14 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
potentiating VBG 1 0 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
depression NN 0 1 6 O
produced VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clearance NN 0 1 16 O
by IN 0 0 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxytolbutamide NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
carboxytolbutamide NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
groups NNS 1 1 1 O
( ( 0 0 2 O
ie NN 0 0 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
to TO 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
that WDT 0 0 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
per IN 0 0 1 O
day NN 0 1 12 O
and CC 0 0 12 O
from IN 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
to TO 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
that WDT 0 0 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
per IN 0 0 1 O
day NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
muscle NN 0 1 6 O
biopsy NN 0 1 6 O
revealed VBD 1 1 12 O
necrotizing VBG 0 1 8 O
myopathy JJ 0 1 8 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
toxin NN 0 1 14 O
. . 0 0 12 O

Combined VBN 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
and CC 0 0 12 O
TAM NNP 0 1 UNK B-Drug_n
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
apoptosis NN 0 1 UNK O
assessed VBN 1 1 1 O
using VBG 1 1 1 O
morphological JJ 0 1 13 O
markers NNS 1 1 1 O
that WDT 0 0 12 O
identify VBP 0 0 1 O
chromatin NN 0 1 UNK O
and CC 0 0 12 O
nuclear JJ 0 1 1 O
matrix NN 0 1 1 O
protein NN 0 1 14 O
condensation NN 0 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
hour NN 0 1 12 O
after IN 0 0 12 O
starting VBG 1 1 12 O
the DT 0 0 12 O
oxycodone NN 0 1 0 B-Drug
or CC 0 0 12 O
levofloxacin $ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
p.o NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
minocycline NN 0 1 13 B-Drug
combined VBN 1 1 1 O
with IN 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
against IN 0 0 12 O
clinical JJ 0 1 6 O
isolates NNS 0 1 14 O
of IN 0 0 12 O
methicillin NN 0 1 14 B-Drug
- : 0 0 2 O
resistant JJ 0 1 3 O
Staphylococcus NNP 0 1 14 O
aureus NN 0 0 14 O
. . 0 0 12 O

the DT 0 0 12 O
remainder NN 0 0 1 O
were VBD 1 0 12 O
of IN 0 0 12 O
uncertain JJ 0 1 1 O
cause NN 0 1 12 O
. . 0 0 12 O

Jacalin NNP 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
a DT 0 0 12 O
D NNP 0 1 2 O
- : 0 0 2 O
Gal NNP 0 1 UNK O
binding VBG 1 1 1 O
lectin NN 0 1 UNK O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
useful JJ 0 1 UNK O
tool NN 0 1 13 O
for IN 0 0 12 O
studying VBG 1 1 UNK O
of IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
secretory NN 0 1 UNK O
IgA NNP 0 1 14 O
. . 0 0 12 O

9 CD 0 0 2 O
mg JJ 0 1 0 O
result NN 0 1 1 O
in IN 0 0 12 O
incomplete JJ 0 1 1 O
depletion NN 0 1 1 O
which WDT 0 0 12 O
becomes VBZ 1 0 12 O
complete JJ 0 1 1 O
after IN 0 0 12 O
a DT 0 0 12 O
second JJ 0 1 12 O
additional JJ 0 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

Rhabdomyolysis NNP 0 1 UNK O
secondary JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
simvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
. . 0 0 12 O

ulcerans JJ 0 0 UNK O
infection NN 0 1 6 O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
Macrolide NNP 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
inhibit VBP 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
i.e. FW 0 1 1 O
atorvastatin NN 0 1 0 B-Drug
cerivastatin NN 0 1 UNK B-Drug
lovastatin NN 0 1 13 B-Drug
simvastatin NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Chapter NN 0 1 UNK O
9 CD 0 0 2 O
considers NNS 0 1 1 O
the DT 0 0 12 O
mode NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
including VBG 1 1 1 O
ovulation NN 0 1 13 O
prevention NN 0 1 1 O
; : 0 0 2 O

and CC 0 0 12 O
glutamate NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
e.w NN 0 0 UNK O
. . 0 0 12 O
) ) 0 0 2 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
with IN 0 0 12 O
different JJ 0 1 1 O
anti NNS 0 0 3 B-Group
- : 0 0 2 O
cancer NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
is VBZ 1 0 12 O
antagonistic JJ 0 1 UNK O
in IN 0 0 12 O
breast NN 0 1 6 O
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
other JJ 0 0 12 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

OBJECTIVES NNP 0 1 UNK O
. . 0 0 12 O

Primary NNP 0 1 2 O
and CC 0 0 12 O
secondary JJ 0 1 1 O
magnesium NN 0 1 14 B-Drug
deficiencies NNS 1 1 13 O
constitute VBP 0 0 UNK O
the DT 0 0 12 O
sole JJ 0 1 UNK O
indication NN 0 1 1 O
of IN 0 0 12 O
physiological JJ 0 1 13 O
oral JJ 0 1 6 O
magnesium NN 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

aeruginosa NN 0 0 14 O
serotype NN 0 1 UNK O
O9 NNP 0 0 UNK O
strains NNS 1 1 6 O
but CC 0 0 12 O
not RB 0 1 12 O
S NNP 0 1 2 O
. . 0 0 12 O

Antitumor NNP 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
CRM9 NNP 0 0 UNK B-Drug_n
a DT 0 0 12 O
specific JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
in IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
cell NN 0 1 1 O
acute JJ 0 1 6 O
lymphoblastic JJ 0 1 13 O
leukemia NN 0 1 6 O
. . 0 0 12 O

Intermediate JJ 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
( ( 0 0 2 O
+ NNP 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
or CC 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
produced VBD 1 0 1 O
transient JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
FI NNP 0 1 UNK O
responding VBG 1 0 1 O
in IN 0 0 12 O
monkeys NNS 1 1 UNK O
and CC 0 0 12 O
sustained JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
FI NNP 0 1 UNK O
responding VBG 1 0 1 O
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
; : 0 0 2 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
on IN 0 0 12 O
voltage NN 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
channel NN 0 1 1 O
subtypes NNS 0 1 UNK O
in IN 0 0 12 O
bovine NN 0 1 13 O
chromaffin NN 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

antinociception NN 0 0 UNK O
was VBD 1 0 12 O
assessed VBN 1 1 1 O
with IN 0 0 12 O
hot JJ 0 1 3 O
- : 0 0 2 O
plate NN 0 1 3 O
test NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
locomotor NN 0 0 UNK O
exploratory NN 0 0 1 O
activities NNS 1 1 1 O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
with IN 0 0 12 O
holed JJ 0 1 UNK O
open JJ 0 1 12 O
field NN 0 1 1 O
test NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
potent JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme VBZ 0 1 14 O
- : 0 0 2 O
inducer NN 0 1 UNK O
phenytoin NN 0 1 16 B-Drug
did VBD 1 0 12 O
indeed RB 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
marked JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
quetiapine JJ 0 1 16 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
clearance NN 0 1 16 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
DSM NNP 0 0 UNK O
- : 0 0 2 O
IV NNP 0 1 2 O
- : 0 0 2 O
diagnosed VBD 1 1 6 O
schizophrenia JJ 0 1 13 O
schizoaffective JJ 0 0 13 O
disorder NN 0 1 6 O
or CC 0 0 12 O
bipolar JJ 0 1 6 O
disorder NN 0 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
are VBP 1 0 12 O
negatively RB 0 0 1 O
coupled VBN 1 1 UNK O
to TO 0 0 12 O
three CD 0 1 12 O
types NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
channels NNS 1 1 13 O
in IN 0 0 12 O
bovine NN 0 1 13 O
chromaffin NN 0 0 UNK O
cell NN 0 1 1 O
including VBG 1 1 1 O
an DT 0 0 12 O
omega JJ 0 1 16 B-Drug_n
- : 0 0 2 O
conotoxin NN 0 1 UNK I-Drug_n
GVIA NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
sensitive JJ 0 1 1 O
( ( 0 0 2 O
N NNP 0 1 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
channel VBZ 0 1 1 O
an DT 0 0 12 O
omega JJ 0 1 16 B-Drug_n
- : 0 0 2 O
agatoxin NN 0 0 UNK I-Drug_n
IVA NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
sensitive JJ 0 1 1 O
( ( 0 0 2 O
P NNP 0 1 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
channel NN 0 1 1 O
and CC 0 0 12 O
nimodipine JJ 0 1 16 B-Drug
/ NNP 0 0 2 O
omega MD 0 1 16 B-Drug_n
- : 0 0 2 O
conotoxin NN 0 1 UNK I-Drug_n
GVIA NNP 0 0 UNK I-Drug_n
/ NNP 0 0 2 O
omega SYM 0 1 16 B-Drug_n
- : 0 0 2 O
agatoxin NN 0 0 UNK I-Drug_n
VIA NNP 0 0 11 I-Drug_n
- : 0 0 2 O
resistant NN 0 1 3 O
( ( 0 0 2 O
presumptive JJ 0 1 1 O
Q NNP 0 0 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
channel NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
predominantly RB 0 0 1 O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
Dihydroxycholecalciferol NN 0 1 UNK I-Drug
D9 NNP 0 1 UNK I-Drug
( ( 0 0 2 O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
) ) 0 0 2 O
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
D NNP 0 1 2 I-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
cell NN 0 1 1 O
growth NN 0 1 1 O
both DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
and CC 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
: : 0 0 2 O
( ( 0 0 2 O
a DT 0 0 12 O
) ) 0 0 2 O
the DT 0 0 12 O
maximal JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
resveratrol NN 0 1 UNK B-Drug_n
on IN 0 0 12 O
resistance NN 0 1 1 O
arteries NNS 1 1 6 O
from IN 0 0 12 O
lean JJ 0 0 13 O
and CC 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
effected VBN 1 1 UNK O
by IN 0 0 12 O
endothelial JJ 0 1 13 O
dysfunction NN 0 1 6 O
and CC 0 0 12 O
( ( 0 0 2 O
b NN 0 0 16 O
) ) 0 0 2 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
resveratrol NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
lean JJ 0 0 13 O
animals NNS 1 1 12 O
( ( 0 0 2 O
where WRB 0 0 12 O
endothelial JJ 0 1 13 O
function NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
impaired JJ 0 1 6 O
) ) 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
are VBP 1 0 12 O
mediated VBN 1 1 13 O
via IN 0 0 1 O
NO NNP 0 1 11 O
. . 0 0 12 O

Both DT 0 0 2 O
ibogaine NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
block NN 0 1 3 O
morphine NN 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
and CC 0 0 12 O
nicotine JJ 0 1 6 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
dopamine NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
nucleus JJ 0 1 UNK O
accumbens NNS 0 0 UNK O
; : 0 0 2 O

The DT 0 0 2 O
rats NNS 1 1 UNK O
treated VBD 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
highest JJS 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
TML NNP 0 0 UNK B-Drug_n
manifested VBD 1 1 UNK O
significantly RB 0 0 1 O
longer JJR 1 1 12 O
latencies NNS 1 1 8 O
to TO 0 0 12 O
lose VB 0 0 12 O
the DT 0 0 12 O
righting NN 0 1 UNK O
reflex NN 0 1 6 O
and CC 0 0 12 O
shorter JJR 1 1 UNK O
durations NNS 1 1 1 O
of IN 0 0 12 O
sleep NN 0 1 12 O
than IN 0 0 12 O
did VBD 1 0 12 O
controls NNS 1 1 UNK O
. . 0 0 12 O

AAV9 NNP 0 0 UNK B-Drug_n
containing VBG 1 1 1 O
cDNA NN 0 1 UNK O
encoding VBG 1 1 UNK O
enhanced VBD 1 1 1 O
green JJ 0 1 3 O
fluorescent NN 0 1 UNK O
protein NN 0 1 14 O
( ( 0 0 2 O
GFP NNP 0 1 UNK O
) ) 0 0 2 O
under IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
chicken JJ 0 1 3 O
- : 0 0 2 O
actin NN 0 1 14 O
promoter NN 0 1 UNK O
was VBD 1 0 12 O
delivered VBN 1 1 12 O
by IN 0 0 12 O
intravitreal NN 0 0 UNK O
injection NN 0 1 3 O
to TO 0 0 12 O
adult VB 0 1 12 O
mice NN 1 1 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
enzymes NNS 1 1 14 O
including VBG 1 1 1 O
collagenase NN 0 1 16 B-Drug_n
hyaluronan NN 0 1 UNK B-Drug_n
lyase NN 0 1 UNK I-Drug_n
heparinase NN 0 1 UNK B-Drug_n
III NNP 0 1 2 I-Drug_n
or CC 0 0 12 O
chondroitin VB 0 1 13 B-Drug_n
ABC NNP 0 1 UNK I-Drug_n
lyase NN 0 1 UNK I-Drug_n
. . 0 0 12 O

Injection NN 0 1 7 O
of IN 0 0 12 O
estradiol $ 0 1 13 B-Drug
9 CD 0 0 2 O
min NN 0 1 16 O
before IN 0 1 12 O
a DT 0 0 12 O
nonlethal JJ 0 0 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
changed VBD 1 1 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
sex NN 0 1 13 O
steroid VBD 0 1 6 O
hormone JJ 0 1 6 O
response NN 0 1 1 O
of IN 0 0 12 O
male NN 0 1 12 O
rats NNS 1 1 UNK O
to TO 0 0 12 O
endotoxin VB 0 1 UNK B-Drug_n
. . 0 0 12 O

Pretreatment NN 0 1 UNK O
of IN 0 0 12 O
rats NNS 1 1 UNK O
with IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
ip NN 0 1 13 O
) ) 0 0 2 O
or CC 0 0 12 O
Vitamin NNP 0 1 2 B-Drug
E NNP 0 0 2 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg FW 0 1 18 O
per IN 0 0 1 O
day NN 0 1 12 O
ig NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
on IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
day NN 0 1 12 O
) ) 0 0 2 O
provided VBD 1 1 1 O
significant JJ 0 1 1 O
protection NN 0 1 1 O
against IN 0 0 12 O
the DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
TBARS NNP 0 1 UNK O
levels NNS 1 1 1 O
in IN 0 0 12 O
cerebral JJ 0 0 6 O
and CC 0 0 12 O
hepatic JJ 0 1 14 O
tissues NNS 1 1 6 O
induced VBN 1 1 6 O
by IN 0 0 12 O
single JJ 0 1 12 O
high JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
oral JJ 0 1 6 O
cypermethrin NN 0 1 UNK B-Drug
administration NN 0 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
h NN 0 1 16 O
. . 0 0 12 O

This DT 0 0 2 O
cluster NN 0 1 13 O
of IN 0 0 12 O
metabolic JJ 0 1 6 O
abnormalities NNS 1 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
termed VBN 1 1 UNK O
the DT 0 0 12 O
insulin NN 0 1 14 O
resistance NN 0 1 1 O
or CC 0 0 12 O
cardiovascular JJ 0 1 6 O
dysmetabolic JJ 0 0 13 O
syndrome NN 0 1 6 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
ERMBT NNP 0 0 UNK O
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
are VBP 1 0 12 O
equipotent JJ 0 0 UNK O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
ERMBT NNP 0 0 UNK O
. . 0 0 12 O

Some DT 0 0 2 O
preliminary JJ 0 1 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
calcium NN 0 1 14 B-Group
blockers NNS 1 0 6 I-Group
also RB 0 0 12 O
increase VBP 0 1 1 O
generation NN 0 1 UNK O
of IN 0 0 12 O
vasodilator NN 0 1 14 O
and CC 0 0 12 O
platelet NN 0 1 14 O
antiaggregant NN 0 0 UNK O
prostacyclin NN 0 1 UNK O
which WDT 0 0 12 O
could MD 0 0 12 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
decrease VB 0 1 1 O
in IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
. . 0 0 12 O

Furthermore IN 0 0 1 O
we PRP 0 0 12 O
present VBP 0 1 1 O
a DT 0 0 12 O
case NN 0 1 12 O
report NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
a DT 0 0 12 O
second JJ 0 1 12 O
Herceptin NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
following VBG 1 1 1 O
lapatinib NN 0 1 13 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
marked JJ 0 1 1 O
shrinkage NN 0 1 UNK O
of IN 0 0 12 O
multiple JJ 0 1 1 O
metastatic JJ 0 1 6 O
tumors NNS 1 1 6 O
in IN 0 0 12 O
HER9 NNP 0 0 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
synergistic JJ 0 1 UNK O
combinations NNS 1 1 1 O
celecoxib VBP 0 1 16 O
- : 0 0 2 O
induced JJ 0 1 6 O
abrogation NN 0 0 UNK O
of IN 0 0 12 O
G9 NNP 0 0 13 O
/ NNP 0 0 2 O
M NNP 0 1 2 O
arrest NN 0 1 12 O
was VBD 1 0 12 O
not RB 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
apoptosis NN 0 1 UNK O
but CC 0 0 12 O
permanent JJ 0 1 1 O
arrest NN 0 1 12 O
in IN 0 0 12 O
G9 NNP 0 0 13 O
phase NN 0 1 1 O
. . 0 0 12 O

bone NN 0 1 6 O
density NN 0 1 1 O
; : 0 0 2 O

Chapter NN 0 1 UNK O
9 CD 0 0 2 O
focuses NNS 1 1 UNK O
on IN 0 0 12 O
metabolic JJ 0 1 6 O
effects NNS 1 1 1 O
specifically RB 0 0 1 O
lipid JJ 0 1 14 O
metabolism NN 0 1 16 O
carbohydrate NN 0 1 13 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
diabetes VBZ 0 1 6 O
coagulation NN 0 1 14 O
factors NNS 1 1 1 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
gentamycin NN 0 1 14 B-Drug
and CC 0 0 12 O
atracurium NN 0 1 13 B-Drug
in IN 0 0 12 O
anaesthetised JJ 0 1 UNK O
horses NNS 1 1 UNK O
. . 0 0 12 O

MEASUREMENTS NNP 0 1 11 O
AND CC 0 0 11 O
MAIN NNP 0 1 11 O
RESULTS NNP 0 1 11 O
: : 0 0 2 O
In IN 0 0 2 O
December NNP 0 1 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
following NN 0 1 1 O
was VBD 1 0 12 O
gathered VBN 1 0 UNK O
for IN 0 0 12 O
every DT 0 0 12 O
MAC NNP 0 1 UNK O
with IN 0 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
one CD 0 1 12 O
drug NN 0 1 1 O
treatment NN 0 1 6 O
: : 0 0 2 O
age NN 0 1 12 O
sex NN 0 1 13 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
intrinsic JJ 0 1 1 O
value NN 0 1 1 O
drugs NNS 1 1 6 O
prescribed VBD 1 1 1 O
daily RB 0 1 12 O
dose JJ 0 1 6 O
and CC 0 0 12 O
pharmacological JJ 0 1 14 O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
PI NNP 0 1 UNK O
) ) 0 0 2 O
classified VBD 1 1 13 O
( ( 0 0 2 O
using VBG 1 1 1 O
the DT 0 0 12 O
scale NN 0 1 1 O
of IN 0 0 12 O
Hansten NNP 0 0 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
into IN 0 0 12 O
light NN 0 1 3 O
and CC 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
preclinical JJ 0 1 UNK O
combination NN 0 1 1 O
of IN 0 0 12 O
lenalidomide NN 0 1 UNK B-Drug
with IN 0 0 12 O
the DT 0 0 12 O
mTOR NN 0 1 UNK O
inhibitor NN 0 1 14 O
CCI NNP 0 1 UNK B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
has VBZ 1 0 12 O
displayed VBN 1 1 1 O
synergy NN 0 0 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
represents VBZ 1 1 1 O
a DT 0 0 12 O
novel JJ 0 1 13 O
combination NN 0 1 1 O
in IN 0 0 12 O
MM NNP 0 0 13 O
. . 0 0 12 O

About IN 0 1 2 O
three CD 0 1 12 O
weeks NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
admission VB 0 1 1 O
the DT 0 0 12 O
patient NN 0 1 6 O
was VBD 1 0 12 O
started VBN 1 1 12 O
on IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
for IN 0 0 12 O
sinusitis NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
does VBZ 1 0 12 O
not RB 0 1 12 O
produce VB 0 0 1 O
these DT 0 0 12 O
effects NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
D9 NNP 0 1 UNK O
receptors NNS 1 1 13 O
are VBP 1 0 12 O
coupled VBN 1 1 UNK O
to TO 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
arc NN 0 0 13 O
gene NN 0 1 13 O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
functional JJ 0 1 1 O
or CC 0 0 12 O
structural JJ 0 1 1 O
alterations NNS 1 1 1 O
underlying VBG 1 0 1 O
neural JJ 0 1 6 O
plasticity NN 0 1 UNK O
triggered VBN 1 1 1 O
by IN 0 0 12 O
METH NNP 0 1 UNK B-Drug
. . 0 0 12 O

More RBR 0 1 UNK O
specific JJ 0 1 1 O
applications NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
assay NN 0 1 14 O
of IN 0 0 12 O
thio JJ 0 1 UNK O
compounds NNS 1 1 13 O
in IN 0 0 12 O
urine JJ 0 1 6 O
allow JJ 0 1 1 O
development NN 0 1 1 O
of IN 0 0 12 O
selective JJ 0 1 13 O
methods NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
useful JJ 0 1 UNK O
for IN 0 0 12 O
biological JJ 0 1 13 O
monitoring NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
spite NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
kidney NN 0 1 6 O
function NN 0 1 1 O
the DT 0 0 12 O
value NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
rate NN 0 1 1 O
constant NN 0 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
( ( 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
/ NNP 0 0 2 O
h NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

Spermine NN 0 1 UNK B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
extent NN 0 1 1 O
spermidine NN 0 1 UNK B-Drug_n
enhanced VBD 1 1 1 O
the DT 0 0 12 O
translocating VBG 1 0 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
oleate NN 0 1 UNK O
and CC 0 0 12 O
increased VBD 1 1 1 O
its PRP$ 1 0 12 O
effectiveness NN 0 1 UNK O
in IN 0 0 12 O
transferring VBG 1 1 13 O
the DT 0 0 12 O
phosphohydrolase NN 0 0 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
soluble JJ 0 1 16 O
to TO 0 0 12 O
the DT 0 0 12 O
microsomal JJ 0 1 UNK O
fraction NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
last JJ 0 1 12 O
9 CD 0 0 2 O
chapters NNS 1 1 UNK O
cover JJ 0 1 3 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
common JJ 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
breast VBP 0 1 6 O
feeding NN 0 1 3 O
and CC 0 0 12 O
effective JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
POCs NNP 0 1 UNK B-Group
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
Interaction NNP 0 1 2 O
between IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
and CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
or CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
. . 0 0 12 O

RESULTS NNP 0 1 11 O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
the DT 0 0 12 O
modified JJ 0 1 16 O
histidine NN 0 1 13 O
residues NNS 1 1 UNK O
on IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
are VBP 1 0 12 O
critical JJ 0 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
cytotoxic NN 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
users NNS 1 1 UNK O
who WP 0 0 12 O
initiated VBD 1 1 1 O
citalopram JJ 0 1 16 B-Drug
fluoxetine JJ 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
amitriptyline NN 0 1 16 B-Drug
or CC 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
had VBD 1 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
hospitalization NN 0 1 6 O
for IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Ibogaine NNP 0 1 UNK B-Drug_n
attenuates VBZ 1 1 UNK O
but CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
potentiates VBZ 1 0 UNK O
the DT 0 0 12 O
acute JJ 0 1 6 O
locomotor NN 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
; : 0 0 2 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
RAS NNP 0 1 UNK O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
with IN 0 0 12 O
nucleophosmin JJ 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
antisense NN 0 1 UNK O
oligomer NN 0 0 UNK O
significantly RB 0 0 1 O
potentiated VBD 1 0 UNK O
the DT 0 0 12 O
apoptosis NN 0 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
serum JJ 0 1 14 O
deprivation NN 0 1 13 O
. . 0 0 12 O

BACKGROUND NNP 0 1 UNK O
. . 0 0 12 O

Conversely RB 0 0 UNK O
at IN 0 0 12 O
exposure NN 0 1 1 O
levels NNS 1 1 1 O
close RB 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
`` `` 0 0 13 O
limit NN 0 1 1 O
values NNS 1 1 1 O
'' '' 0 0 13 O

Benzodiazepines NNS 0 1 UNK B-Group
were VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
mice VB 0 1 UNK O
9 CD 0 0 2 O
min NNS 0 1 16 O
before IN 0 1 12 O
applying VBG 1 1 1 O
the DT 0 0 12 O
analgesic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

These DT 0 0 1 O
usually RB 0 1 12 O
clear VBP 0 1 12 O
within IN 0 0 1 O
a DT 0 0 12 O
week NN 0 1 12 O
leaving VBG 1 0 12 O
only RB 0 1 12 O
the DT 0 0 12 O
`` `` 0 0 13 O
drug NN 0 1 1 O
hunger NN 0 1 12 O
'' '' 0 0 13 O

Other JJ 0 0 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
level NN 0 1 1 O
of IN 0 0 12 O
evidence NN 0 1 1 O
were VBD 1 0 12 O
less JJR 0 1 12 O
convincing NN 0 0 UNK O
. . 0 0 12 O

Atropine NNP 0 1 0 B-Drug
either CC 0 1 12 O
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
produced VBN 1 0 1 O
approximately RB 0 1 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
component NN 0 1 1 O
P9 NNP 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
lines NNS 1 1 3 O
it PRP 0 0 12 O
abrogates VBZ 1 0 UNK O
the DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
G9 NNP 0 0 13 O
/ NNP 0 0 2 O
M NNP 0 1 2 O
arrest IN 0 1 12 O
enhancing VBG 1 1 1 O
pre JJ 0 1 1 O
- : 0 0 2 O
mature NN 0 1 12 O
entry NN 0 1 1 O
into IN 0 0 12 O
mitosis NN 0 1 UNK O
with IN 0 0 12 O
damaged VBN 1 1 3 O
DNA NNP 0 1 1 O
thus RB 0 0 1 O
increasing VBG 1 1 1 O
apoptosis NN 0 1 UNK O
and CC 0 0 12 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
synergism NN 0 1 UNK O
. . 0 0 12 O

Piperine NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
CAS NNP 0 0 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
an DT 0 0 12 O
alkaloid NN 0 1 UNK O
obtained VBN 1 1 1 O
from IN 0 0 12 O
Piper NNP 0 1 UNK O
nigrum NN 0 0 UNK O
and CC 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

In IN 0 0 2 O
seven CD 0 1 12 O
experiments NNS 1 1 UNK O
reactions NNS 1 1 1 O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
and CC 0 0 12 O
oxytocin VB 0 1 13 B-Drug
were VBD 1 0 12 O
PGF9alpha NNP 0 0 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
enantiomer NN 0 1 UNK O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
failed VBD 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
FI NNP 0 1 UNK O
responding VBG 1 0 1 O
significantly RB 0 0 1 O
in IN 0 0 12 O
either CC 0 1 12 O
species NNS 1 1 1 O
; : 0 0 2 O

Tumors NNS 0 1 UNK O
of IN 0 0 12 O
more JJR 0 1 12 O
malignant JJ 0 1 6 O
phenotype NN 0 1 UNK O
were VBD 1 0 12 O
demonstrated VBN 1 0 1 O
only RB 0 1 12 O
in IN 0 0 12 O
genetically RB 0 0 UNK O
predisposed VBN 1 1 UNK O
mice NN 1 1 UNK O
( ( 0 0 2 O
C9BL NNP 0 0 UNK O
/ VBZ 0 0 2 O
9N CD 0 0 UNK O
X NNP 0 0 2 O
C9H NNP 0 0 UNK O
/ NNP 0 0 2 O
HeN NNP 0 0 UNK O
F9 NNP 0 1 UNK O
) ) 0 0 2 O
that WDT 0 0 12 O
received VBD 1 1 12 O
one CD 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
carcinogen NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
cecectomized VBN 0 0 UNK O
and CC 0 0 12 O
control VB 0 1 1 O
rats NNS 1 1 UNK O
in IN 0 0 12 O
basal NN 0 1 6 O
small JJ 0 1 12 O
intestinal JJ 0 1 13 O
transits NNS 1 1 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
dmPGE9 NN 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p.o NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
- : 0 0 2 O
induced JJ 0 1 6 O
enhancements NNS 1 1 UNK O
. . 0 0 12 O

Molecular JJ 0 1 UNK O
basis NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
for IN 0 0 12 O
yeast NN 0 1 6 O
and CC 0 0 12 O
filipin NN 0 1 UNK B-Drug_n
for IN 0 0 12 O
animal JJ 0 1 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

NSCLC NNP 0 1 UNK O
cell NN 0 1 1 O
lines NNS 1 1 3 O
with IN 0 0 12 O
EGFR NNP 0 1 UNK O
T9M NNP 0 0 UNK O
mutation NN 0 1 13 O
and CC 0 0 12 O
K NNP 0 1 2 O
- : 0 0 2 O
ras NN 1 1 UNK O
mutation NN 0 1 13 O
were VBD 1 0 12 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
either DT 0 1 12 O
sunitinib NN 0 1 13 B-Drug
or CC 0 0 12 O
docetaxel NN 0 1 13 B-Drug
or CC 0 0 12 O
both DT 0 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
various JJ 0 1 1 O
sequential JJ 0 1 1 O
administrations NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
sensitivity NN 0 1 1 O
cell NN 0 1 1 O
cycle NN 0 1 1 O
apoptosis NN 0 1 UNK O
and CC 0 0 12 O
DNA NNP 0 1 1 O
damage NN 0 1 1 O
of IN 0 0 12 O
five CD 0 1 12 O
different JJ 0 1 1 O
cancer NN 0 1 6 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
( ( 0 0 2 O
HeLa NNP 0 1 UNK O
HCT9 NNP 0 0 UNK O
HepG9 NNP 0 0 UNK O
MCF9 NNP 0 0 UNK O
and CC 0 0 12 O
U9 NNP 0 0 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
FU NNP 0 1 11 I-Drug
cisplatin NN 0 1 14 B-Drug
doxorubicin NN 0 1 13 B-Drug
and CC 0 0 12 O
etoposide JJ 0 1 13 B-Drug
celecoxib NN 0 1 16 B-Drug
following VBG 1 1 1 O
different JJ 0 1 1 O
incubation NN 0 0 UNK O
schedules NNS 1 1 UNK O
were VBD 1 0 12 O
analyzed VBN 1 1 13 O
. . 0 0 12 O

Emergence NN 0 1 UNK O
agitation NN 0 1 1 O
( ( 0 0 2 O
EA NNP 0 1 UNK O
) ) 0 0 2 O
can MD 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
distressing JJ 0 1 UNK O
side NN 0 1 3 O
effect NN 0 1 1 O
of IN 0 0 12 O
pediatric JJ 0 1 6 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

descending VBG 1 1 3 O
epsilon NN 0 1 UNK O
and CC 0 0 12 O
mu NN 0 1 13 O
systems NNS 1 1 1 O
for IN 0 0 12 O
beta JJ 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
respectively RB 0 0 1 O
are VBP 1 0 12 O
proposed VBN 1 1 UNK O
. . 0 0 12 O

Blood NN 0 1 2 O
samples NNS 1 1 UNK O
were VBD 1 0 12 O
drawn VBN 1 0 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
Cmax NNP 0 1 UNK O
tmax NN 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
determinations NNS 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
evidence NN 0 1 1 O
for IN 0 0 12 O
longitudinal JJ 0 1 13 O
stability NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
during IN 0 0 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
. . 0 0 12 O

Information NN 0 1 2 O
on IN 0 0 12 O
precautions NNS 1 1 1 O
and CC 0 0 12 O
contraindications NNS 1 1 13 O
indications NNS 1 1 1 O
use VBP 0 1 1 O
instructions NNS 1 1 1 O
and CC 0 0 12 O
instructions NNS 1 1 1 O
for IN 0 0 12 O
appropriate JJ 0 1 1 O
actions NNS 1 1 UNK O
after IN 0 0 12 O
missing VBG 1 1 12 O
a DT 0 0 12 O
pill NN 0 1 6 O
is VBZ 1 0 12 O
appended VBN 1 1 UNK O
. . 0 0 12 O

Acute NNP 0 1 7 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
failed VBN 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
in IN 0 0 12 O
either CC 0 1 12 O
procedure VB 0 1 1 O
even RB 0 0 12 O
when WRB 0 0 12 O
tested VBN 1 1 1 O
up RP 0 0 12 O
to TO 0 0 12 O
doses NNS 1 1 6 O
that WDT 0 0 12 O
produced VBD 1 0 1 O
pharmacological JJ 0 1 14 O
effects NNS 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
steps NNS 1 1 12 O
physicians NNS 1 1 6 O
can MD 0 0 12 O
take VB 0 1 12 O
to TO 0 0 12 O
ensure VB 0 1 1 O
that IN 0 0 12 O
their PRP$ 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
not RB 0 1 12 O
being VBG 1 0 12 O
undertreated VBN 0 0 UNK O
. . 0 0 12 O

Clinical JJ 0 1 7 O
implications NNS 1 0 UNK O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
interactions NNS 1 1 UNK O
with IN 0 0 12 O
five CD 0 1 12 O
sedatives NNS 1 1 6 B-Group
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
cocaine NN 0 1 6 B-Drug
or CC 0 0 12 O
amphetamine NN 0 1 13 B-Drug
compounds NNS 1 1 13 O
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
neuronal JJ 0 1 13 O
reuptake NN 0 1 13 O
of IN 0 0 12 O
norepinephrine JJ 0 1 14 O
disrupts NNS 0 1 UNK O
the DT 0 0 12 O
behavioral JJ 0 1 13 O
response NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
genetically RB 0 0 UNK O
nervous JJ 0 1 6 O
E NNP 0 0 2 O
- : 0 0 2 O
strain NN 0 1 3 O
subjects NNS 1 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
far RB 0 1 12 O
greater JJR 1 1 1 O
extent NN 0 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
stable JJ 0 1 1 O
A NNP 0 0 2 O
- : 0 0 2 O
strain NN 0 1 3 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Ticlopidine NNP 0 1 0 B-Drug
treatment NN 0 1 6 O
increased VBD 1 1 1 O
the DT 0 0 12 O
mean JJ 0 1 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
extrapolated VBD 1 0 UNK O
to TO 0 0 12 O
infinity NN 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
oral JJ 0 1 6 O
ketamine NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
whereas JJ 0 0 UNK O
itraconazole JJ 0 1 0 B-Drug
treatment NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
ketamine NN 0 1 13 I-Drug
. . 0 0 12 O

amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
however RB 0 0 12 O
is VBZ 1 0 12 O
useful JJ 0 1 UNK O
in IN 0 0 12 O
therapy NN 0 1 6 O
of IN 0 0 12 O
human JJ 0 1 1 O
fungal JJ 0 1 6 O
infections NNS 1 1 6 O
because IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
less RBR 0 1 12 O
toxic JJ 0 1 1 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
contrary JJ 0 0 UNK O
neurotensin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
tuftsin NN 0 1 UNK B-Drug_n
were VBD 1 0 12 O
agonists NNS 1 1 UNK O
in IN 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
analgesia NN 0 1 6 O
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
markedly RB 0 1 1 O
increases VBZ 1 1 1 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
and CC 0 0 12 O
coadministration NN 0 1 UNK O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Stereoselective JJ 0 0 UNK O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
allylnormetazocine NN 0 0 UNK I-Drug_n
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
and CC 0 0 12 O
squirrel JJ 0 1 UNK O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
authors NNS 1 1 UNK O
investigated VBD 1 1 1 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
oxycodone NN 0 1 0 B-Drug
and CC 0 0 12 O
levofloxacin NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
first JJ 0 1 12 O
phase NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
sequence NN 0 1 UNK O
initiation NN 0 1 1 O
is VBZ 1 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
from IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
one CD 0 1 12 O
event NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
genetic JJ 0 1 13 O
apparatus NN 0 1 13 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
and CC 0 0 12 O
midazolam NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
metamizol NN 0 1 UNK B-Drug
and CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
problem NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
analysed VBN 1 0 UNK O
using VBG 1 1 1 O
two CD 0 1 12 O
different JJ 0 1 1 O
tasks NNS 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
: : 0 0 2 O
a DT 0 0 12 O
bar NN 0 1 3 O
- : 0 0 2 O
press NN 0 0 13 O
conditioning NN 0 1 13 O
and CC 0 0 12 O
a DT 0 0 12 O
spatial JJ 0 1 UNK O
discrimination NN 0 1 13 O
task NN 0 1 16 O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
thyroxine NN 0 1 14 B-Drug
with IN 0 0 12 O
simeticone NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
previously RB 0 0 1 O
and CC 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
listed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
British JJ 0 1 UNK O
National NNP 0 1 UNK O
Formulary NNP 0 1 UNK O
for IN 0 0 12 O
Children NNP 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
differ VBP 0 0 UNK O
and CC 0 0 12 O
they PRP 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
act VB 0 1 13 O
on IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
target NN 0 1 1 O
sites NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
although IN 0 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
share NN 0 1 UNK O
or CC 0 0 12 O
partly RB 0 0 UNK O
share NN 0 1 UNK O
certain JJ 0 1 1 O
properties NNS 1 1 UNK O
. . 0 0 12 O

whereas NNS 0 0 UNK O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
cases NNS 1 1 UNK O
. . 0 0 12 O

DISCUSSION NN 0 1 UNK O
: : 0 0 2 O
Clarithromycin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
the DT 0 0 12 O
major JJ 0 1 1 O
enzyme NN 0 1 14 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
simvastatin JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
dimethylprostaglandin NN 0 0 UNK I-Drug_n
E9 NNP 0 0 UNK I-Drug_n
( ( 0 0 2 O
dmPGE9 NN 0 0 UNK B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
induced JJ 0 1 6 O
diarrhea NN 0 1 6 O
was VBD 1 0 12 O
analyzed VBN 1 1 13 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
prepared VBN 1 1 12 O
by IN 0 0 12 O
resecting VBG 1 1 UNK O
the DT 0 0 12 O
cecum NN 0 1 8 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
vasculature NN 0 1 8 O
without IN 0 0 12 O
disturbing VBG 1 0 12 O
the DT 0 0 12 O
ileocecal JJ 0 1 UNK O
junction NN 0 1 3 O
. . 0 0 12 O

Several JJ 0 1 2 O
beta SYM 0 1 16 O
- : 0 0 2 O
adrenergic JJ 0 1 UNK O
neuroeffector NN 0 1 UNK O
defects NNS 1 1 6 O
occur VBP 0 1 1 O
in IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
neurochemical JJ 0 0 UNK O
and CC 0 0 12 O
functional JJ 0 1 1 O
consequences NNS 1 1 UNK O
following VBG 1 1 1 O
MPTP NNP 0 1 UNK B-Drug_n
administration NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
rat NN 0 1 13 O
were VBD 1 0 12 O
evaluated VBN 1 1 1 O
and CC 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
following VBG 1 1 1 O
methamphetamine JJ 0 1 UNK B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Altered NNP 0 1 13 O
mental JJ 0 1 1 O
status NN 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
adolescent JJ 0 1 13 O
presents NNS 1 1 12 O
a DT 0 0 12 O
diagnostic JJ 0 1 6 O
challenge NN 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
clinician JJ 0 1 13 O
depends VBZ 1 1 UNK O
on IN 0 0 12 O
clinical JJ 0 1 6 O
evaluation NN 0 1 1 O
and CC 0 0 12 O
laboratory NN 0 1 1 O
studies NNS 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
therapy NN 0 1 6 O
and CC 0 0 12 O
prognosis NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
reduction NN 0 1 1 O
in IN 0 0 12 O
PTH NNP 0 0 14 O
level NN 0 1 1 O
of IN 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
was VBD 1 0 12 O
experienced VBN 1 0 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
our PRP$ 0 0 12 O
cohort NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
from IN 0 0 12 O
prospective JJ 0 1 UNK O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
currently RB 0 1 12 O
exist VBP 0 1 UNK O
comparing VBG 1 1 UNK O
the DT 0 0 12 O
9 CD 0 0 2 O
approved VBD 1 1 1 O
agents NNS 1 1 1 O
( ( 0 0 2 O
efavirenz JJ 0 1 13 B-Drug
nevirapine NN 0 1 13 B-Drug
or CC 0 0 12 O
delavirdine NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Cisplatin NNP 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
over IN 0 1 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
thiosulfate JJ 0 1 16 B-Drug
infusion NN 0 1 14 O
. . 0 0 12 O

Sildenafil JJ 0 1 UNK B-Drug
citrate NN 0 1 14 I-Drug
: : 0 0 2 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
update NN 0 1 12 O
. . 0 0 12 O

Lack NNP 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
and CC 0 0 12 O
dideoxyinosine NN 0 1 UNK B-Drug
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

injection NN 0 1 3 O
of IN 0 0 12 O
phencyclidine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
PCP NNP 0 1 13 B-Drug_n
) ) 0 0 2 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
by IN 0 0 12 O
measuring VBG 1 1 1 O
locomotor NN 0 0 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
stereotyped VBD 1 1 UNK O
behavior NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
behavioral JJ 0 1 13 O
changes NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
related VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
negative JJ 0 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

Concomitantly RB 0 0 UNK O
given VBN 1 1 12 O
thiazide RP 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
did VBD 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
tablet NN 0 1 16 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
precipitating VBG 1 1 14 O
anticonvulsant JJ 0 1 14 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Both DT 0 0 2 O
ibogaine NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NNP 0 1 UNK I-Drug_n
decrease NN 0 1 1 O
extracellular JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
dopamine NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
nucleus JJ 0 1 UNK O
accumbens NNS 0 0 UNK O
but CC 0 0 12 O
only RB 0 1 12 O
ibogaine JJ 0 1 UNK B-Drug_n
increases NNS 1 1 1 O
extracellular JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
serotonin NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
nucleus NN 0 1 UNK O
accumbens VBZ 0 0 UNK O
. . 0 0 12 O

Prothrombin NNP 0 1 7 O
times NNS 1 1 12 O
were VBD 1 0 12 O
measured VBN 1 1 1 O
four CD 0 1 12 O
times NNS 1 1 12 O
weekly RB 0 1 12 O
during IN 0 0 12 O
five CD 0 1 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
experiments NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
natural JJ 0 1 13 O
and CC 0 0 12 O
synthetic JJ 0 1 3 O
galloyl NN 0 0 UNK O
esters NNS 1 1 UNK O
on IN 0 0 12 O
glucocorticoid JJ 0 1 13 O
- : 0 0 2 O
induced JJ 0 1 6 O
gene NN 0 1 13 O
expression NN 0 1 1 O
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
by IN 0 0 12 O
using VBG 1 1 1 O
rat NN 0 1 13 O
fibroblast VBD 0 1 UNK O
9Y9 CD 0 0 UNK O
cells NNS 1 1 6 O
stably RB 0 0 UNK O
transfected VBD 0 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
luciferase NN 0 1 UNK O
reporter NN 0 1 UNK O
gene NN 0 1 13 O
under IN 0 0 12 O
the DT 0 0 12 O
transcriptional JJ 0 1 UNK O
regulation NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
mouse NN 0 1 UNK O
mammary JJ 0 1 6 O
tumor NN 0 1 6 O
virus NN 0 1 6 O
promoter NN 0 1 UNK B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
inhibitors NNS 1 1 14 O
on IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
metabolism NN 0 1 16 O
and CC 0 0 12 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
slices NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
the DT 0 0 12 O
potency NN 0 1 UNK O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
failing VBG 1 1 13 O
hearts NNS 1 1 UNK O
( ( 0 0 2 O
New NNP 0 1 2 O
York NNP 0 0 2 O
Heart NNP 0 1 2 O
Association NNP 0 1 2 O
functional JJ 0 1 1 O
class NN 0 1 12 O
IV NNP 0 1 2 O
) ) 0 0 2 O
in IN 0 0 12 O
relation NN 0 1 13 O
to TO 0 0 12 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
producing VBG 1 0 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
maximal JJ 0 1 1 O
effect NN 0 1 1 O
( ( 0 0 2 O
EC9 NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Previous JJ 0 1 2 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
tumor NN 0 1 6 O
activity NN 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
non SYM 0 1 1 O
- : 0 0 2 O
small JJ 0 1 12 O
cell NN 0 1 1 O
lung NN 0 1 6 O
cancer NN 0 1 6 O
( ( 0 0 2 O
NSCLC NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Cancer NN 0 1 7 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
: : 0 0 2 O
basic JJ 0 1 1 O
science NN 0 1 UNK O
and CC 0 0 12 O
clinical JJ 0 1 6 O
aspects NNS 1 1 1 O
. . 0 0 12 O

Regulatory NN 0 1 UNK O
agencies NNS 1 1 UNK O
state NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
omeprazole VBP 0 1 0 B-Drug
and CC 0 0 12 O
esomeprazole VB 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Careful JJ 0 1 UNK O
observations NNS 1 1 1 O
on IN 0 0 12 O
hepatotoxicity NN 0 1 13 O
are VBP 1 0 12 O
suggested VBN 1 1 12 O
when WRB 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
is VBZ 1 0 12 O
prescribed VBN 1 1 1 O
with IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
low JJ 0 1 1 O
dietary JJ 0 1 6 O
cobalt NN 0 1 UNK B-Drug
concentration NN 0 1 1 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
iron NN 0 1 3 B-Drug
contents NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diets NNS 1 1 UNK O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
cobalt NN 0 1 UNK B-Drug
on IN 0 0 12 O
iron NN 0 1 3 B-Drug
absorption NN 0 1 1 O
and CC 0 0 12 O
excretion NN 0 1 14 O
occurred VBD 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
initiated JJ 0 1 1 O
cells NNS 1 1 6 O
that WDT 0 0 12 O
result VBP 0 1 1 O
from IN 0 0 12 O
this DT 0 0 12 O
hit NN 0 1 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
from IN 0 0 12 O
those DT 0 0 12 O
that WDT 0 0 12 O
demonstrate VBP 0 0 1 O
very RB 0 1 12 O
little JJ 0 1 12 O
progression NN 0 1 1 O
in IN 0 0 12 O
cell NN 0 1 1 O
type NN 0 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
or CC 0 0 12 O
may MD 0 0 1 O
not RB 0 1 12 O
require VB 0 0 1 O
exogenous JJ 0 1 UNK O
enhancement NN 0 1 1 O
of IN 0 0 12 O
growth NN 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
that WDT 0 0 12 O
can MD 0 0 12 O
progress VB 0 1 1 O
very RB 0 1 12 O
rapidly RB 0 1 1 O
to TO 0 0 12 O
fully RB 0 0 1 O
malignant JJ 0 1 6 O
behavior NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
presentation NN 0 1 1 O
and CC 0 0 12 O
natural JJ 0 1 13 O
history NN 0 1 12 O
of IN 0 0 12 O
neoplasia NN 0 1 8 O
are VBP 1 0 12 O
also RB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
aging VBG 1 1 UNK O
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
selective JJ 0 1 13 O
regulation NN 0 1 13 O
of IN 0 0 12 O
voltage NN 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
subtypes NNS 0 1 UNK O
by IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
in IN 0 0 12 O
bovine NN 0 1 13 O
chromaffin NN 0 0 UNK O
cell NN 0 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
the DT 0 0 12 O
cellular JJ 0 1 13 O
basis NN 0 1 1 O
of IN 0 0 12 O
antistress JJ 0 0 UNK O
effects NNS 1 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
ginseng NN 0 1 14 B-Drug
. . 0 0 12 O

Responses NNS 0 1 UNK O
to TO 0 0 12 O
arginine VB 0 1 13 B-Drug
of IN 0 0 12 O
the DT 0 0 12 O
perfused JJ 0 1 8 O
pancreas NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
genetically RB 0 0 UNK O
diabetic JJ 0 1 6 O
Chinese NNP 0 1 UNK O
hamster NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
relative JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
during IN 0 0 12 O
sexual JJ 0 1 12 O
activity NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
than IN 0 0 12 O
for IN 0 0 12 O
healthy JJ 0 1 12 O
persons NNS 1 1 13 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
estradiol NN 0 1 13 B-Drug
on IN 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
changes NNS 1 1 1 O
in IN 0 0 12 O
steroid JJ 0 1 6 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
lethality NN 0 1 UNK O
in IN 0 0 12 O
male JJ 0 1 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
approach NN 0 1 1 O
combines VBZ 1 1 UNK O
liquid JJ 0 1 3 O
chromatography NN 0 1 UNK O
mass NN 0 1 1 O
spectrometry NN 0 1 UNK O
( ( 0 0 2 O
LC NNP 0 0 UNK O
MS NNP 0 1 2 O
) ) 0 0 2 O
detection NN 0 1 1 O
methods NNS 1 1 1 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
toxicity NN 0 1 6 O
endpoints NNS 1 1 UNK O
to TO 0 0 12 O
enable VB 0 1 UNK O
identification NN 0 1 1 O
of IN 0 0 12 O
critical JJ 0 1 1 O
metabolic NN 0 1 6 O
pathways NNS 1 1 13 O
for IN 0 0 12 O
hepatotoxicity NN 0 1 13 O
. . 0 0 12 O

Prostatic JJ 0 1 7 O
epithelium NN 0 1 8 O
proliferates NNS 0 0 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
defined JJ 0 1 1 O
medium NN 0 1 3 O
consisting NN 0 1 1 O
of IN 0 0 12 O
basal NN 0 1 6 O
medium NN 0 1 3 O
RPMI9 NNP 0 0 UNK O
containing VBG 1 1 1 O
transferrin NN 0 1 14 B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
microgram NN 0 1 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
EGF NNP 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
ng RB 0 1 13 O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
ml NN 0 1 16 O
or CC 0 0 12 O
9 CD 0 0 2 O
IU NNP 0 1 13 O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
warfarin JJ 0 1 14 B-Drug
requirement NN 0 1 1 O
of IN 0 0 12 O
our PRP$ 0 0 12 O
patient NN 0 1 6 O
appeared VBD 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
maximal JJ 0 1 1 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
extended VBD 1 1 1 O
a DT 0 0 12 O
similar JJ 0 1 1 O
length NN 0 1 3 O
of IN 0 0 12 O
time NN 0 1 12 O
after IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
withdrawal NN 0 1 1 O
. . 0 0 12 O

Therapeutic JJ 0 1 UNK O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
( ( 0 0 2 O
TDM NNP 0 0 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
gentamicin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
and CC 0 0 12 O
bone NN 0 1 6 O
scintigraphy NN 0 1 UNK O
employing VBG 1 1 UNK O
9mTc CD 0 0 UNK B-Drug
- : 0 0 2 O
MDP NN 0 1 UNK I-Drug
as IN 1 0 12 O
the DT 0 0 12 O
radiopharmaceutical NN 0 1 UNK B-Group
was VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

To TO 0 0 2 O
study VB 0 1 1 O
the DT 0 0 12 O
pancreatic JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
dynamic JJ 0 1 1 O
insulin NN 0 1 14 O
and CC 0 0 12 O
glucagon NN 0 1 14 O
release NN 0 1 12 O
was VBD 1 0 12 O
measured VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
perfused JJ 0 1 8 O
pancreases NNS 1 1 UNK O
of IN 0 0 12 O
normal JJ 0 1 1 O
and CC 0 0 12 O
diabetic JJ 0 1 6 O
Chinese JJ 0 1 UNK O
hamsters NNS 1 1 UNK O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
various JJ 0 1 1 O
combinations NNS 1 1 1 O
of IN 0 0 12 O
arginine NN 0 1 13 B-Drug
( ( 0 0 2 O
9mM CD 0 0 UNK O
) ) 0 0 2 O
glucose NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg. NNS 0 1 0 O
per IN 0 0 1 O
9 CD 0 0 2 O
ml NN 0 1 16 O
. . 0 0 12 O
) ) 0 0 2 O
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
9 CD 0 0 2 O
PI NNP 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
low JJ 0 1 1 O
intrinsic JJ 0 1 1 O
value NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
; : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Measurement NN 0 1 UNK O
of IN 0 0 12 O
nociception NN 0 1 UNK O
was VBD 1 0 12 O
performed VBN 1 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
h NN 0 1 16 O
after IN 0 0 12 O
benzodiazepine JJ 0 1 14 B-Group
administration NN 0 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
several JJ 0 1 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
which WDT 0 0 12 O
it PRP 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
successive JJ 0 0 UNK O
application NN 0 1 1 O
of IN 0 0 12 O
glycine NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
egg NN 0 1 13 O
weight NN 0 1 3 O
( ( 0 0 2 O
e.w FW 0 0 UNK O
. . 0 0 12 O
) ) 0 0 2 O
and CC 0 0 12 O
glutamate NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
e.w NN 0 0 UNK O
. . 0 0 12 O
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
interval NN 0 1 1 O
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
motility NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
- : 0 0 2 O
old JJ 0 1 12 O
chick NN 0 1 UNK O
embryos NN 1 1 UNK O
in IN 0 0 12 O
comparison NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
glutamate NN 0 1 UNK B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
taken VBN 1 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
indinavir NN 0 1 16 B-Drug
( ( 0 0 2 O
IDV NNP 0 1 UNK B-Drug
) ) 0 0 2 O
didanosine NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
IDV NNP 0 1 UNK B-Drug
exposure NN 0 1 1 O
despite IN 0 0 12 O
persistent JJ 0 1 1 O
buffering NN 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
observations NNS 1 1 1 O
strongly RB 0 0 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
homodimeric JJ 0 0 UNK O
structure NN 0 1 1 O
of IN 0 0 12 O
contortrostatin NN 0 1 UNK B-Drug_n
functionally RB 0 0 UNK O
distinguishes VBZ 1 0 UNK O
it PRP 0 0 12 O
from IN 0 0 12 O
other JJ 0 0 12 O
monomeric JJ 0 1 UNK O
members NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
disintegrin JJ 0 0 UNK O
family NN 0 1 12 O
. . 0 0 12 O

Five CD 0 1 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
dofetilide JJ 0 1 13 B-Drug
treatment NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
variables NNS 1 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
compared VBN 1 1 1 O
with IN 0 0 12 O
placebo NN 0 1 13 O
; : 0 0 2 O

Electrophilic JJ 0 0 UNK O
agents NNS 1 1 1 O
- : 0 0 2 O
- : 0 0 2 O
a DT 0 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
chemicals NNS 1 1 13 O
that WDT 0 0 12 O
includes VBZ 1 1 1 O
most RBS 0 0 12 O
genotoxic JJ 0 1 UNK O
compounds NNS 1 1 13 O
- : 0 0 2 O
- : 0 0 2 O
can MD 0 0 12 O
be VB 0 0 12 O
inactivated VBN 1 0 UNK O
by IN 0 0 12 O
reaction NN 0 1 1 O
with IN 0 0 12 O
glutathione NN 0 1 13 O
or CC 0 0 12 O
other JJ 0 0 12 O
SH NNP 0 1 13 O
- : 0 0 2 O
bearing NN 0 1 3 O
molecules NNS 1 1 UNK O
. . 0 0 12 O

Sertraline NNP 0 1 0 B-Drug
neutralized VBD 1 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
of IN 0 0 12 O
glycemia NN 0 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
oral JJ 0 1 6 O
glucose JJ 0 1 14 B-Drug
overload NN 0 0 1 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
coadministered VBN 0 0 UNK O
drugs NNS 1 1 6 O
and CC 0 0 12 O
ethanol NN 0 1 1 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
drugs NNS 1 1 6 O
to TO 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Thirty NNP 0 1 2 O
male NN 0 1 12 O
rats NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
Fischer NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
strain NN 0 1 3 O
were VBD 1 0 12 O
divided VBN 1 1 1 O
into IN 0 0 12 O
three CD 0 1 12 O
equal JJ 0 1 1 O
groups NNS 1 1 1 O
and CC 0 0 12 O
were VBD 1 0 12 O
given VBN 1 1 12 O
injections NNS 1 1 6 O
of IN 0 0 12 O
trimethyl JJ 0 0 UNK B-Drug_n
lead NN 0 1 12 I-Drug_n
( ( 0 0 2 O
TML NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
/ FW 0 0 2 O
ml FW 0 1 16 O
SC NNP 0 1 2 O
) ) 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
saline JJ 0 1 14 O
vehicle NN 0 1 1 O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
combination NN 0 1 1 O
of IN 0 0 12 O
CHOP NNP 0 1 UNK O
plus CC 0 1 16 O
HAART NNP 0 1 14 O
is VBZ 1 0 12 O
feasible JJ 0 0 1 O
and CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
morbidity NN 0 1 13 O
from IN 0 0 12 O
OIs NNP 0 1 UNK O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
NHL NN 0 1 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
impact NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
combined JJ 0 1 1 O
chemotherapy NN 0 1 6 O
plus CC 0 1 16 O
HAART NNP 0 1 14 O
treatment NN 0 1 6 O
on IN 0 0 12 O
patient JJ 0 1 6 O
survival NN 0 1 1 O
needs VBZ 1 1 12 O
urgently RB 0 0 1 O
to TO 0 0 12 O
be VB 0 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
prospective JJ 0 1 UNK O
studies NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
administered VBN 1 1 1 O
at IN 0 0 12 O
either CC 0 1 12 O
dose VB 0 1 6 O
had VBD 1 0 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
carcinogenesis NN 0 1 UNK O
by IN 0 0 12 O
bombesin NN 0 1 UNK B-Drug_n
or CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
location NN 0 1 1 O
histologic NN 0 1 13 O
type NN 0 1 1 O
depth NN 0 1 13 O
of IN 0 0 12 O
involvement NN 0 1 1 O
labeling VBG 1 1 UNK O
index NN 0 1 1 O
apoptotic JJ 0 1 UNK O
index NN 0 1 1 O
or CC 0 0 12 O
tumor NN 0 1 6 O
vascularity NN 0 1 8 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
cancers NNS 1 1 6 O
it PRP 0 0 12 O
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
cancer NN 0 1 6 O
metastasis NN 0 1 6 O
. . 0 0 12 O

Synergism NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
GL NNP 0 1 UNK B-Drug_n
was VBD 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
cefazolin NN 0 1 14 B-Drug
against IN 0 0 12 O
Bacillus NNP 0 1 UNK O
subtilis NNS 0 0 13 O
and CC 0 0 12 O
Klebsiella NNP 0 1 14 O
oxytoca NN 0 0 16 O
. . 0 0 12 O

This DT 0 0 2 O
increased VBD 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
atherosclerotic JJ 0 1 8 O
disease NN 0 1 6 O
is VBZ 1 0 12 O
intricately RB 0 0 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
insulin NN 0 1 14 O
resistance NN 0 1 1 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
pathophysiologic NN 0 1 UNK O
abnormality NN 0 1 6 O
in IN 0 0 12 O
type NN 0 1 1 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
. . 0 0 12 O

Ibogaine NN 0 1 UNK B-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
decreases VBZ 1 1 UNK O
heart NN 0 1 12 O
rate NN 0 1 1 O
at IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
. . 0 0 12 O

Dose NNP 0 1 7 O
- : 0 0 2 O
response NN 0 1 1 O
curves NNS 1 1 UNK O
( ( 0 0 2 O
derived VBN 1 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
tablets NNS 1 1 3 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
pure JJ 0 1 13 O
powders NNS 1 1 3 O
) ) 0 0 2 O
showed VBD 1 1 12 O
that IN 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug
was VBD 1 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
which WDT 0 0 12 O
was VBD 1 0 12 O
partially RB 0 0 1 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
pentazocine NN 0 1 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
blockers NNS 1 0 6 I-Group
calcium VBP 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
thiazide RB 0 1 UNK B-Group
and CC 0 0 12 O
loop JJ 0 1 3 B-Group
diuretics NNS 1 1 14 I-Group
and CC 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Increased VBN 0 1 7 O
D NNP 0 1 2 O
- : 0 0 2 O
like IN 0 0 12 O
receptor NN 0 1 14 O
sensitivity NN 0 1 1 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
enhanced VBN 1 1 1 O
the DT 0 0 12 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
but CC 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
more RBR 0 1 12 O
prevalent JJ 0 1 UNK O
in IN 0 0 12 O
adolescent JJ 0 1 13 O
female NN 0 1 12 O
rats NNS 1 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
male JJ 0 1 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Depression NN 0 1 2 O
does VBZ 1 0 12 O
not RB 0 1 12 O
always RB 0 1 12 O
require VBP 0 0 1 O
antidepressant JJ 0 1 6 B-Group
drug NN 0 1 1 I-Group
therapy NN 0 1 6 O
and CC 0 0 12 O
antidepressants NNS 1 1 13 B-Group
have VBP 0 0 12 O
no DT 0 0 12 O
proven JJ 0 1 1 O
preventive JJ 0 1 13 O
impact NN 0 1 1 O
on IN 0 0 12 O
hot JJ 0 1 3 O
flushes NNS 1 1 13 O
linked VBN 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
menopause NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
role NN 0 1 1 O
of IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
electrically RB 0 1 UNK O
stimulated VBN 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
Hz NNP 0 1 13 O
9 CD 0 0 2 O
degrees NNS 1 1 1 O
C NNP 0 0 2 O
) ) 0 0 2 O
human VBD 0 1 1 O
ventricular JJ 0 1 8 O
cardiac JJ 0 1 6 O
preparations NNS 1 1 13 O
and CC 0 0 12 O
isolated JJ 0 1 1 O
myocardial JJ 0 1 6 O
membranes NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
loss NN 0 1 1 O
of IN 0 0 12 O
microtubules NNS 1 1 UNK O
on IN 0 0 12 O
cooling VBG 1 1 3 O
the DT 0 0 12 O
nerves NNS 1 1 6 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
reappearance NN 0 0 UNK O
on IN 0 0 12 O
rewarming NN 0 1 UNK O
was VBD 1 0 12 O
a DT 0 0 12 O
rapid JJ 0 1 1 O
process NN 0 1 1 O
; : 0 0 2 O

The DT 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
a DT 0 0 12 O
spinal JJ 0 1 6 O
naloxone NN 0 1 16 B-Drug
- : 0 0 2 O
sensitive JJ 0 1 1 O
endorphinergic NN 0 0 UNK O
system NN 0 1 1 O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
morphine VB 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
and CC 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
intraventricular JJ 0 1 8 O
beta SYM 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
elicit VBP 0 1 1 O
their PRP$ 0 0 12 O
pharmacological JJ 0 1 14 O
actions NNS 1 1 UNK O
via IN 0 0 1 O
the DT 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
different JJ 0 1 1 O
descending VBG 1 1 3 O
pain NN 0 1 6 O
inhibitory JJ 0 1 UNK O
systems NNS 1 1 1 O
; : 0 0 2 O

Comparative JJ 0 0 UNK O
analysis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
stimulation NN 0 1 6 O
and CC 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cholino NN 0 0 UNK O
- : 0 0 2 O
and CC 0 0 12 O
adrenoreceptors NNS 0 1 UNK O
on IN 0 0 12 O
this DT 0 0 12 O
inhibitory JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
angiotensins NNS 1 1 UNK B-Drug_n
suggested VBD 1 1 12 O
the DT 0 0 12 O
mediation NN 0 1 UNK O
of IN 0 0 12 O
angiotensin NN 0 1 UNK B-Drug_n
influence NN 0 0 UNK O
through IN 0 0 12 O
the DT 0 0 12 O
modulation NN 0 1 13 O
of IN 0 0 12 O
cholinergic JJ 0 1 13 O
reactions NNS 1 1 1 O
of IN 0 0 12 O
parietal JJ 0 1 8 O
cells NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
. . 0 0 12 O

Interest NN 0 1 UNK O
in IN 0 0 12 O
administering VBG 1 1 1 O
compounds NNS 1 1 13 O
in IN 0 0 12 O
combination NN 0 1 1 O
lies VBZ 1 0 UNK O
both DT 0 0 12 O
in IN 0 0 12 O
enhancing VBG 1 1 1 O
efficacious JJ 0 1 UNK O
effects NNS 1 1 1 O
and CC 0 0 12 O
in IN 0 0 12 O
limiting VBG 1 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
studied VBN 1 0 1 O
at IN 0 0 12 O
neutral JJ 0 1 1 O
acidic NN 0 1 UNK O
and CC 0 0 12 O
basic JJ 0 1 1 O
conditions NNS 1 1 1 O
both DT 0 0 12 O
at IN 0 0 12 O
room NN 0 1 12 O
temperature NN 0 1 3 O
and CC 0 0 12 O
9 CD 0 0 2 O
C NNP 0 0 2 O
. . 0 0 12 O

Evaluation NN 0 1 2 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
interface NN 0 1 1 O
between IN 0 0 12 O
bone NN 0 1 6 O
and CC 0 0 12 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
in IN 0 0 12 O
uremia JJ 0 1 8 O
represents VBZ 1 1 1 O
a DT 0 0 12 O
critical JJ 0 1 1 O
step NN 0 1 12 O
in IN 0 0 12 O
red JJ 0 1 3 O
blood NN 0 1 6 O
cell NN 0 1 1 O
production NN 0 1 1 O
which WDT 0 0 12 O
merits VBZ 1 0 UNK O
further JJ 0 1 1 O
investigation NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
comparison NN 0 1 1 O
with IN 0 0 12 O
haloperidol PDT 0 1 16 B-Drug
the DT 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
reported VBD 1 1 1 O
significantly RB 0 0 1 O
more RBR 0 1 12 O
frequently RB 0 1 1 O
with IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
in IN 0 0 12 O
> NN 0 0 2 O
or CC 0 0 12 O
= VB 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
bodyweight VBD 0 1 UNK O
gain NN 0 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
appetite NN 0 1 6 O
and CC 0 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
risperidone NN 0 1 0 B-Drug
only RB 0 1 12 O
bodyweight VBD 0 1 UNK O
gain NN 0 1 1 O
occurred VBD 1 1 1 O
significantly RB 0 0 1 O
more RBR 0 1 12 O
frequently RB 0 1 1 O
with IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
. . 0 0 12 O

Modification NN 0 1 UNK O
of IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
with IN 0 0 12 O
diethyl JJ 0 0 UNK B-Drug_n
pyrocarbonate NN 0 1 UNK I-Drug_n
abolished VBD 1 0 UNK O
both DT 0 0 12 O
its PRP$ 1 0 12 O
cytotoxic NN 0 1 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
toxin NN 0 1 14 O
to TO 0 0 12 O
bind VB 0 1 UNK O
Zn NNP 0 0 UNK O
- : 0 0 2 O
Sepharose NNP 0 1 UNK O
gel NN 0 1 3 O
. . 0 0 12 O

An DT 0 0 2 O
intravenous JJ 0 1 14 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
perchlorate NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
in IN 0 0 12 O
respect NN 0 1 1 O
of IN 0 0 12 O
competitive JJ 0 1 UNK O
suppression NN 0 1 1 O
of IN 0 0 12 O
organs NNS 1 1 16 O
actively RB 0 0 1 O
concentrating VBG 1 1 UNK O
pertechnetate NN 0 1 UNK B-Drug
as RB 0 0 12 O
effective JJ 0 1 1 O
as IN 1 0 12 O
intravenous JJ 0 1 14 O
9 CD 0 0 2 O
mg NN 0 1 0 O
ClO NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
simultaneously RB 0 1 13 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
orally RB 0 1 14 O
9 CD 0 0 2 O
min NN 0 1 16 O
before IN 0 1 12 O
the DT 0 0 12 O
injection NN 0 1 3 O
of IN 0 0 12 O
radiopertechnetate NN 0 0 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
minimal JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
concentration NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
minimal JJ 0 1 1 O
bactericidal JJ 0 1 UNK O
concentration NN 0 1 1 O
of IN 0 0 12 O
KRM NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
against IN 0 0 12 O
M NNP 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
heparinase NN 0 1 UNK B-Drug_n
III NNP 0 1 2 I-Drug_n
or CC 0 0 12 O
chondroitin VB 0 1 13 B-Drug_n
ABC NNP 0 1 UNK I-Drug_n
lyase NN 0 1 UNK I-Drug_n
greatly RB 0 1 1 O
enhanced VBD 1 1 1 O
transduction NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
retinal JJ 0 1 6 O
ganglion NN 0 1 8 O
cell NN 0 1 1 O
layer NN 0 1 3 O
and CC 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
depth NN 0 1 13 O
of IN 0 0 12 O
transduction NN 0 1 UNK O
into IN 0 0 12 O
the DT 0 0 12 O
outer NN 0 1 UNK O
retina NN 0 1 13 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
elevated VBN 1 1 1 O
risk NN 0 1 1 O
with IN 0 0 12 O
mirtazapine JJ 0 1 0 B-Drug
suggests NNS 0 1 1 O
that IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
not RB 0 1 12 O
have VB 0 0 12 O
been VBN 1 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
all DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
observed VBN 1 1 1 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
. . 0 0 12 O

Infusion NN 0 1 UNK O
of IN 0 0 12 O
arginine NN 0 1 13 B-Drug
alone RB 0 1 12 O
markedly RB 0 1 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
extractable JJ 0 0 UNK O
pancreatic JJ 0 1 6 O
insulin NN 0 1 14 O
and CC 0 0 12 O
glucagon NN 0 1 14 O
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
sirolimus NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Similarly RB 0 0 1 O
diazepam NN 0 1 0 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
metamizol NN 0 1 UNK B-Drug
( ( 0 0 2 O
only RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick JJ 0 0 UNK O
test NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
ketamine NN 0 1 13 I-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ticlopidine NN 0 1 16 B-Drug
. . 0 0 12 O

Fluoxetine NNP 0 1 0 B-Drug
and CC 0 0 12 O
moclobemide RB 0 1 UNK B-Drug
increased VBD 1 1 1 O
blood NN 0 1 6 O
glucose NN 0 1 14 B-Drug
at IN 0 0 12 O
different JJ 0 1 1 O
times NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
glucose JJ 0 1 14 O
overload NN 0 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
pronounced JJ 0 0 12 O
intersubject JJ 0 0 UNK O
variability NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
sirolimus NN 0 1 16 B-Drug
- : 0 0 2 O
diltiazem NN 0 1 0 B-Drug
interaction NN 0 1 UNK O
whole JJ 0 1 12 O
blood NN 0 1 6 O
sirolimus NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
apparent JJ 0 1 1 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
and CC 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
. . 0 0 12 O

higher JJR 1 1 1 O
doses NNS 1 1 6 O
decreased VBN 1 1 1 O
FI NNP 0 1 UNK O
and CC 0 0 12 O
FR NNP 0 1 UNK O
responding NN 0 0 1 O
in IN 0 0 12 O
both DT 0 0 12 O
species NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
which WDT 0 0 12 O
metabolizes VBZ 1 0 UNK O
sildenafil NN 0 1 16 B-Drug
may MD 0 0 1 O
experience VB 0 1 12 O
increased VBN 1 1 1 O
drug NN 0 1 1 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
possible JJ 0 1 1 O
toxicity NN 0 1 6 O
from IN 0 0 12 O
normal JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
sildenafil NN 0 1 16 B-Drug
. . 0 0 12 O

Like IN 0 0 UNK O
all DT 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
certain JJ 0 1 1 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
principles NNS 1 0 UNK O
observed VBD 1 1 1 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
fo VBP 0 0 UNK O
these DT 0 0 12 O
hormones NNS 1 1 13 O
were VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
of IN 0 0 12 O
dogs NNS 1 1 UNK O
deprived VBN 1 0 UNK O
of IN 0 0 12 O
water NN 0 1 3 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
then RB 0 1 12 O
allowed VBD 1 1 12 O
to TO 0 0 12 O
drink VB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
pathophysiologic NN 0 1 UNK O
consequences NNS 1 1 UNK O
could MD 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
synaptic JJ 0 0 UNK O
concentration NN 0 1 1 O
of IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
predisposing VBG 1 1 UNK O
to TO 0 0 12 O
adenylyl VB 0 0 UNK O
cyclase NN 0 0 UNK O
desensitization NN 0 1 14 O
. . 0 0 12 O

Each DT 0 0 2 O
serum NN 0 1 14 O
without IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
added JJ 0 1 12 O
drug NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
supplemented VBD 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
three CD 0 1 12 O
concentrations NNS 1 1 13 O
was VBD 1 0 12 O
dialyzed VBN 1 0 UNK O
against IN 0 0 12 O
phosphate NN 0 1 14 O
buffer NN 0 1 UNK O
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
During IN 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
median NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
from IN 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
to TO 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ JJ 0 0 2 O
h NN 0 1 16 O
among IN 0 0 12 O
the DT 0 0 12 O
volunteers NNS 1 1 UNK O
who WP 0 0 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
d NN 0 1 16 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
dacarbazine NN 0 1 13 B-Drug
and CC 0 0 12 O
imexon NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
in IN 0 0 12 O
human JJ 0 1 1 O
A9 NNP 0 1 UNK O
melanoma NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

Collectively RB 0 0 UNK O
these DT 0 0 12 O
findings NNS 1 1 1 O
contribute VBP 0 1 UNK O
to TO 0 0 12 O
increase VB 0 1 1 O
our PRP$ 0 0 12 O
knowledge NN 0 1 1 O
of IN 0 0 12 O
DEB NNP 0 1 UNK O
- : 0 0 2 O
induce NN 0 1 6 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
will MD 0 0 12 O
be VB 0 0 12 O
very RB 0 1 12 O
useful JJ 0 1 UNK O
when WRB 0 0 12 O
applied VBN 1 1 1 O
in IN 0 0 12 O
studies NNS 1 1 1 O
with IN 0 0 12 O
lymphocytes NNS 1 1 14 O
from IN 0 0 12 O
FA NNP 0 0 13 O
patients NNS 1 1 6 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
find VB 0 1 12 O
out RP 0 1 12 O
a DT 0 0 12 O
protective JJ 0 0 3 O
agent NN 0 1 1 O
against IN 0 0 12 O
spontaneous JJ 0 1 1 O
and CC 0 0 12 O
DEB NNP 0 1 UNK O
- : 0 0 2 O
induced VBD 1 1 6 O
chromosome JJ 0 1 13 O
instability NN 0 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
necessitate VB 0 0 UNK O
an DT 0 0 12 O
adjustment NN 0 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
maintain VB 0 1 1 O
therapeutic JJ 0 1 6 O
digoxin NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Metal JJ 0 1 UNK O
mixture NN 0 1 3 O
toxicity NN 0 1 6 O
investigation NN 0 1 1 O
was VBD 1 0 12 O
undertaken VBN 1 0 1 O
with IN 0 0 12 O
equal JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
metals NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
in IN 0 0 12 O
Ontario NNP 0 1 UNK O
alone RB 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
there EX 0 0 12 O
were VBD 1 0 12 O
9 CD 0 0 2 O
deaths NNS 1 1 UNK O
in IN 0 0 12 O
amphetamine JJ 0 1 13 B-Drug
users NNS 1 1 UNK O
of IN 0 0 12 O
which WDT 0 0 12 O
9 CD 0 0 2 O
were VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
accident VB 0 1 12 O
suicide NN 0 1 12 O
or CC 0 0 12 O
homicide NN 0 1 UNK O
. . 0 0 12 O

Studies NNS 0 1 2 O
on IN 0 0 12 O
two CD 0 1 12 O
strains NNS 1 1 6 O
of IN 0 0 12 O
pointer NN 0 1 UNK O
dogs NNS 1 1 UNK O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
benzodiazepine NN 0 1 14 B-Group
( ( 0 0 2 O
chlordiazepoxide NN 0 1 16 B-Drug
) ) 0 0 2 O
facilitates VBZ 1 0 UNK O
acquisition NN 0 1 UNK O
of IN 0 0 12 O
goal NN 0 1 12 O
- : 0 0 2 O
directed VBN 1 1 1 O
behavior NN 0 1 1 O
in IN 0 0 12 O
`` `` 0 0 13 O
genetically RB 0 0 UNK O
nervous JJ 0 1 6 O
'' '' 0 0 13 O

Although IN 0 0 12 O
neither DT 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
nor CC 0 0 12 O
retinyl JJ 0 0 UNK B-Drug
acetate NN 0 1 14 I-Drug
affected VBD 1 1 1 O
the DT 0 0 12 O
proliferation NN 0 1 1 O
of IN 0 0 12 O
prostatic JJ 0 1 6 O
epithelium NN 0 1 8 O
in IN 0 0 12 O
RPMI9 NNP 0 0 UNK O
containing VBG 1 1 1 O
transferrin NN 0 1 14 B-Drug_n
alone RB 0 1 12 O
they PRP 0 0 12 O
modify VBP 0 1 UNK O
the DT 0 0 12 O
mitogenic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
EGF NNP 0 0 UNK B-Drug_n
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

Current JJ 0 1 2 O
immunosuppressive JJ 0 1 14 O
therapies NNS 1 1 6 O
are VBP 1 0 12 O
effective JJ 0 1 1 O
but CC 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
Methoxycoronaridine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
: : 0 0 2 O
comparison NN 0 1 1 O
of IN 0 0 12 O
antiaddictive JJ 0 0 UNK O
efficacy NN 0 1 UNK O
toxicity NN 0 1 6 O
and CC 0 0 12 O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
action NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
susceptibility NN 0 1 6 O
results NNS 1 1 1 O
for IN 0 0 12 O
minocycline NN 0 1 13 B-Drug
and CC 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
were VBD 1 0 12 O
interpreted VBN 1 1 UNK O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
relevant JJ 0 1 1 O
criteria NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
environmental JJ 0 1 13 O
lead NN 0 1 12 B-Drug_n
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
biological JJ 0 1 13 O
and CC 0 0 12 O
behavioral JJ 0 1 13 O
responsiveness NN 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
animal NN 0 1 13 O
to TO 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

To TO 0 0 2 O
determine VB 0 0 1 O
whether IN 0 0 12 O
injection NN 0 1 3 O
of IN 0 0 12 O
thiosulfate NN 0 1 16 B-Drug
would MD 0 0 12 O
permit VB 0 1 UNK O
larger JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
a DT 0 0 12 O
fixed JJ 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
g NN 0 1 16 O
/ JJ 0 0 2 O
m9 NN 0 1 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
thiosulfate NN 0 1 16 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
intravenously RB 0 0 14 O
over IN 0 1 12 O
three CD 0 1 12 O
hours NNS 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
escalating VBG 1 0 UNK O
doses NNS 1 1 6 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
. . 0 0 12 O

Vancomycin NNP 0 1 0 O
resistance NN 0 1 1 O
reversal NN 0 1 1 O
in IN 0 0 12 O
enterococci NN 0 1 UNK O
by IN 0 0 12 O
flavonoids NNS 1 1 UNK O
. . 0 0 12 O

Conjugation NN 0 1 UNK O
at IN 0 0 12 O
NaCMC NNP 0 0 UNK B-Drug_n
with IN 0 0 12 O
cysteine NN 0 1 13 B-Drug
moieties NNS 1 0 UNK O
significantly RB 0 0 1 O
improves VBZ 1 1 1 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
permeation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
hydrophilic JJ 0 1 UNK O
molecule NN 0 1 UNK O
NaFlu NNP 0 0 UNK B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
model NN 0 1 UNK O
peptide NN 0 1 13 O
drugs NNS 1 1 6 O
bacitracin NN 0 1 16 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
therefore NN 0 0 1 O
this DT 0 0 12 O
conjugated JJ 0 1 14 O
system NN 0 1 1 O
maybe RB 0 1 12 O
useful JJ 0 1 UNK O
for IN 0 0 12 O
peroral JJ 0 0 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
peptide JJ 0 1 13 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
future NN 0 1 12 O
. . 0 0 12 O

Twenty NNP 0 1 2 O
- : 0 0 2 O
four CD 0 1 12 O
h NN 0 1 16 O
exposures NNS 1 1 UNK O
of IN 0 0 12 O
fully RB 0 0 1 O
formed VBN 1 1 UNK O
cysts NNS 1 1 6 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
excystment NN 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
glucocorticoid JJ 0 1 13 O
- : 0 0 2 O
induced JJ 0 1 6 O
gene NN 0 1 13 O
expression NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
antioxidative JJ 0 1 UNK O
gallates NNS 0 0 UNK O
is VBZ 1 0 12 O
of IN 0 0 12 O
great JJ 0 1 12 O
interest NN 0 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
point NN 0 1 12 O
of IN 0 0 12 O
view NN 0 1 12 O
. . 0 0 12 O

and CC 0 0 12 O
clinical JJ 0 1 6 O
implications NNS 1 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
and CC 0 0 12 O
of IN 0 0 12 O
Innovar NNP 0 1 UNK B-Brand
anesthesia NN 0 1 6 O
on IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
tolerance NN 0 1 1 O
in IN 0 0 12 O
dogs NNS 1 1 UNK O
. . 0 0 12 O

Successful JJ 0 1 2 O
prophylaxis NN 0 1 6 O
of IN 0 0 12 O
manic JJ 0 1 13 O
- : 0 0 2 O
depressive JJ 0 0 13 O
disorder NN 0 1 6 O
requires VBZ 1 0 1 O
more JJR 0 1 12 O
than IN 0 0 12 O
the DT 0 0 12 O
prescription NN 0 1 0 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
carbonate NN 0 1 14 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
in IN 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
force NN 0 1 13 O
of IN 0 0 12 O
contraction NN 0 1 6 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
relation NN 0 1 13 O
to TO 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
. . 0 0 12 O

Fourteen NNP 0 1 UNK O
days NNS 1 1 12 O
later RB 0 1 12 O
all DT 0 0 12 O
animals NNS 1 1 12 O
were VBD 1 0 12 O
challenged VBN 1 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
hypnotic JJ 0 1 13 O
dose NN 0 1 6 O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
IP NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

All DT 0 0 2 O
antagonists NNS 1 1 13 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
time NN 0 1 12 O
spent VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
light JJ 0 1 3 O
zone NN 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
test NN 0 1 1 O
which WDT 0 0 12 O
suggested VBD 1 1 12 O
that IN 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
have VBP 0 0 12 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
well RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

METHODS NNP 0 1 UNK O
AND CC 0 0 11 O
AIMS NNP 0 1 UNK O
: : 0 0 2 O
We PRP 0 0 12 O
conducted VBD 1 1 1 O
a DT 0 0 12 O
retrospective JJ 0 1 UNK O
cohort NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
end NN 0 1 12 O
- : 0 0 2 O
stage NN 0 1 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
( ( 0 0 2 O
ESRD NNP 0 1 7 O
) ) 0 0 2 O
patients NNS 1 1 6 O
( ( 0 0 2 O
age NN 0 1 12 O
: : 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
mean JJ 0 1 12 O
SD NNP 0 1 UNK O
; : 0 0 2 O
9 CD 0 0 2 O
: : 0 0 2 O
male NN 0 1 12 O
) ) 0 0 2 O
who WP 0 0 12 O
had VBD 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
of IN 0 0 12 O
cinacalcet JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
arsenate NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
phosphate VB 0 1 14 B-Drug
do VBP 0 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
share NN 0 1 UNK O
a DT 0 0 12 O
common JJ 0 1 1 O
transport NN 0 1 1 O
pathway NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
duodenum NN 0 1 8 O
and CC 0 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
was VBD 1 0 12 O
obtained VBN 1 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
at IN 0 0 12 O
this DT 0 0 12 O
level NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
corrected JJ 0 1 1 O
QT NNP 0 1 13 O
intervals NNS 1 1 1 O
during IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
cisapride JJ 0 1 UNK B-Drug
alone CD 0 1 12 O
or CC 0 0 12 O
with IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

Close JJ 0 1 2 O
monitoring NN 0 1 1 O
allows NNS 0 1 UNK O
physicians NNS 1 1 6 O
to TO 0 0 12 O
minimize VB 0 0 1 O
risks NNS 1 1 1 O
maximize VB 0 0 1 O
benefits NNS 1 1 1 O
and CC 0 0 12 O
get VB 0 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
out IN 0 1 12 O
of IN 0 0 12 O
what WP 0 0 12 O
modern JJ 0 0 UNK O
medications NNS 1 1 6 O
can MD 0 0 12 O
do VB 0 0 12 O
to TO 0 0 12 O
help VB 0 1 12 O
older JJR 1 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Leukopenia NNP 0 1 UNK O
was VBD 1 0 12 O
similar JJ 0 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
but CC 0 0 12 O
colony NN 0 1 12 O
stimulating NN 0 1 1 O
factor NN 0 1 1 O
support NN 0 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
greater JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
HAART NNP 0 1 14 O
group NN 0 1 12 O
than IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
group NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
; : 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

[ VB 0 0 2 O
A DT 0 0 2 O
pharmacological JJ 0 1 14 O
analysis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
angiotensin NN 0 1 UNK B-Drug_n
on IN 0 0 12 O
stimulated JJ 0 1 13 O
gastric JJ 0 1 6 O
secretion NN 0 1 14 O
] NNP 0 0 2 O
Chronic NNP 0 1 7 O
experiments NNS 1 1 UNK O
on IN 0 0 12 O
dogs NNS 1 1 UNK O
with IN 0 0 12 O
gastric JJ 0 1 6 O
fistulas NNS 1 1 13 O
were VBD 1 0 12 O
carried VBN 1 1 12 O
out IN 0 1 12 O
to TO 0 0 12 O
study VB 0 1 1 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
angiotensin NN 0 1 UNK B-Drug_n
9 CD 0 0 2 I-Drug_n
and CC 0 0 12 O
angiotensin RB 0 1 UNK B-Drug_n
9 CD 0 0 2 I-Drug_n
on IN 0 0 12 O
pentagastrin NN 0 1 UNK B-Drug
- : 0 0 2 O
and CC 0 0 12 O
histamine VB 0 1 UNK B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
gastric JJ 0 1 6 O
acid NN 0 1 14 O
secretion NN 0 1 14 O
. . 0 0 12 O

Barbiturates NNS 0 1 UNK B-Group
and CC 0 0 12 O
glutethimide NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
coumarin NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Excystment NN 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
was VBD 1 0 12 O
only RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
cercariae NN 1 1 UNK O
exposed VBN 1 1 3 O
to TO 0 0 12 O
cadmium VB 0 1 13 O
/ NNP 0 0 2 O
zinc NNP 0 1 14 O
mixtures VBZ 0 1 13 O
whilst JJ 0 0 UNK O
encysting NN 0 1 UNK O
. . 0 0 12 O

Therefore IN 0 0 1 O
we PRP 0 0 12 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
biocytin JJ 0 1 UNK O
inclusion NN 0 1 13 O
on IN 0 0 12 O
opioid JJ 0 1 13 B-Group
responses NNS 1 1 1 O
and CC 0 0 12 O
other JJ 0 0 12 O
membrane NN 0 1 3 O
properties NNS 1 1 UNK O
during IN 0 0 12 O
whole JJ 0 1 12 O
- : 0 0 2 O
cell NN 0 1 1 O
tight JJ 0 1 3 O
seal JJ 0 1 UNK O
recordings NNS 1 0 1 O
of IN 0 0 12 O
these DT 0 0 12 O
neurons NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
administration NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient JJ 0 1 6 O
population NN 0 1 13 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
insufficiency NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
both CC 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
relative NN 0 1 1 O
to TO 0 0 12 O
controls NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
dissolution NN 0 0 UNK O
rate NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
aerosol NN 0 1 3 O
particles NNS 1 1 UNK O
in IN 0 0 12 O
saline NN 0 1 14 O
was VBD 1 0 12 O
low JJ 0 1 1 O
and CC 0 0 12 O
variable JJ 0 1 1 O
. . 0 0 12 O

Cardiovascular JJ 0 1 7 O
disease NN 0 1 6 O
is VBZ 1 0 12 O
a DT 0 0 12 O
common JJ 0 1 1 O
comorbidity NN 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
cause NN 0 1 12 O
of IN 0 0 12 O
mortality NN 0 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
implications NNS 1 0 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
results NNS 1 1 1 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
especially RB 0 0 12 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
observations NNS 1 1 1 O
which WDT 0 0 12 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
homocysteine NN 0 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
precipitating JJ 0 1 14 O
factor NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
thrombosis NN 0 1 6 O
. . 0 0 12 O

Aortic JJ 0 1 7 O
rings NNS 1 1 3 O
with IN 0 0 12 O
intact JJ 0 1 1 O
endothelium NN 0 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
estradiol NN 0 1 13 B-Drug
group NN 0 1 12 O
were VBD 1 0 12 O
supersensitive JJ 0 0 UNK O
to TO 0 0 12 O
noradrenaline VB 0 1 UNK B-Drug
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
vehicle NN 0 1 1 O
or CC 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
estradiol NN 0 1 13 O
groups NNS 1 1 1 O
( ( 0 0 2 O
pD9 JJ 0 0 UNK O
values NNS 1 1 1 O
= VBP 0 0 2 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9+ CD 0 0 16 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Ibuprofen NNP 0 1 0 B-Drug
plasma NN 0 1 14 O
concentration NN 0 1 1 O
was VBD 1 0 12 O
also RB 0 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
piperine NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Photic JJ 0 1 UNK O
evoked VBD 1 1 13 O
potentials NNS 1 1 UNK O
were VBD 1 0 12 O
recorded VBN 1 1 12 O
from IN 0 0 12 O
the DT 0 0 12 O
visual JJ 0 1 1 O
cortex NN 0 1 6 O
of IN 0 0 12 O
chronically RB 0 0 6 O
implanted VBN 1 1 6 O
albino NN 0 1 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

DESIGN NN 0 1 UNK O
: : 0 0 2 O
Open JJ 0 1 2 O
- : 0 0 2 O
label NN 0 1 13 O
three CD 0 1 12 O
- : 0 0 2 O
phase NN 0 1 1 O
sequential JJ 0 1 1 O
study NN 0 1 1 O
. . 0 0 12 O

Differences NNS 0 1 UNK O
can MD 0 0 12 O
occur VB 0 1 1 O
in IN 0 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
and CC 0 0 12 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
to TO 0 0 12 O
rats VB 1 1 UNK O
in IN 0 0 12 O
vivo NN 0 1 13 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
erythro SYM 0 1 13 I-Drug_n
- : 0 0 2 O
fluorocitrate JJ 0 1 UNK I-Drug_n
synthesis NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
kidney NN 0 1 6 O
which WDT 0 0 12 O
was VBD 1 0 12 O
preceded VBN 1 1 12 O
by IN 0 0 12 O
an DT 0 0 12 O
elevation NN 0 1 1 O
in IN 0 0 12 O
fluoride NN 0 1 16 O
levels NNS 1 1 1 O
and CC 0 0 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
citrate NN 0 1 14 O
accumulation NN 0 1 1 O
. . 0 0 12 O

Flavoridin NNP 0 0 UNK B-Drug_n
alone RB 0 1 12 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
CAS NNP 0 0 UNK O
but CC 0 0 12 O
can MD 0 0 12 O
completely RB 0 1 12 O
block VB 0 1 3 O
contortrostatin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
protein NN 0 1 14 O
in IN 0 0 12 O
MDA NNP 0 1 UNK O
- : 0 0 2 O
MB NNP 0 1 10 O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
role NN 0 1 1 O
of IN 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
- : 0 0 2 O
enhanced VBN 1 1 1 O
paclitaxel JJ 0 1 13 B-Drug
cytotoxicity NN 0 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
mode NN 0 1 1 O
of IN 0 0 12 O
toxic JJ 0 1 1 O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
pesticide NN 0 1 UNK O
gliftor NN 0 1 UNK B-Drug_n
: : 0 0 2 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
to TO 0 0 12 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
erythro SYM 0 1 13 I-Drug_n
- : 0 0 2 O
fluorocitrate NN 0 1 UNK I-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
phentolamine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
the DT 0 0 12 O
second JJ 0 1 12 O
contraction NN 0 1 6 O
was VBD 1 0 12 O
inhibited VBN 1 1 13 O
selectively RB 0 0 UNK O
. . 0 0 12 O

Differential NNP 0 1 7 O
regulation NN 0 1 13 O
of IN 0 0 12 O
tyrosine JJ 0 1 13 O
phosphorylation NN 0 1 UNK O
in IN 0 0 12 O
tumor NN 0 1 6 O
cells NNS 1 1 6 O
by IN 0 0 12 O
contortrostatin NN 0 1 UNK B-Drug_n
a DT 0 0 12 O
homodimeric JJ 0 0 UNK O
disintegrin NN 0 0 UNK O
and CC 0 0 12 O
monomeric JJ 0 1 UNK O
disintegrins NNS 0 1 UNK O
echistatin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
flavoridin NN 0 0 UNK B-Drug_n
. . 0 0 12 O

We PRP 0 0 12 O
demonstrate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
conversion NN 0 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
to TO 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
by IN 0 0 12 O
an DT 0 0 12 O
NAD+ NNP 0 1 UNK O
- : 0 0 2 O
dependent JJ 0 1 1 O
oxidation NN 0 1 13 O
is VBZ 1 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
- : 0 0 2 O
limiting VBG 1 1 1 O
step NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
synthesis NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
toxic JJ 0 1 1 O
product NN 0 1 1 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
erythro SYM 0 1 13 B-Drug_n
- : 0 0 2 O
fluorocitrate NN 0 1 UNK I-Drug_n
from IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
. . 0 0 12 O

According VBG 0 1 2 O
to TO 0 0 12 O
Gibaldi NNP 0 0 UNK O
et FW 0 0 13 O
al NN 0 1 16 O
. . 0 0 12 O

To TO 0 0 2 O
each DT 0 0 12 O
preparation NN 0 1 1 O
was VBD 1 0 12 O
added VBN 1 1 12 O
one CD 0 1 12 O
additional JJ 0 1 1 O
drug NN 0 1 1 O
at IN 0 0 12 O
three CD 0 1 12 O
concentrations NNS 1 1 13 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
therapeutic JJ 0 1 6 O
to TO 0 0 12 O
toxic VB 0 1 1 O
. . 0 0 12 O

Maximal NNP 0 1 UNK O
exercise NN 0 1 1 O
testing VBG 1 1 1 O
a DT 0 0 12 O
maneuver NN 0 0 UNK O
often RB 0 1 12 O
applied VBN 1 1 1 O
to TO 0 0 12 O
cardiac JJ 0 1 6 O
patients NNS 1 1 6 O
does VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
level NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
substantial JJ 0 0 1 O
change NN 0 1 1 O
in IN 0 0 12 O
T NNP 0 1 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
or CC 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

At IN 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
recovery NN 0 1 1 O
of IN 0 0 12 O
fade NN 0 0 UNK O
hoof NN 0 1 UNK O
twitch NN 0 1 3 O
was VBD 1 0 12 O
9 CD 0 0 2 O
+ JJ 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
plus CC 0 1 16 O
gentamycin NN 0 1 14 B-Drug
. . 0 0 12 O

SETTING NN 0 1 UNK O
: : 0 0 2 O
Rural JJ 0 1 UNK O
primary NN 0 1 1 O
care NN 0 1 12 O
centre NN 0 1 UNK O
. . 0 0 12 O

Medication NN 0 1 UNK O
is VBZ 1 0 12 O
rarely RB 0 1 UNK O
needed VBN 1 1 12 O
. . 0 0 12 O

Such JJ 0 0 1 O
observations NNS 1 1 1 O
prompted VBD 1 1 12 O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
methylglyoxal NN 0 1 UNK B-Drug_n
as IN 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
drug NN 0 1 1 O
against IN 0 0 12 O
multidrug NN 0 0 UNK O
resistant JJ 0 1 3 O
Pseudomonas NNP 0 1 14 O
aeruginosa NN 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
data NN 0 1 1 O
suggest NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
histidine NN 0 1 13 O
residues NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
crucial JJ 0 0 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
receptor NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
activity NN 0 1 1 O
of IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
be VB 0 0 12 O
well RB 0 1 12 O
acquainted VBN 1 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
and CC 0 0 12 O
paraclinical JJ 0 0 UNK O
pattern NN 0 1 3 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
deficit NN 0 1 1 O
and CC 0 0 12 O
to TO 0 0 12 O
discriminate VB 0 1 UNK O
between IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
deficiency NN 0 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
insufficient JJ 0 1 1 O
magnesium NN 0 1 14 B-Drug
intake NN 0 1 3 O
which WDT 0 0 12 O
only RB 0 1 12 O
requires VBZ 1 0 1 O
oral JJ 0 1 6 O
physiological JJ 0 1 13 O
supplementation NN 0 1 14 O
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
depletion NN 0 1 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
dysregulation NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
status NN 0 1 1 O
which WDT 0 0 12 O
requires VBZ 1 0 1 O
more JJR 0 1 12 O
or CC 0 0 12 O
less RBR 0 1 12 O
specific JJ 0 1 1 O
regulation NN 0 1 13 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
causal NN 0 1 UNK O
dysregulation NN 0 0 UNK O
. . 0 0 12 O

and CC 0 0 12 O
the DT 0 0 12 O
remaining VBG 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
by IN 0 0 12 O
monitoring NN 0 1 1 O
and CC 0 0 12 O
follow VB 0 1 12 O
- : 0 0 2 O
up IN 0 0 12 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Misonidazole NNP 0 1 UNK B-Drug_n
protects VBZ 1 0 UNK O
mouse VB 0 1 UNK O
tumour JJ 0 1 UNK O
and CC 0 0 12 O
normal JJ 0 1 1 O
tissues NNS 1 1 6 O
from IN 0 0 12 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
doses VBZ 1 1 6 O
9 CD 0 0 2 O
mg NN 0 1 0 O
diminished VBN 1 1 1 O
nonheme JJ 0 0 UNK B-Drug
iron NN 0 1 3 I-Drug
absorption NN 0 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Two CD 0 1 2 O
weeks NNS 1 1 12 O
later RBR 0 1 12 O
retinal JJ 0 1 6 O
flatmounts NNS 0 0 UNK O
were VBD 1 0 12 O
examined VBN 1 1 1 O
for IN 0 0 12 O
GFP NNP 0 1 UNK O
expression NN 0 1 1 O
using VBG 1 1 1 O
confocal JJ 0 0 UNK O
microscopy NN 0 1 16 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
after IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
PGF9alpha NNP 0 0 UNK B-Drug
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
among IN 0 0 12 O
the DT 0 0 12 O
pD9 NN 0 0 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
noradrenaline NN 0 1 UNK B-Drug
in IN 0 0 12 O
aortic JJ 0 1 8 O
rings NNS 1 1 3 O
without IN 0 0 12 O
endothelium NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
expression NN 0 1 1 O
of IN 0 0 12 O
EGFR NNP 0 1 UNK O
and CC 0 0 12 O
EGFR NNP 0 1 UNK O
ligands NNS 1 1 UNK O
was VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
flow JJ 0 1 1 O
cytometry NN 0 1 UNK O
RT NNP 0 1 UNK O
- : 0 0 2 O
PCR NNP 0 1 14 O
and CC 0 0 12 O
real JJ 0 1 12 O
- : 0 0 2 O
time NN 0 1 12 O
quantitative JJ 0 1 1 O
PCR NNP 0 1 14 O
. . 0 0 12 O

Hemoglobin NNP 0 1 UNK O
remained VBD 1 0 12 O
unchanged JJ 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
while IN 0 0 12 O
darbepoetin NN 0 0 13 B-Drug
requirement NN 0 1 1 O
decreased VBD 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
g NN 0 1 16 O
/ JJ 0 0 2 O
week NN 0 1 12 O
p NN 0 1 2 O
= VBD 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Depression NNP 0 1 2 O
is VBZ 1 0 12 O
reaching VBG 1 1 12 O
epidemic JJ 0 1 13 O
proportions NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
western JJ 0 1 13 O
world NN 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
dmPGE9 JJ 0 0 UNK B-Drug_n
induces NNS 0 1 UNK O
a DT 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
secretory NN 0 1 UNK O
diarrhea NN 0 1 6 O
in IN 0 0 12 O
cecectomized VBN 0 0 UNK O
than IN 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NN 1 1 UNK O
probably RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
reservoir NN 0 1 UNK O
function NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
cecum NN 0 1 8 O
in IN 0 0 12 O
the DT 0 0 12 O
operated JJ 0 1 1 O
animals NNS 1 1 12 O
. . 0 0 12 O

Conclusions NNS 0 1 7 O
and CC 0 0 12 O
the DT 0 0 12 O
types NNS 1 1 1 O
of IN 0 0 12 O
studies NNS 1 1 1 O
which WDT 0 0 12 O
support VBP 0 1 1 O
these DT 0 0 12 O
conclusions NNS 1 1 1 O
are VBP 1 0 12 O
given VBN 1 1 12 O
for IN 0 0 12 O
each DT 0 0 12 O
major JJ 0 1 1 O
section NN 0 1 1 O
. . 0 0 12 O

ADL NNP 0 1 UNK B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
novel JJ 0 1 13 O
peripherally RB 0 0 8 B-Group
restricted VBN 1 1 1 I-Group
opioid JJ 0 1 13 I-Group
antagonist NN 0 1 13 I-Group
that WDT 0 0 12 O
may MD 0 0 1 O
selectively RB 0 0 UNK O
prevent VB 0 1 1 O
opioid JJ 0 1 13 B-Group
- : 0 0 2 O
induced JJ 0 1 6 O
gastrointestinal JJ 0 1 6 O
effects NNS 1 1 1 O
without IN 0 0 12 O
reversing VBG 1 1 UNK O
analgesia NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
paper NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
study VB 0 1 1 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
neurotensin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
both DT 0 0 12 O
enkephalins NNS 1 1 UNK B-Drug_n
or CC 0 0 12 O
its PRP$ 1 0 12 O
synthetic JJ 0 1 3 O
analogue NN 0 1 UNK O
D NNP 0 1 2 B-Drug_n
- : 0 0 2 O
Ala9 NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
metenkephalinamide NN 0 0 UNK I-Drug_n
or CC 0 0 12 O
tuftsin NN 0 1 UNK B-Drug_n
on IN 0 0 12 O
the DT 0 0 12 O
antinonciceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
peptides NNS 1 1 UNK O
in IN 0 0 12 O
mice NN 1 1 UNK O
after IN 0 0 12 O
intracisternal JJ 0 0 UNK O
injection NN 0 1 3 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
simeticone NN 0 1 UNK B-Drug
are VBP 1 0 12 O
documented VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
current JJ 0 1 1 O
summary NN 0 1 1 O
of IN 0 0 12 O
product NN 0 1 1 O
characteristics NNS 1 1 UNK O
. . 0 0 12 O

All DT 0 0 2 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
of IN 0 0 12 O
enterococcus NN 0 1 14 O
three CD 0 1 12 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Clostridium NNP 0 1 14 O
three CD 0 1 12 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Escherichia NNP 0 1 14 O
coli NN 0 0 14 O
and CC 0 0 12 O
one CD 0 1 12 O
strain NN 0 1 3 O
of IN 0 0 12 O
Proteus NNP 0 1 UNK O
rettgeri NN 0 0 16 O
were VBD 1 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
both DT 0 0 12 O
clindamycin NN 0 1 0 B-Drug
( ( 0 0 2 O
minimal JJ 0 1 1 O
inhibitory NN 0 1 UNK O
concentration NN 0 1 1 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mug JJ 0 1 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
( ( 0 0 2 O
minimal JJ 0 1 1 O
inhibitory NN 0 1 UNK O
concentration NN 0 1 1 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mug JJ 0 1 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
present VBP 0 1 1 O
a DT 0 0 12 O
comprehensive NN 0 1 13 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
approach NN 0 1 1 O
to TO 0 0 12 O
assessing VBG 1 1 UNK O
metabolism NN 0 1 16 O
- : 0 0 2 O
mediated VBN 1 1 13 O
hepatotoxicity NN 0 1 13 O
using VBG 1 1 1 O
male JJ 0 1 12 O
Sprague NNP 0 0 UNK O
- : 0 0 2 O
Dawley NNP 0 0 UNK O
rat NN 0 1 13 O
liver NN 0 1 6 O
slices NNS 1 1 UNK O
incubated VBN 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
well NN 0 1 12 O
characterized VBN 1 1 1 O
hepatotoxicant JJ 0 0 UNK O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
enzymes VBZ 0 1 14 O
. . 0 0 12 O

At IN 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
the DT 0 0 12 O
diarrhea NN 0 1 6 O
- : 0 0 2 O
inducing JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
dmPGE9 NN 0 0 UNK B-Drug_n
were VBD 1 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
than IN 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
. . 0 0 12 O

aureus NN 0 0 14 O
to TO 0 0 12 O
survive VB 0 1 UNK O
in IN 0 0 12 O
pentazocine NN 0 1 UNK B-Drug
and CC 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug
may MD 0 0 1 O
explain VB 0 0 12 O
in IN 0 0 12 O
part NN 0 1 12 O
a DT 0 0 12 O
shift NN 0 1 1 O
from IN 0 0 12 O
S NNP 0 1 2 O
. . 0 0 12 O

Moreover RB 0 0 1 O
combination NN 0 1 1 O
of IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
tailored VBN 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
tumor NN 0 1 6 O
type JJ 0 1 1 O
drug NN 0 1 1 O
and CC 0 0 12 O
administration NN 0 1 1 O
schedule NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
FDA NNP 0 1 UNK O
has VBZ 1 0 12 O
approved VBN 1 1 1 O
ticagrelor NN 0 1 13 B-Drug
( ( 0 0 2 O
Brilinta NNP 0 1 UNK B-Brand
- : 0 0 2 O
AstraZeneca NNP 0 0 UNK O
) ) 0 0 2 O
an DT 0 0 12 O
oral JJ 0 1 6 O
antiplatelet NN 0 0 13 B-Group
drug NN 0 1 1 I-Group
for IN 0 0 12 O
use NN 0 1 1 O
with IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
thrombotic JJ 0 1 8 O
cardiovascular JJ 0 1 6 O
events NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
coronary JJ 0 1 6 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
ACS NNP 0 0 13 O
) ) 0 0 2 O
. . 0 0 12 O

Results NNS 0 1 2 O
showed VBD 1 1 12 O
that IN 0 0 12 O
depending VBG 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
task NN 0 1 16 O
considered VBD 1 1 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
pharmacological JJ 0 1 14 O
treatment NN 0 1 6 O
produced VBD 1 0 1 O
either CC 0 1 12 O
a DT 0 0 12 O
facilitation NN 0 1 13 O
or CC 0 0 12 O
an DT 0 0 12 O
impairment NN 0 1 16 O
of IN 0 0 12 O
acquisition NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
different JJ 0 1 1 O
responses NNS 1 1 1 O
in IN 0 0 12 O
locomotor NN 0 0 UNK O
activity NN 0 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
cocaine NN 0 1 6 B-Drug
suggest NN 0 1 1 O
that IN 0 0 12 O
genetic JJ 0 1 13 O
factors NNS 1 1 1 O
may MD 0 0 1 O
play VB 0 1 13 O
a DT 0 0 12 O
role NN 0 1 1 O
in IN 0 0 12 O
determining VBG 1 0 UNK O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

To TO 0 0 2 O
date NN 0 1 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
conclusive JJ 0 1 UNK O
evidence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
- : 0 0 2 O
relevant JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
. . 0 0 12 O

Activation NN 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
effector NN 0 0 UNK O
immediate JJ 0 1 1 O
- : 0 0 2 O
early JJ 0 1 12 O
gene NN 0 1 13 O
arc NN 0 0 13 O
by IN 0 0 12 O
methamphetamine NN 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
aimed VBD 1 1 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
minocycline NN 0 1 13 B-Drug
combined VBN 1 1 1 O
with IN 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
against IN 0 0 12 O
isolates NNS 0 1 14 O
of IN 0 0 12 O
methicillin NN 0 1 14 B-Drug
- : 0 0 2 O
resistant JJ 0 1 3 O
Staphylococcus NNP 0 1 14 O
aureus NN 0 0 14 O
( ( 0 0 2 O
MRSA NNP 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

By IN 0 0 2 O
inhibiting VBG 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
piperine VBP 0 1 UNK B-Drug_n
improves VBZ 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
world NN 0 1 12 O
medical JJ 0 1 1 O
literature NN 0 1 UNK O
contains VBZ 1 1 1 O
9 CD 0 0 2 O
reports NNS 1 1 1 O
of IN 0 0 12 O
deaths NNS 1 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
amphetamines NNS 1 1 14 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
period NN 0 1 1 O
. . 0 0 12 O

Ultimately RB 0 0 1 O
however RB 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
type NN 0 1 1 O
9 CD 0 0 2 O
diabetics NNS 1 1 UNK O
die VBP 0 1 UNK O
from IN 0 0 12 O
macrovascular JJ 0 0 UNK O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Further RB 0 1 2 O
no DT 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
either DT 0 1 12 O
warfarin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
or CC 0 0 12 O
prothrombin NN 0 1 14 O
times NNS 1 1 12 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
involving VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
. . 0 0 12 O

Cysteine JJ 0 1 UNK B-Drug
conjugation NN 0 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
m NN 0 1 2 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
R NNP 0 1 2 O
- : 0 0 2 O
values NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

Recombinant JJ 0 1 UNK O
shuttle JJ 0 0 UNK O
vectors NNS 1 1 UNK O
containing VBG 1 1 1 O
a DT 0 0 12 O
vanH NN 0 0 UNK O
promoter NN 0 1 UNK O
- : 0 0 2 O
vanA NN 0 0 UNK O
antisense JJ 0 1 UNK O
gene NN 0 1 13 O
cassette NN 0 1 16 O
fully RB 0 0 1 O
restored VBD 1 0 12 O
vancomycin JJ 0 1 14 B-Drug
susceptibility NN 0 1 6 O
through IN 0 0 12 O
a DT 0 0 12 O
combined JJ 0 1 1 O
transcriptional JJ 0 1 UNK O
activator NN 0 0 UNK O
binding VBG 1 1 1 O
domain NN 0 1 UNK O
decoy NN 0 0 13 O
and CC 0 0 12 O
inducible JJ 0 1 14 O
vanA NN 0 0 UNK O
antisense NN 0 1 UNK O
RNA NNP 0 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
simplest JJS 1 1 UNK O
inference NN 0 1 UNK O
is VBZ 1 0 12 O
that IN 0 0 12 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
polyenes NNS 0 1 UNK O
are VBP 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
their PRP$ 0 0 12 O
relative JJ 0 1 1 O
avidities NNS 1 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
predominant JJ 0 1 13 O
sterol NN 0 1 UNK O
in IN 0 0 12 O
cell NN 0 1 1 O
membranes NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
observations NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
exogenous JJ 0 1 UNK O
co SYM 0 1 12 O
- : 0 0 2 O
factors NNS 1 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
ARE NNP 0 0 UNK O
. . 0 0 12 O

Acid NNP 0 1 2 O
secretion NN 0 1 14 O
in IN 0 0 12 O
isolated JJ 0 1 1 O
rabbit NN 0 1 16 O
gastric JJ 0 1 6 O
glands NNS 1 1 6 O
was VBD 1 0 12 O
monitored VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
[ NNP 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
C NNP 0 0 2 O
] NNP 0 0 2 O
aminopyrine NN 0 1 UNK B-Drug
. . 0 0 12 O

[ JJ 0 0 2 O
Interaction NNP 0 1 2 O
between IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
and CC 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
] VBP 0 0 2 O
. . 0 0 12 O

Interferon NNP 0 1 0 O
induction NN 0 1 1 O
: : 0 0 2 O
tool NN 0 1 13 O
for IN 0 0 12 O
establishing VBG 1 1 UNK O
interactions NNS 1 1 UNK O
among IN 0 0 12 O
homopolyribonucleotides NNS 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
synergistic JJ 0 1 UNK O
antinociception NN 0 0 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
piperine NN 0 1 UNK B-Drug_n
can MD 0 0 12 O
be VB 0 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
. . 0 0 12 O

Prevention NN 0 1 UNK O
of IN 0 0 12 O
emergence NN 0 1 1 O
agitation NN 0 1 1 O
in IN 0 0 12 O
seven CD 0 1 12 O
children NNS 1 1 12 O
receiving VBG 1 1 1 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
ketamine NN 0 1 13 B-Drug
and CC 0 0 12 O
propofol JJ 0 1 14 B-Drug
total NN 0 1 1 O
intravenous JJ 0 1 14 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

Olanzapine NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
significantly RB 0 0 1 O
fewer JJR 1 1 UNK O
extrapyramidal NN 0 0 13 O
symptoms NNS 1 1 6 B-Group
than IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
and CC 0 0 12 O
risperidone NN 0 1 0 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
methylpyrazole NN 0 1 UNK I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
to TO 0 0 12 O
rats VB 1 1 UNK O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
was VBD 1 0 12 O
ineffective JJ 0 1 UNK O
in IN 0 0 12 O
preventing VBG 1 1 1 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
erythro SYM 0 1 13 I-Drug_n
- : 0 0 2 O
fluorocitrate NN 0 1 UNK I-Drug_n
synthesis NN 0 1 UNK O
and CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
diminish VB 0 1 UNK O
fluoride NN 0 1 16 O
or CC 0 0 12 O
citrate NN 0 1 14 O
accumulation NN 0 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
supplementary JJ 0 0 UNK O
oral JJ 0 1 6 O
cobalt NN 0 1 UNK B-Drug
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
both DT 0 0 12 O
at IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
site NN 0 1 12 O
fecal JJ 0 1 6 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
retention NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
trace NN 0 1 1 O
elements NNS 1 1 1 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
using VBG 1 1 1 O
four CD 0 1 12 O
diets NNS 1 1 UNK O
containing VBG 1 1 1 O
either CC 0 1 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
Co NNP 0 1 2 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
Fe NNP 0 1 2 B-Drug
over IN 0 1 12 O
a DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
rats NNS 1 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
differences NNS 1 1 UNK O
were VBD 1 0 12 O
reflected VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
roughly RB 0 0 1 O
twofold JJ 0 0 UNK O
greater JJR 1 1 1 O
antitumour NN 0 1 UNK O
activity NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
route NN 0 1 12 O
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
Everolimus NNP 0 1 UNK B-Drug
steady JJ 0 1 1 O
state NN 0 1 1 O
was VBD 1 0 12 O
reached VBN 1 1 12 O
on IN 0 0 12 O
or CC 0 0 12 O
before IN 0 1 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
with IN 0 0 12 O
a DT 0 0 12 O
median JJ 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
exposure NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
that DT 0 0 12 O
after IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
postoperative JJ 0 1 6 O
dose NN 0 1 6 O
. . 0 0 12 O

the DT 0 0 12 O
third JJ 0 1 12 O
group NN 0 1 12 O
( ( 0 0 2 O
SH NNP 0 1 13 O
/ NNP 0 0 2 O
EA NNP 0 1 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
hydroalcoholic JJ 0 0 UNK O
solution NN 0 1 1 O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
; : 0 0 2 O

In IN 0 0 2 O
dogs NNS 1 1 UNK O
cimetidine VBP 0 1 13 B-Drug
unchanged JJ 0 1 1 O
the DT 0 0 12 O
secretion NN 0 1 14 O
of IN 0 0 12 O
cardiotrast NN 0 1 UNK B-Drug
a DT 0 0 12 O
test NN 0 1 1 O
agent NN 0 1 1 O
for IN 0 0 12 O
anionic JJ 0 1 UNK O
transport NN 0 1 1 O
. . 0 0 12 O

Twelve NNP 0 1 UNK O
strains NNS 1 1 6 O
of IN 0 0 12 O
Staphylococcus NNP 0 1 14 O
aureus NN 0 0 14 O
( ( 0 0 2 O
a DT 0 0 12 O
frequent NN 0 1 1 O
cause NN 0 1 12 O
of IN 0 0 12 O
infection NN 0 1 6 O
in IN 0 0 12 O
heroin NN 0 1 13 B-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
pentazocine NN 0 1 UNK B-Drug
and CC 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug
addicts NNS 1 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
completely RB 0 1 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
combination NN 0 1 1 O
. . 0 0 12 O

Differential JJ 0 1 7 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
intrathecal JJ 0 1 16 O
naloxone NN 0 1 16 B-Drug
on IN 0 0 12 O
blocking VBG 1 1 UNK O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
IC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
was VBD 1 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
microgram NNS 0 1 UNK O
/ JJ 0 0 2 O
ml NN 0 1 16 O
. . 0 0 12 O

But CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
now RB 0 1 12 O
difficult JJ 0 1 12 O
to TO 0 0 12 O
situate VB 0 0 UNK O
the DT 0 0 12 O
exact JJ 0 1 1 O
place NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacological JJ 0 1 14 O
indications NNS 1 1 1 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
Src NNP 0 1 UNK O
family NN 0 1 12 O
and CC 0 0 12 O
Abl NNP 0 1 UNK O
kinases VBZ 0 1 14 O
with IN 0 0 12 O
either DT 0 1 12 O
siRNAs NN 0 1 UNK O
or CC 0 0 12 O
dasatinib NN 0 1 13 B-Drug
enhances NNS 0 1 UNK O
paclitaxel VBP 0 1 13 B-Drug
sensitivity NN 0 1 1 O
of IN 0 0 12 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
through IN 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
- : 0 0 2 O
mediated VBN 1 1 13 O
suppression NN 0 1 1 O
of IN 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Cdk9 NNP 0 1 UNK O
expression NN 0 1 1 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
piperine NN 0 1 UNK B-Drug_n
on IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
induced VBN 1 1 6 O
antinociception NN 0 0 UNK O
and CC 0 0 12 O
its PRP$ 1 0 12 O
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Determinants NNS 0 1 UNK O
of IN 0 0 12 O
cellular JJ 0 1 13 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
topoisomerase VB 0 1 UNK B-Group
- : 0 0 2 O
targeting VBG 1 1 UNK I-Group
antitumor NN 0 1 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Medicaid NNP 0 1 1 O
claims VBZ 1 0 1 O
data NNS 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
perform VB 0 1 1 O
an DT 0 0 12 O
observational JJ 0 1 UNK O
case NN 0 1 12 O
- : 0 0 2 O
control NN 0 1 1 O
study NN 0 1 1 O
nested VBD 1 0 UNK O
within IN 0 0 1 O
person NN 0 1 12 O
- : 0 0 2 O
time NN 0 1 12 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
warfarin VB 0 1 14 B-Drug
in IN 0 0 12 O
those DT 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
. . 0 0 12 O

diseases NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
gallbladder NN 0 1 6 O
and CC 0 0 12 O
bowel NN 0 1 6 O
; : 0 0 2 O

NNRTI NNP 0 1 UNK B-Group
- : 0 0 2 O
based VBN 1 1 1 O
regimens NNS 1 1 UNK O
may MD 0 0 1 O
have VB 0 0 12 O
several JJ 0 1 12 O
advantages NNS 1 0 UNK O
over IN 0 1 12 O
PI NNP 0 1 UNK B-Group
- : 0 0 2 O
based VBN 1 1 1 O
therapy NN 0 1 6 O
for IN 0 0 12 O
initial JJ 0 1 1 O
or CC 0 0 12 O
prolonged JJ 0 1 6 O
therapy NN 0 1 6 O
including VBG 1 1 1 O
more RBR 0 1 12 O
convenient JJ 0 1 1 O
administration NN 0 1 1 O
regimens VBZ 0 1 UNK O
lower JJR 1 1 1 O
tablet NN 0 1 16 O
volume NN 0 1 1 O
fewer JJR 1 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
and CC 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
penetration NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
proposed VBN 1 1 UNK O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
analgesic JJ 0 1 13 O
action NN 0 1 13 O
of IN 0 0 12 O
antihistaminics NNS 0 1 UNK B-Group
are VBP 1 0 12 O
reviewed VBN 1 1 1 O
and CC 0 0 12 O
discussed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
coadministered JJ 0 0 UNK O
drugs NNS 1 1 6 O
and CC 0 0 12 O
ethanol NN 0 1 1 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
drugs NNS 1 1 6 O
to TO 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
down RP 0 0 12 O
- : 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
ALOX9 NNP 0 0 UNK O
by IN 0 0 12 O
RNA NNP 0 1 UNK O
interference NN 0 1 13 O
could MD 0 0 12 O
also RB 0 0 12 O
induce VB 0 1 6 O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
H9 NNP 0 0 UNK O
. . 0 0 12 O

Withdrawal NN 0 1 7 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
requirement NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
an DT 0 0 12 O
anionic JJ 0 1 UNK O
- : 0 0 2 O
binding NN 0 1 1 O
resin NN 0 1 UNK O
has VBZ 1 0 12 O
a DT 0 0 12 O
considerable JJ 0 0 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
lowering VBG 1 1 UNK O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
fluvastatin JJ 0 1 13 B-Drug
bioavailability NN 0 1 UNK O
. . 0 0 12 O

Together RB 0 1 2 O
with IN 0 0 12 O
previous JJ 0 1 12 O
findings NNS 1 1 1 O
these DT 0 0 12 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
both DT 0 0 12 O
the DT 0 0 12 O
so RB 0 1 12 O
- : 0 0 2 O
called VBN 1 1 12 O
`` `` 0 0 13 O
hippocampal JJ 0 1 8 O
- : 0 0 2 O
dependent NN 0 1 1 O
'' '' 0 0 13 O

Inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
ruthenium NN 0 1 UNK B-Drug_n
red VBN 0 1 3 I-Drug_n
on IN 0 0 12 O
inositol NN 0 1 UNK O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
trisphosphate NN 0 0 UNK O
- : 0 0 2 O
induced JJ 0 1 6 O
responses NNS 1 1 1 O
in IN 0 0 12 O
rat NN 0 1 13 O
megakaryocytes NNS 1 1 UNK O
. . 0 0 12 O

Absorption NN 0 1 UNK O
of IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
virtually RB 0 0 1 O
complete JJ 0 1 1 O
across IN 0 0 12 O
all DT 0 0 12 O
species NNS 1 1 1 O
including VBG 1 1 1 O
man NN 0 1 12 O
and CC 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
food NN 0 1 12 O
. . 0 0 12 O

We PRP 0 0 12 O
conclude VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
prophylactic JJ 0 1 6 O
and CC 0 0 12 O
antidotal JJ 0 1 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
methylpyrazole NN 0 1 UNK I-Drug
seen VBN 1 1 12 O
in IN 0 0 12 O
animals NNS 1 1 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
derive NN 0 0 UNK O
from IN 0 0 12 O
its PRP$ 1 0 12 O
capacity NN 0 1 1 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
NAD+ NNP 0 1 UNK O
- : 0 0 2 O
dependent JJ 0 1 1 O
oxidation NN 0 1 13 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
converting VBG 1 0 UNK O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
to TO 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
committed JJ 0 1 UNK O
step NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
toxic JJ 0 1 1 O
pathway NN 0 1 UNK O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
users NNS 1 1 UNK O
had VBD 1 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
odds NNS 0 0 UNK O
ratio NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
upon IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
OR NNP 0 0 11 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
fluoxetine NN 0 1 16 B-Drug
( ( 0 0 2 O
OR NNP 0 0 11 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
paroxetine NN 0 1 16 B-Drug
( ( 0 0 2 O
OR NNP 0 0 11 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
amitriptyline NN 0 1 16 B-Drug
( ( 0 0 2 O
OR NNP 0 0 11 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Electrocardiograms NNS 0 1 15 O
were VBD 1 0 12 O
done VBN 1 0 12 O
at IN 0 0 12 O
baseline NN 0 1 1 O
and CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
day NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
washout NN 0 1 3 O
period NN 0 1 1 O
and CC 0 0 12 O
phase NN 0 1 1 O
9 CD 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
antagonism NN 0 1 UNK O
between IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
four CD 0 1 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
MCF9 NNP 0 0 UNK O
following VBG 1 1 1 O
all DT 0 0 12 O
incubation NN 0 0 UNK O
schedules NNS 1 1 UNK O
and CC 0 0 12 O
between IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
and CC 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
in IN 0 0 12 O
all DT 0 0 12 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
except IN 0 0 12 O
for IN 0 0 12 O
two CD 0 1 12 O
combinations NNS 1 1 1 O
in IN 0 0 12 O
HCT9 NNP 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

Pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
calcium NN 0 1 14 B-Group
- : 0 0 2 O
entry NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

For IN 0 0 2 O
digoxin NN 0 1 14 B-Drug
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
infinity NN 0 1 UNK O
) ) 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
the DT 0 0 12 O
geometric JJ 0 1 UNK O
mean JJ 0 1 12 O
ratios NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
) ) 0 0 2 O
for IN 0 0 12 O
( ( 0 0 2 O
rofecoxib JJ 0 1 16 B-Drug
+ NNP 0 0 2 O
digoxin NN 0 1 14 B-Drug
/ NNP 0 0 2 O
placebo NN 0 1 13 O
+ NNP 0 0 2 O
digoxin NN 0 1 14 B-Drug
) ) 0 0 2 O
were VBD 1 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

however RB 0 0 12 O
a DT 0 0 12 O
comparison NN 0 1 1 O
of IN 0 0 12 O
fluvastatin JJ 0 1 13 B-Drug
administration NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
evening VBG 1 1 12 O
meal NN 0 1 12 O
or CC 0 0 12 O
at IN 0 0 12 O
bedtime NN 0 1 3 O
has VBZ 1 0 12 O
revealed VBN 1 1 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
) ) 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
regimens NNS 1 1 UNK O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
as IN 1 0 12 O
calcium NN 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
in IN 0 0 12 O
all DT 0 0 12 O
studies NNS 1 1 1 O
and CC 0 0 12 O
minerals NNS 1 1 16 B-Group
were VBD 1 0 12 O
ingested VBN 1 1 14 O
on IN 0 0 12 O
an DT 0 0 12 O
empty JJ 0 1 3 O
stomach NN 0 1 6 O
. . 0 0 12 O

At IN 0 0 2 O
9 CD 0 0 2 O
degrees NNS 1 1 1 O
C NNP 0 0 2 O
the DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
myelinated VBN 0 1 UNK O
axons NNS 1 1 UNK O
contained VBD 1 1 1 O
9 CD 0 0 2 O
plus CC 0 1 16 O
or CC 0 0 12 O
minus CC 0 1 3 O
9 CD 0 0 2 O
S.E.M NNP 0 1 UNK O
. . 0 0 12 O

Specifically RB 0 0 1 O
they PRP 0 0 12 O
have VBP 0 0 12 O
focused VBN 1 1 1 O
on IN 0 0 12 O
aspects NNS 1 1 1 O
of IN 0 0 12 O
learning NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
impaired VBN 1 1 6 O
( ( 0 0 2 O
vs. FW 0 1 2 O
spared VBN 1 0 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
lesions NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
hippocampal JJ 0 1 8 O
formation NN 0 1 1 O
. . 0 0 12 O

After IN 0 0 2 O
9 CD 0 0 2 O
h JJ 0 1 16 O
atracurium NN 0 1 13 B-Drug
was VBD 1 0 12 O
discontinued VBN 1 1 1 O
and CC 0 0 12 O
hoof JJ 0 1 UNK O
twitch NN 0 1 3 O
allowed VBD 1 1 12 O
to TO 0 0 12 O
recover VB 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
six CD 0 1 12 O
cases NNS 1 1 UNK O
it PRP 0 0 12 O
was VBD 1 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
dosage NN 0 1 0 O
was VBD 1 0 12 O
inappropriate JJ 0 1 1 O
being VBG 1 0 12 O
either CC 0 1 12 O
too RB 0 0 12 O
high JJ 0 1 1 O
or CC 0 0 12 O
too RB 0 0 12 O
low JJ 0 1 1 O
as IN 1 0 12 O
judged NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
majority NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
with IN 0 0 12 O
NNRTIs NNP 0 1 UNK B-Group
occur VBP 0 1 1 O
within IN 0 0 1 O
the DT 0 0 12 O
first JJ 0 1 12 O
month NN 0 1 12 O
and CC 0 0 12 O
are VBP 1 0 12 O
predictable JJ 0 1 UNK O
and CC 0 0 12 O
manageable JJ 0 0 UNK O
without IN 0 0 12 O
therapy NN 0 1 6 O
interruption NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
that IN 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
induced VBD 1 1 6 O
long JJ 0 1 12 O
lasting JJ 0 0 1 O
depletions NNS 1 1 UNK O
of IN 0 0 12 O
striatal JJ 0 1 UNK O
dopamine NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
this DT 0 0 12 O
neurotoxic JJ 0 1 UNK O
effect NN 0 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
prevented VBN 1 1 UNK O
by IN 0 0 12 O
pargyline JJ 0 1 UNK B-Drug
pretreatment NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
ARE NNP 0 0 UNK O
suddenly RB 0 0 12 O
exceeded VBD 1 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
by IN 0 0 12 O
melarsoprol NN 0 1 UNK B-Drug
during IN 0 0 12 O
August NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
September NNP 0 1 2 O
9 CD 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
current JJ 0 1 1 O
study NN 0 1 1 O
the DT 0 0 12 O
nonpredisposed JJ 0 0 UNK O
strain NN 0 1 3 O
C9BL NNP 0 0 UNK O
/ VBD 0 0 2 O
9N CD 0 0 UNK O
was VBD 1 0 12 O
also RB 0 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
highly RB 0 1 1 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
diethylnitrosamine VB 0 1 UNK O
during IN 0 0 12 O
the DT 0 0 12 O
neonatal JJ 0 1 6 O
period NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
method NN 0 1 13 O
to TO 0 0 12 O
maximize VB 0 0 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
benefit NN 0 1 1 O
of IN 0 0 12 O
gentamicin NN 0 1 14 B-Drug
while IN 0 0 12 O
minimizing VBG 1 0 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
appearance NN 0 1 12 O
of IN 0 0 12 O
a DT 0 0 12 O
hot JJ 0 1 3 O
kidney NN 0 1 6 O
on IN 0 0 12 O
scintigraphy NN 0 1 UNK O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Except IN 0 0 UNK O
for IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
- : 0 0 2 O
sensitive JJ 0 1 1 O
isolates NNS 0 1 14 O
synergy VBP 0 0 1 O
was VBD 1 0 12 O
usually RB 0 1 12 O
observed VBN 1 1 1 O
only RB 0 1 12 O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
readily RB 0 0 1 O
obtainable JJ 0 0 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
objective NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
analyze VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
neonatal JJ 0 1 6 O
quinpirole JJ 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
on IN 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
in IN 0 0 12 O
adolescent JJ 0 1 13 O
rats NNS 1 1 UNK O
using VBG 1 1 1 O
locomotor NN 0 0 UNK O
sensitization NN 0 1 13 O
and CC 0 0 12 O
conditioned JJ 0 1 UNK O
place NN 0 1 12 O
preference NN 0 1 1 O
procedures NNS 1 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
could MD 0 0 12 O
observe VB 0 1 1 O
that DT 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
inhibited VBD 1 1 13 O
high JJ 0 1 1 O
threshold NN 0 1 1 O
voltage NN 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
currents NNS 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
previous JJ 0 1 12 O
reports NNS 1 1 1 O
we PRP 0 0 12 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
inhibit VBP 0 1 13 O
high JJ 0 1 1 O
threshold NN 0 1 1 O
voltage NN 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
channels NNS 1 1 13 O
in IN 0 0 12 O
neuronal JJ 0 1 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

Serum NNP 0 1 7 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
using VBG 1 1 1 O
an DT 0 0 12 O
9I CD 0 1 UNK O
- : 0 0 2 O
labelled VBN 1 1 UNK O
antigen NN 0 1 14 O
: : 0 0 2 O
Validation NN 0 1 UNK O
of IN 0 0 12 O
method NN 0 1 13 O
and CC 0 0 12 O
observations NNS 1 1 1 O
on IN 0 0 12 O
cardiac JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
might MD 0 0 12 O
be VB 0 0 12 O
explained VBN 1 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
blockade NN 0 1 1 O
by IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
of IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
by IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

Stimulation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
glands NNS 1 1 6 O
with IN 0 0 12 O
carbachol NN 0 1 13 B-Drug
synergistically RB 0 0 UNK O
augmented VBD 1 1 1 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
dibutyryl VB 0 0 UNK O
cAMP NN 0 1 UNK O
. . 0 0 12 O

Twenty NNP 0 1 2 O
- : 0 0 2 O
four CD 0 1 12 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
subjects NNS 1 1 UNK O
were VBD 1 0 12 O
randomized VBN 1 1 6 O
to TO 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
two CD 0 1 12 O
cohorts NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
fluoroquinolones NNS 0 1 UNK B-Group
are VBP 1 0 12 O
a DT 0 0 12 O
rapidly RB 0 1 1 O
growing VBG 1 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
with IN 0 0 12 O
a DT 0 0 12 O
broad JJ 0 1 1 O
spectrum NN 0 1 1 O
of IN 0 0 12 O
activity NN 0 1 1 O
against IN 0 0 12 O
gram JJ 0 1 16 O
- : 0 0 2 O
negative JJ 0 1 1 O
and CC 0 0 12 O
some DT 0 0 12 O
gram JJ 0 1 16 O
- : 0 0 2 O
positive JJ 0 1 1 O
aerobic JJ 0 1 6 O
bacteria NNS 0 1 6 O
. . 0 0 12 O

Male JJ 0 1 2 O
rats NNS 1 1 UNK O
demonstrated VBD 1 0 1 O
sensitization NN 0 1 13 O
to TO 0 0 12 O
amphetamine VB 0 1 13 B-Drug
although IN 0 0 12 O
this DT 0 0 12 O
was VBD 1 0 12 O
muted VBN 1 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
neonatal JJ 0 1 6 O
quinpirole NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Growth NNP 0 1 2 O
inhibition NN 0 1 13 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
was VBD 1 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Again NNP 0 0 2 O
sertraline NN 0 1 16 B-Drug
neutralized VBD 1 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
glycemia NN 0 1 UNK O
after IN 0 0 12 O
glucose JJ 0 1 14 B-Drug
overload NN 0 0 1 O
both DT 0 0 12 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
diabetic JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
Everolimus NNP 0 1 UNK B-Drug
exhibited VBD 1 1 1 O
dose JJ 0 1 6 O
- : 0 0 2 O
proportional JJ 0 1 UNK O
stable JJ 0 1 1 O
exposure NN 0 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
post NN 0 1 12 O
- : 0 0 2 O
transplant JJ 0 1 6 O
year NN 0 1 12 O
. . 0 0 12 O

longum NN 0 1 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
known JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
various JJ 0 1 1 O
enzymes NNS 1 1 14 O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
isozymes RB 0 1 UNK O
) ) 0 0 2 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
biotransformation NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

acanthus RB 0 1 UNK O
. . 0 0 12 O

Blood NN 0 1 2 O
samples NNS 1 1 UNK O
also RB 0 0 12 O
were VBD 1 0 12 O
taken VBN 1 1 12 O
before RB 0 1 12 O
morning NN 0 1 12 O
doses NNS 1 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
9rd CD 0 0 UNK O
9th CD 0 0 13 O
and CC 0 0 12 O
9th CD 0 0 13 O
days NNS 1 1 12 O
of IN 0 0 12 O
phases NNS 1 1 UNK O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Antiretroviral NNP 0 0 UNK B-Group
plasma NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
sampling NN 0 1 13 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
on IN 0 0 12 O
Days NNS 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
for IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
and CC 0 0 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
for IN 0 0 12 O
dideoxyinosine NN 0 1 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
was VBD 1 0 12 O
found VBN 1 1 12 O
between IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
values NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
liters NNS 1 1 3 O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
hatching NN 0 1 UNK O
of IN 0 0 12 O
miracidia NN 0 0 UNK O
from IN 0 0 12 O
eggs NNS 1 1 3 O
was VBD 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
99 CD 0 0 10 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
of IN 0 0 12 O
single JJ 0 1 12 O
metals NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
vivo JJ 0 1 13 O
CYP9A NNP 0 0 UNK O
activity NN 0 1 1 O
is VBZ 1 0 12 O
significantly RB 0 0 1 O
lower JJR 1 1 1 O
in IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
as IN 1 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
tacrolimus JJ 0 1 16 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
renal JJ 0 1 6 O
allograft NN 0 1 8 O
recipients NNS 1 1 UNK O
. . 0 0 12 O

nitrosourea JJ 0 1 UNK B-Group
AUC NNP 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
reduction NN 0 1 1 O
depending VBG 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
minimum JJ 0 1 1 O
effective JJ 0 1 1 O
concentration NN 0 1 1 O
( ( 0 0 2 O
MEC NNP 0 0 UNK O
) ) 0 0 2 O
chosen NN 0 1 12 O
. . 0 0 12 O

Two CD 0 1 2 O
retrospective JJ 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

fecal JJ 0 1 6 O
excretion NN 0 1 14 O
too RB 0 0 12 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
supplementary JJ 0 0 UNK O
iron NN 0 1 3 B-Drug
; : 0 0 2 O

Glucose NNP 0 1 7 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
caused VBN 1 1 1 O
subnormal JJ 0 0 UNK O
insulin NN 0 1 14 O
release NN 0 1 12 O
and CC 0 0 12 O
less JJR 0 1 12 O
suppression NN 0 1 1 O
of IN 0 0 12 O
glucagon NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
diabectics NNS 0 0 UNK O
than IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
normals NNS 1 1 UNK O
. . 0 0 12 O

SETTING NN 0 1 UNK O
: : 0 0 2 O
Clinical JJ 0 1 7 O
research NN 0 1 13 O
center NN 0 1 12 O
. . 0 0 12 O

uterine JJ 0 1 6 O
fibroids NNS 1 1 6 O
; : 0 0 2 O

Antidepressant NNP 0 1 UNK B-Group
- : 0 0 2 O
warfarin NN 0 1 14 B-Drug
interaction NN 0 1 UNK O
and CC 0 0 12 O
associated VBN 1 1 1 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
risk NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
case NN 0 1 12 O
- : 0 0 2 O
control NN 0 1 1 O
study NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
although IN 0 0 12 O
gentamycin NN 0 1 14 B-Drug
did VBD 1 0 12 O
augment VB 0 1 13 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
of IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
the DT 0 0 12 O
effect NN 0 1 1 O
was VBD 1 0 12 O
minimal JJ 0 1 1 O
. . 0 0 12 O

Postoperatively RB 0 0 15 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
randomly RB 0 0 UNK O
assigned VBN 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
fashion NN 0 0 12 O
to TO 0 0 12 O
receive VB 0 1 1 O
ADL NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
or CC 0 0 12 O
placebo NN 0 1 13 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
to TO 0 0 12 O
receive VB 0 1 1 O
oral JJ 0 1 6 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
placebo NN 0 1 13 O
. . 0 0 12 O

and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
antibiotic JJ 0 1 6 B-Group
drug NN 0 1 1 I-Group
doxycycline NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p NN 0 1 2 O
. . 0 0 12 O
o NN 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
neurotoxin NN 0 1 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
MPTP NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
x RB 0 0 10 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
i. NN 0 1 UNK O
p NN 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

The DT 0 0 2 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
agent NN 0 1 1 O
has VBZ 1 0 12 O
slight VBN 0 1 3 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
tested JJ 0 1 1 O
activities NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ruthenium NN 0 1 UNK B-Drug_n
red JJ 0 1 3 I-Drug_n
( ( 0 0 2 O
RR NNP 0 0 13 B-Drug_n
) ) 0 0 2 O
on IN 0 0 12 O
inositol NN 0 1 UNK B-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
trisphosphate NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
InsP9 NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
induced JJ 0 1 6 O
responses NNS 1 1 1 O
were VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
rat NN 0 1 13 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
megakaryocytes VBZ 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
patch NN 0 1 3 O
- : 0 0 2 O
clamp NN 0 1 3 O
whole JJ 0 1 12 O
- : 0 0 2 O
cell NN 0 1 1 O
recording VBG 1 0 1 O
technique NN 0 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
fura JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
microfluorometry NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
influence NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
when WRB 0 0 12 O
used VBN 1 1 12 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
adequately RB 0 0 1 O
randomized JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

[ IN 0 0 2 O
The DT 0 0 2 O
GABA NNP 0 1 UNK O
- : 0 0 2 O
ergic NN 0 1 UNK O
system NN 0 1 1 O
and CC 0 0 12 O
brain NN 0 1 6 O
edema NN 0 1 6 O
] NN 0 0 2 O
It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
with IN 0 0 12 O
experimental JJ 0 1 UNK O
toxic NN 0 1 1 O
and CC 0 0 12 O
traumatic JJ 0 1 6 O
edemas NN 1 1 UNK O
that WDT 0 0 12 O
picrotoxin NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
removes VBZ 1 1 UNK O
the DT 0 0 12 O
antiedematous JJ 0 0 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
phenazepam NN 0 1 UNK B-Drug_n
phenibut NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
amizyl NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
phentolamine NN 0 1 14 B-Drug
. . 0 0 12 O

and CC 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
putative JJ 0 0 UNK O
protective JJ 0 0 3 O
compounds NNS 1 1 13 O
including VBG 1 1 1 O
antioxidants NNS 1 1 UNK O
and CC 0 0 12 O
mitochondrial JJ 0 1 14 O
protective JJ 0 0 3 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
plasma NN 0 1 14 O
and CC 0 0 12 O
tumour JJ 0 1 UNK O
total JJ 0 1 1 O
nitrosourea JJ 0 1 UNK B-Group
peak NN 0 1 1 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
fold NN 0 1 3 O
respectively RB 0 0 1 O
. . 0 0 12 O

Green JJ 0 1 2 B-Drug
tea NN 0 1 13 I-Drug
polyphenols NNS 0 1 UNK I-Drug
as IN 1 0 12 O
potent JJ 0 1 UNK O
enhancers NNS 1 1 UNK B-Drug
of IN 0 0 12 O
glucocorticoid JJ 0 1 13 O
- : 0 0 2 O
induced JJ 0 1 6 O
mouse NN 0 1 UNK O
mammary JJ 0 1 6 O
tumor NN 0 1 6 O
virus NN 0 1 6 O
gene NN 0 1 13 O
expression NN 0 1 1 O
. . 0 0 12 O

Imexon NNP 0 1 UNK B-Drug
and CC 0 0 12 O
dacarbazine VB 0 1 13 B-Drug
show NN 0 1 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
in IN 0 0 12 O
human JJ 0 1 1 O
A9 NNP 0 1 UNK O
melanoma NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
blockade NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
spinal JJ 0 1 6 O
endorphinergic NN 0 0 UNK O
system NN 0 1 1 O
by IN 0 0 12 O
intrathecal JJ 0 1 16 O
naloxone NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
was VBD 1 0 12 O
then RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Cholecystokinin NNP 0 1 UNK O
octapeptide NN 0 0 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
necessary JJ 0 0 1 O
factor NN 0 1 1 O
for IN 0 0 12 O
realization NN 0 0 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
demonstrated VBN 1 0 1 O
for IN 0 0 12 O
cigarette NN 0 1 3 O
smokers NNS 1 1 UNK O
and CC 0 0 12 O
industrial JJ 0 1 13 O
workers NNS 1 1 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
chemical JJ 0 1 13 O
waste NN 0 0 13 O
incineration NN 0 1 UNK O
. . 0 0 12 O

Distinct NNP 0 0 UNK O
synergistic JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
piperacillin NN 0 1 16 B-Drug
and CC 0 0 12 O
methylglyoxal NN 0 1 UNK B-Drug_n
against IN 0 0 12 O
Pseudomonas NNP 0 1 14 O
aeruginosa NN 0 0 14 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
differences NNS 1 1 UNK O
in IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
dosing NN 0 0 14 O
and CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
at IN 0 0 12 O
different JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
exposure NN 0 1 1 O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
context NN 0 1 1 O
of IN 0 0 12 O
ANOVA NNP 0 0 UNK O
. . 0 0 12 O

With IN 0 0 2 O
each DT 0 0 12 O
successive JJ 0 0 UNK O
generation NN 0 1 UNK O
more RBR 0 1 12 O
people NNS 0 1 12 O
are VBP 1 0 12 O
becoming VBG 1 0 12 O
more RBR 0 1 12 O
severely RB 0 1 1 O
depressed VBN 1 1 12 O
at IN 0 0 12 O
a DT 0 0 12 O
younger JJR 1 1 12 O
age NN 0 1 12 O
. . 0 0 12 O

Sildenafil NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
long JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
nitrates NNS 1 1 14 I-Group
or CC 0 0 12 O
who WP 0 0 12 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
use VB 0 1 1 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
nitrates NNS 1 1 14 I-Group
because IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
sharp JJ 0 1 3 O
fall NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
serum NN 0 1 14 O
estrogen NN 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
estradiol JJ 0 1 13 B-Drug
+ NNP 0 0 2 O
endotoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
treated JJ 0 1 1 O
rats NNS 1 1 UNK O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
while IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
treated JJ 0 1 1 O
rats NNS 1 1 UNK O
increased VBD 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
other JJ 0 0 12 O
cells NNS 1 1 6 O
it PRP 0 0 12 O
enhances VBZ 1 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
G9 NNP 0 0 13 O
/ NNP 0 0 2 O
M NNP 0 1 2 O
arrest IN 0 1 12 O
allowing VBG 1 1 1 O
time NN 0 1 12 O
to TO 0 0 12 O
repair VB 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
induced VBN 1 1 6 O
DNA NNP 0 1 1 O
damage NN 0 1 1 O
before IN 0 1 12 O
entry NN 0 1 1 O
into IN 0 0 12 O
mitosis NN 0 1 UNK O
and CC 0 0 12 O
decreasing VBG 1 1 1 O
cell NN 0 1 1 O
death NN 0 1 12 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
antagonism NN 0 1 UNK O
. . 0 0 12 O

however RB 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
or CC 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
from IN 0 0 12 O
time NN 0 1 12 O
zero CD 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
and CC 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
clopidogrel VB 0 1 16 O
's POS 0 1 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
to TO 0 0 12 O
sharply RB 0 0 1 O
increase VB 0 1 1 O
platelet NN 0 1 14 O
reactivity NN 0 1 14 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
by IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
a DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
enzyme NN 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
approximate VB 0 1 1 O
the DT 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
level NN 0 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
drawn VBN 1 0 12 O
either DT 0 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
six CD 0 1 12 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
tablet NN 0 1 16 O
. . 0 0 12 O

Minimum NNP 0 1 UNK O
inhibitory JJ 0 1 UNK O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
MICs NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
viable JJ 0 1 1 O
counts NNS 1 1 1 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
in IN 0 0 12 O
Iso NNP 0 1 UNK O
- : 0 0 2 O
sensitest JJS 0 0 UNK O
broth NN 0 0 UNK O
using VBG 1 1 1 O
a DT 0 0 12 O
microtitre NN 0 0 UNK O
method NN 0 1 13 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
renally RB 0 0 14 O
. . 0 0 12 O

Two CD 0 1 2 O
groups NNS 1 1 1 O
( ( 0 0 2 O
SH NNP 0 1 13 O
/ NNP 0 0 2 O
DA NNP 0 1 11 O
; : 0 0 2 O
SH NNP 0 1 13 O
/ NNP 0 0 2 O
FA NNP 0 0 13 O
) ) 0 0 2 O
were VBD 1 0 12 O
submitted VBN 1 1 UNK O
to TO 0 0 12 O
daily VB 0 1 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
synthetic JJ 0 1 3 O
hydroalcoholic JJ 0 0 UNK O
solutions NNS 1 1 UNK O
containing VBG 1 1 1 O
ethanol NN 0 1 1 B-Drug
methanol NN 0 1 UNK B-Drug_n
higher JJR 1 1 1 O
alcohols NNS 1 1 13 B-Drug_n
and CC 0 0 12 O
acetaldehyde NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
proportions NNS 1 1 UNK O
as IN 1 0 12 O
those DT 0 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
most JJS 0 0 12 O
common JJ 0 1 1 O
distilled VBN 1 1 UNK O
and CC 0 0 12 O
fermented VBN 1 0 UNK O
alcoholic JJ 0 1 12 O
beverages NNS 1 1 1 O
; : 0 0 2 O

A DT 0 0 2 O
greater JJR 1 1 1 O
understanding NN 0 1 1 O
of IN 0 0 12 O
pain NN 0 1 6 O
mechanisms NNS 1 1 UNK O
will MD 0 0 12 O
aid VB 0 1 1 O
in IN 0 0 12 O
elucidating VBG 1 0 UNK O
the DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
antihistaminics NNS 0 1 UNK B-Group
in IN 0 0 12 O
analgesia NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
much JJ 0 0 12 O
statistical JJ 0 1 UNK O
work NN 0 1 12 O
has VBZ 1 0 12 O
focused VBN 1 1 1 O
on IN 0 0 12 O
developing VBG 1 0 1 O
mathematical JJ 0 1 UNK O
functions NNS 1 1 13 O
to TO 0 0 12 O
model VB 0 1 UNK O
the DT 0 0 12 O
joint JJ 0 1 1 O
dose JJ 0 1 6 O
- : 0 0 2 O
response NN 0 1 1 O
curves VBZ 1 1 UNK O
relatively RB 0 0 1 O
little JJ 0 1 12 O
work NN 0 1 12 O
exists NNS 0 1 UNK O
in IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
designing VBG 1 0 UNK O
experiments NNS 1 1 UNK O
for IN 0 0 12 O
assessing VBG 1 1 UNK O
joint JJ 0 1 1 O
action NN 0 1 13 O
. . 0 0 12 O

Administering VBG 0 1 UNK O
InsP9 NNP 0 0 UNK B-Drug_n
together RB 0 1 12 O
with IN 0 0 12 O
RR NNP 0 0 13 B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
microM NN 0 0 UNK O
) ) 0 0 2 O
inhibited VBD 1 1 13 O
InsP NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
induced VBN 1 1 6 O
responses NNS 1 1 1 O
( ( 0 0 2 O
both DT 0 0 12 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
and CC 0 0 12 O
current JJ 0 1 1 O
responses NNS 1 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
fashion NN 0 0 12 O
. . 0 0 12 O

Cardiovascular JJ 0 1 7 O
disease NN 0 1 6 O
is VBZ 1 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
next JJ 0 1 12 O
chapter NN 0 1 UNK O
and CC 0 0 12 O
chapter NN 0 1 UNK O
9 CD 0 0 2 O
presents NNS 1 1 12 O
findings NNS 1 1 1 O
on IN 0 0 12 O
endometrial JJ 0 1 6 O
ovarian JJ 0 1 6 O
cervical JJ 0 1 6 O
breast NN 0 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
cancers NNS 1 1 6 O
. . 0 0 12 O

Intraventricular JJ 0 1 UNK O
injection NN 0 1 3 O
of IN 0 0 12 O
naloxone NN 0 1 16 B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
equally RB 0 0 12 O
antagonized VBN 1 0 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
Hydrocortisone NNP 0 1 0 B-Drug
elevated VBD 1 1 1 O
salivary JJ 0 1 6 O
cortisol NN 0 1 14 O
levels NNS 1 1 1 O
produced VBN 1 0 1 O
modest JJ 0 1 1 O
dysphoria NN 0 1 UNK O
and CC 0 0 12 O
reduced JJ 0 1 1 O
subjects NNS 1 1 UNK O
' POS 0 0 2 O
reports NNS 1 1 1 O
of IN 0 0 12 O
wanting VBG 1 0 12 O
more JJR 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Group
blockers NNS 1 0 6 I-Group
on IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
and CC 0 0 12 O
arachidonic JJ 0 0 UNK O
acid NN 0 1 14 O
metabolism NN 0 1 16 O
could MD 0 0 12 O
contribute VB 0 1 UNK O
in IN 0 0 12 O
part NN 0 1 12 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
efficacy NN 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
ischemic JJ 0 1 6 O
heart NN 0 1 12 O
disease NN 0 1 6 O
. . 0 0 12 O

the DT 0 0 12 O
fourth JJ 0 1 12 O
group NN 0 1 12 O
served VBD 1 0 12 O
as IN 1 0 12 O
control NN 0 1 1 O
and CC 0 0 12 O
received VBD 1 1 12 O
an DT 0 0 12 O
equivalent JJ 0 1 1 O
volume NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
isocaloric JJ 0 0 UNK O
solution NN 0 1 1 O
of IN 0 0 12 O
dextrose NN 0 1 14 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
ouabain NN 0 1 UNK B-Drug
was VBD 1 0 12 O
applied VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
phentolamine NN 0 1 14 B-Drug
both DT 0 0 12 O
first JJ 0 1 12 O
and CC 0 0 12 O
second JJ 0 1 12 O
contractile NN 0 1 8 O
responses NNS 1 1 1 O
to TO 0 0 12 O
PTX NNP 0 1 15 B-Drug_n
were VBD 1 0 12 O
abolished VBN 1 0 UNK O
. . 0 0 12 O

These DT 0 0 1 O
included VBD 1 1 1 O
seven CD 0 1 12 O
cerebrovascular JJ 0 1 8 O
accidents NNS 1 1 1 O
six CD 0 1 12 O
sudden JJ 0 1 12 O
cardiac NNS 0 1 6 O
deaths NNS 1 1 UNK O
three CD 0 1 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
hyperpyrexia JJ 0 1 UNK O
eight CD 0 1 12 O
poisonings NNS 1 1 UNK O
of IN 0 0 12 O
uncertain JJ 0 1 1 O
mechanism NN 0 1 13 O
and CC 0 0 12 O
seven CD 0 1 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
medical JJ 0 1 1 O
complications NNS 1 1 6 O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
injection NN 0 1 3 O
; : 0 0 2 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
may MD 0 0 1 O
be VB 0 0 12 O
exploited VBN 1 0 UNK O
therapeutically RB 0 0 14 O
for IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
MM NNP 0 0 13 O
. . 0 0 12 O

Enhancement NN 0 1 UNK O
of IN 0 0 12 O
humoral JJ 0 1 14 O
immune JJ 0 1 6 O
responses NNS 1 1 1 O
to TO 0 0 12 O
inactivated VB 1 0 UNK O
Newcastle NNP 0 0 UNK O
disease NN 0 1 6 O
and CC 0 0 12 O
avian JJ 0 1 13 B-Group
influenza NN 0 1 6 I-Group
vaccines NNS 1 1 6 I-Group
by IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ginseng JJ 0 1 14 B-Drug_n
stem NN 0 1 3 I-Drug_n
- : 0 0 2 O
and CC 0 0 12 I-Drug_n
- : 0 0 2 O
leaf NN 0 1 UNK I-Drug_n
saponins NNS 1 1 UNK I-Drug_n
in IN 0 0 12 O
chickens NNS 1 1 UNK O
. . 0 0 12 O

Specific JJ 0 1 UNK O
and CC 0 0 12 O
aspecific JJ 0 0 UNK O
treatments NNS 1 1 6 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
depletion NN 0 1 1 O
are VBP 1 0 12 O
tricky JJ 0 0 UNK O
using VBG 1 1 1 O
for IN 0 0 12 O
example NN 0 1 1 O
magnesium NN 0 1 14 B-Group
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
pharmacological JJ 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
physiological JJ 0 1 13 O
doses NNS 1 1 6 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
and CC 0 0 12 O
of IN 0 0 12 O
selenium NN 0 1 13 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
efficient JJ 0 1 13 O
labeling NN 0 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
achieved VBN 1 0 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
biocytin NN 0 1 UNK O
with IN 0 0 12 O
whole JJ 0 1 12 O
- : 0 0 2 O
cell NN 0 1 1 O
recording VBG 1 0 1 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
antagonism NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
theophylline NN 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
by IN 0 0 12 O
CGS99 NNP 0 0 UNK B-Drug_n
was VBD 1 0 12 O
only RB 0 1 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
spent VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
light JJ 0 1 3 O
zone NN 0 1 1 O
and CC 0 0 12 O
DPCPX NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
induced VBD 1 1 6 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
neither RB 0 0 12 O
reversed VBN 1 1 1 O
by IN 0 0 12 O
CGS NNP 0 1 UNK B-Drug
99 CD 0 0 10 I-Drug
nor CC 0 0 12 O
by IN 0 0 12 O
CPA NNP 0 1 19 B-Drug_n
. . 0 0 12 O

Subjects NNS 0 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
dideoxyinosine JJ 0 1 UNK B-Drug
twice JJ 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
an DT 0 0 12 O
equivalent JJ 0 1 1 O
amount NN 0 1 1 O
of IN 0 0 12 O
placebo NN 0 1 13 O
/ NNP 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
Days $ 0 1 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
report VBP 0 1 1 O
the DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
an DT 0 0 12 O
adolescent NN 0 1 13 O
with IN 0 0 12 O
altered JJ 0 1 1 O
consciousness NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
overdose NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
positive JJ 0 1 1 O
tricyclic NN 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
level NN 0 1 1 O
to TO 0 0 12 O
alert VB 0 1 12 O
clinicians NNS 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
cross NN 0 1 12 O
- : 0 0 2 O
reactivity NN 0 1 14 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
with IN 0 0 12 O
a DT 0 0 12 O
toxicology NN 0 1 6 O
screen NN 0 1 3 O
for IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

